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Background: Hepatitis B virus (HBV) infection is a leading cause of illness and death in 
China. In 1992, 60% of the population had a history of HBV infection and 9.8% were 
chronically infected with HBV. Each year, an estimated 263,000 persons died from 
HBV-related hepatocellular carcinoma or cirrhosis, accounting for 37%-50% of HBV-related 
deaths worldwide before 1992. In 1992, the Ministry of Health introduced hepatitis B vaccine 
into the management system of the Expanded Programme on Immunization (EPI) as a 
cost-effective way to prevent HBV infection. The schedule included a timely birth dose 
(within 24 hours of birth, to prevent perinatal infections that are most strongly associated 
with long term chronic infections and adverse outcomes) and subsequent doses at one month 
and six months. However, this introduction into the EPI management system only meant that 
the Government took responsibility over administration and coverage monitoring, but not 
funding support: The cost of vaccination was covered out of pocket. As a result, coverage 
was lower in rural areas, in Western provinces (low economic status) and among females. In 
2002, the Ministry of Health fully integrated free hepatitis B vaccine into EPI with funding 
from the Global Alliance for Vaccines and Immunization (GAVI). The GAVI China project 
financially supported vaccine and auto-disable syringes in Western provinces and 
poverty-affected counties of Central provinces (Chapter 1). As the GAVI China project was 
completed in 2010, we compiled all evaluation work conducted to understand how input and 
process lead to output and outcomes that impacted the heavy HBV associated burden in 
China. 
 
Methods: We compiled data from GAVI China project areas between 2002 and 2009, 
reviewed cross-sectional studies conducted in 2004 and 2006 and conducted a final 
evaluation survey in 2010. These investigations covered input (funds invested into the project 
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for vaccine and AD syringes), process (integration of the vaccine in EPI, increase in 
institutional births, introduction of auto-disable syringes for vaccination and training), output 
(immunization coverage for third dose and timely birth dose, use of auto-disable syringes for 
immunization), outcome (immunity in the population, safe injection practices) and impact 
(prevalence of HBV surface antigen among children included in the vaccination cohort). 
 
Results: With respect to hepatitis B immunization, input included 27 million USD provided 
by the GAVI China project to funds hepatitis B vaccine between 2002 and 2007. These funds 
came from the international GAVI Alliance (50%) and the Government of China (50%). In 
addition, the Chinese government provided an additional 21.5 million USD in government 
co-funding of subsidies from central to provincial to health care workers in provinces 
between 2007 and 2009 so that the vaccine could be administered without user fees. The 
health system efficiently processed these resources. First, in GAVI-supported areas, the 
increase in the HepB3/DPT3 ratio (increased from 57% in 2002 to 94% in 2009), indicated 
indicating that EPI absorbed well the new vaccine. Second, institutionalized deliveries 
increased to reach 96% nationwide in 2009, indicating that maternal and child health services 
created conditions to maximize coverage of the timely birth dose. As a result, from 2002 to 
2009, the national three-dose hepatitis B vaccine coverage progressed from 71% to 93% 
(Chapter 5) and the timely birth dose coverage progressed from 60% to 91% (Chapter 7) with 
a reduction of inequities between Eastern and Western areas. Both of these resulted in 
immunity among vaccinated cohorts (85% of anti-HBs among children 12 to 23 months of 
age in the national 2006 serological survey) (Chapter 2). One key factor strongly associated 
with being HBsAg negative is receiving timely birth dose of hepatitis B vaccine as early as 
possible (Chapter 4). 
II 
Summary 
 
With respect to injection safety, input included 14 million USD of GAVI funds to 
supply auto-disable syringes, safety boxes and needle cutters. In 2009, auto-disable syringes 
and safety boxes were used in 78% and 79% facilities in GAVI supported areas of the 
Western areas, respectively (Chapter 6). In terms of output, sterilizable injection devices 
disappeared and attempts to re-use disposable injection equipment became rare (0% in the 
2010 final evaluation). However, no data regarding the incidence of injection-associated 
infections were available to evaluate the outcome of the progress in injection safety.  
With respect to social mobilization and training, 10 million USD were assigned to 
training between 2002 and 2009. Most of those were not directly funded by GAVI China. 
These funds were provided by the Government because of the leverage effect of the GAVI 
China project. These were used in 28,753 training workshops for health care workers that 
resulted in better knowledge among health care workers (In 2010, 98% of them knew that 
hepatitis B virus can be transmitted from mother to child) and guardians (In 2010, 89% of 
them knew that the first dose of hepatitis B vaccine had to be given in the first 24 hours of 
life). This higher level of knowledge also contributed to higher immunization coverage and 
safer injections.  
Ultimately, the elements of the GAVI China project combined at the impact level to 
prevent HBV infections. The 2006 national serological survey documented these 
achievements and pointed to 1% prevalence of HBsAg among children under five years of 
age, a decrease of 90% from the 9.8% prevalence in the same age group in 1992 (Chapter 3). 
These infections prevented will lead to the future prevention of cirrhosis, hepatocellular 
carcinoma. Those should result in early deaths prevented and benefits in terms of 
disability-adjusted life years (DALYs). However, in 2010, it was too early to measure these 
longer term effects and the final impact of the project on HBsAg prevalence had not yet been 
quantified. 
III 
Summary 
 
 
Conclusion: The introduction of hepatitis B vaccine into the national immunization 
programme was successful and the strategies and policy used for the GAVI China project 
provided a successful case study for the introduction of other new vaccines in China. The 
determinants of the success of the GAVI China included (1) a well documented disease 
burden, (2) a good collaboration between the government of China and the international 
GAVI Alliance that resulted in a strong national GAVI China project, (3) local production of 
vaccine and AD syringes, (4) solid processes for implementation and (5) leverage of 
additional support through national and provincial levels co-funding. Remaining challenges 
include (1) the persistence of an estimated 80,000 perinatal HBV infections each year in 
China, (2) the lack of homogeneous regulations to harmonize injection practices, (3) the 
absence of a scaled implementation for the national policy that recommends vaccination of 
health care workers, (4) the weak specificity and sensitivity of acute hepatitis B surveillance 
and (5) the absence of policy and plans for the management of chronic hepatitis B infection. 
We recommended that China (1) maintain universal hepatitis B infant vaccination, with a 
high priority to reach all infants, especially for those living in remote, mountain areas (2) 
make additional efforts to strengthen the health system and further improve hospital delivery 
rates to increase timely birth dose coverage and decrease perinatal HBV transmission, (3) 
develop clear surveillance guidelines to monitor acute hepatitis B rates (4) immunize health 
care workers, with an emphasis on pre-service delivery (5) collect manage sharps waste in a 
way that is safe for the health care workers, the community and the environment, and (6) 
screen pregnant women to administer adapted immuno-prophylaxis (including hepatitis B 
immune globulin, HBIG) for children born to those HBsAg positive. These should prepare 
the country for the next phase of a policy for the prevention and control of hepatitis B, which 
should ultimately include screening and treatment of patients with chronic infections, 
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particularly those of older age cohorts who were born before the era of universal 
immunization. 
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General Introduction 
 
General Introduction 
1. Hepatitis B in the world and in Asia 
1.1 HBV, its transmission and burden of disease 
Hepatitis B is a liver disease that results from infection with the Hepatitis B virus (HBV). 
It can range in severity from asymptomatic infection, to mild illness lasting several weeks, to 
a serious, lifelong illness. HBV is usually spread when blood, semen, or another body fluid 
from an infected enters the body of someone who is uninfected and susceptible. This can 
happen through sexual contact, blood transfusion and unsafe percutaneous exposures, 
including sharing of needles, syringes, or other drug-injection equipment. HBV can also be 
passed from an infected mother to her baby at birth [1] and through long-term close contacts 
among younger children. HBV is not spread by contaminated food or water, and cannot be 
spread through casual contacts in the workplace. HBV may be detected in the blood of the 
subject 30 to 60 days after initial infection and may persist for a variable period of time. 
HBV was discovered in 1965 and by 1970, diagnostic tests were available for routine 
screening of blood donors to prevent transfusion-transmitted hepatitis [2]. Antigens and 
antibodies associated with HBV infection include hepatitis B surface antigen (HBsAg), 
antibody to HBsAg (anti-HBs), antibody to the HBV core antigen (Anti HBc, including IgG 
and IgM), hepatitis B e antigen (HBeAg), and antibody to HBeAg (anti-HBe). The presence 
of a positive HBsAg result indicates current, active HBV infection. HBV DNA can be 
detected in all persons who are HBsAg positive and indicates active viral replication. All 
HBsAg-positive persons should be considered infectious. Anti-HBc antibodies appear at the 
onset of symptoms or liver test abnormalities in acute HBV infection and persist for life. 
Recently acquired infections, among which acute infections, can be distinguished by the 
presence of the IgM class of anti-HBc. They are detected at the onset of the new HBV 
infection and persist for up to 6 months. In patients who develop chronic hepatitis B, 
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IgManti-HBc can persist at low levels during viral replication (However, this is uncommon). 
The presence of anti-HBs typically indicates immunity resulting from naturally resolved 
HBV infection or from vaccination. In addition, anti-HBs can be detected for several months 
after hepatitis B immune globulin (HBIG) administration. Persons who recover from natural 
infection will typically be positive for both anti-HBs and anti-HBc, whereas persons who 
respond to hepatitis B vaccine develop only anti-HBs. HBV DNA has been detected in the 
blood of 5% of persons with isolated anti-HBc, suggesting that this marker profile can be 
associated with some level of viral replication. HBeAg can be detected in the serum of 
persons with acute or chronic HBV infection. The presence of HBeAg correlates with high 
levels of viral replication. 
All persons who do not acquire immunity are susceptible to HBV. Individual responses 
to HBV infection varies with age. Fewer than 10% of infected children under age 5 have 
initial clinical signs or symptoms of disease (i.e., acute hepatitis B), compared with 30% to 
50% of older children and adults. The risk of developing chronic HBV infection also varies 
with age: approximately 90% of infants infected during the first year of life develop chronic 
infection, compared with 30% of children infected between ages 1 and 4 years and 5% of 
persons infected as adults[3]. Male, cellular immune dysfunction, poor nutritional status are 
also associated with the risk of developing chronic infection. 
Hepatitis B can be either acute or chronic. Acute hepatitis B virus infection is a 
short-term illness that occurs within the first 6 months of exposure. The case fatality of acute 
hepatitis B is around 0.5%[4]. Acute infection rarely leads to chronic infection. Chronic 
Hepatitis B virus infection is a long-term illness and is a serious disease that can result in 
long-term morbidity, including cirrhosis, liver cancer (hepatocellular carcinoma), and even 
death. USA studies suggested that 90%-95% of newborns progressed towards chronic 
infections after being infected with HBV, and that of those, 15%-25% of persons with 
2 
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chronic HBV infection were at risk for premature death from cirrhosis and liver cancer [5, 6]. 
Chronic hepatitis B infection is a lifelong condition for most patients. Hepatitis B is difficult 
to treat. Response rate ranges from 20% to 60% for those receiving anti-viral treatment such 
as lamivudine, adefovir, entecavir, tenofovir or pegylated interferon. The cost of treatment of 
chronic hepatitis B is high, ranging from 4,907-12,450 RMB per year in China. Patients 
suffering from cirrhosis face much higher expenses [7]. While hepatitis B is difficult to treat, it 
is preventable. Options include preventing exposures to the virus through safe sex, safe and 
appropriate use of blood, safe and appropriate use of injections, implementation of universal 
precautions and risk reduction among injection drug users. However, the most effective 
prevention measure for the entire population is active immunization through vaccination [8]. 
In the year 2000, Goldstein used a model to estimate that 620,000 persons died each 
year worldwide from HBV-related causes. This included 580,000 (94%) deaths from chronic 
infection-related complications (i.e., cirrhosis and HCC) and 40,000 (6%) deaths from acute 
hepatitis B [7,9]. In 2010, WHO endorsed these estimate as a basis for worldwide estimates [9, 
10].  
In 2001, a WHO report classified the world into three levels of endemicity based on 
HBsAg prevalence [11]. In areas of high endemicity (>8% HBsAg prevalence in the general 
population) such as Asia and Africa, the lifetime risk for HBV infection is 60% or higher and 
most infections are acquired at birth or early in life. In the absence of any preventive 
measures, more than 70%～90% of infants born to HBsAg and HBeAg positive mothers will 
be infected and develop chronic infections within one year after birth. When the mother is 
HBsAg positive and HBeAg negative, 10% infants will be HBsAg positive within one year 
after birth. Therefore, perinatal transmission is an important mode of transmission in Asia, 
and Africa. Aside from perinatal transmission, horizontal transmission between young 
children, particularly siblings, has been reported. Such transmission within family circles 
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probably occurs through repeated exposures to small quantities of blood (e.g., cuts, bruises, 
abrasions) or sharing of skin-piercing instruments (e.g., razors, "family syringe"). However, 
there is no evidence that casual contacts (e.g., in schools) leads to transmission of HBV. Most 
of these infections in early childhood are asymptomatic. However, rates of chronic liver 
disease and liver cancer are high [10]. In areas of intermediate endemicity (2%-8% HBsAg 
prevalence in the general population), the lifetime risk for HBV infection ranges from 20% to 
60%, and infections occur in all age groups. Acute hepatitis B is common because many 
infections occur in adolescents and adults. However, high rates of chronic HBV infection are 
maintained primarily because of infections occurring in infants and children [12]. In areas of 
low endemicity (<2% HBsAg in the general population), the lifetime risk for HBV infection 
is less than 20%. For example, in 1999, the prevalence of chronic HBV infection in the 
United States was approximately 0.35% and approximately 5% of the general population had 
serologic evidence of HBV infection [12]. Most HBV infections in areas of low endemicity 
occur among adults engaging in high risk behaviours, but a high proportion of chronic 
infections may also occur as a consequence of perinatal and early childhood exposures [13]. 
Among global HBV associated deaths, 21% of were infected at birth, 48% in early childhood 
(<5 years old), and 31% were infected after the age of five. Overall, in 2009, a World Health 
Organization position paper reported that >2 billion people worldwide had been infected with 
HBV. Among those, 360 million people had current chronic HBV infection (6% of the global 
population, of which 2/3 lived in Asia, and 1/3 in China [10, 14].   
In the WHO Western Pacific Region, HBV is often acquired at birth. It can also be 
contracted later in life through exposure during childhood or adulthood. The Western Pacific 
Region, home to 28% of the global population, suffers disproportionately from hepatitis B, 
containing around 45% of all infected individuals. Of the approximately 278,000 deaths 
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attributed to hepatitis B in the region, the greatest proportion is from the consequences of 
chronic liver disease - either cirrhosis or hepatocellular carcinoma. 
 
1.2 Global milestones in vaccine development 
The first vaccines to prevent hepatitis B were developed in the mid1970's. Clinical trials 
conducted in the late 1970's reported efficacy greater than 90% in preventing chronic 
infection, and in 1981, hepatitis B vaccine was first licensed in the United States. 
Since 1982, safe and effective hepatitis B vaccines have been commercially available. 
The first available vaccines were produced by harvesting HBsAg from the plasma of persons 
with chronic HBV infection. Subsequently, in 1986, the development of recombinant DNA 
technology to express HBsAg in other organisms offered the potential to produce unlimited 
supplies of vaccine. Recombinant DNA vaccines are now predominantly used in all countries. 
Hepatitis B vaccines are formulated to contain 3μg to 40μgof HBsAg per milliliter with an 
aluminum phosphate or aluminum hydroxide adjuvant. In 2010, there were 9 international 
manufacturers of hepatitis B vaccine and 6 domestic manufactures in China (Table 1, Table 
2). 
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Table 1: Hepatitis B vaccines available internationally (WHO pre-qualified) and 
in China, 2010 
International market [15] 
Manufacturer Brand name† Country Type 
Berna Biotech Korea Hepavax-Gene South 
Korea 
Recombinant DNA 
Bio Farma Vaksin Hepatitis B Indonesia Recombinant DNA 
Center for Genetic Engineering 
and Biotechnology 
Enivac-HB Cuba Recombinant DNA 
GlaxoSmithKline Engerix-B Belgium Recombinant DNA 
Tritanrix-HB Belgium Combined DTPwP and 
recombinant DNA 
Tritanrix-HB-Hib Belgium Combined DTPwP-Hib 
and recombinant DNA 
LG Life Sciences Euvac B South 
Korea 
Recombinant DNA 
Merck Sharp &Dohme Recombivax HB United 
States 
Recombinant DNA 
Panacea Biotech Enivac B India Recombinant DNA 
Serum Institute of India Genevac-B India Recombinant DNA 
ShanthaBiotechnics Shanevac-B India Recombinant DNA 
China market 
Manufacturer Brand name and Type 
GlaxoSmithKline Engerix-B , Recombinant DNA 
Shenzhenkangtai Hepatitis B vaccine made by recombinant  
DNA techniques in yeast 
Beijing Tiantan Hepatitis B vaccine made by recombinant  
DNA techniques in yeast 
HuabeiZhiyao Hepatitis B vaccine made by recombinant  
DNA techniques in Chinese Hamster Ovary cell 
Dalian Hanxun Hepatitis B vaccine made by recombinant  
DNA techniques in HansenulaPolymorpha yeast 
Changchun Shengwu Hepatitis B vaccine made by recombinant  
DNA techniques in Chinese Hamster Ovary Cell 
Lanzhou Shengwu Hepatitis B vaccine made by recombinant  
DNA techniques in Chinese Hamster Ovary Cell 
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1.3 Global milestones in programme development 
Universal childhood immunization with three doses of hepatitis B vaccine in the first 
year of life is the most effective strategy to control hepatitis B. HBV vaccine became part of 
the recommended immunization schedule in the United States in 1991. There, it had been 
first recommended for use among high risk individuals, then scaled up for universal 
vaccination. In 1992, The World Health Assembly (WHA) set a goal for all countries to 
integrate hepatitis B vaccination into their routine childhood immunization programmes by 
1997[16]. In 1995, WHO suggested that countries and regions with HBsAg prevalence over 5% 
in population should implement the vaccination of all newborns with hepatitis B vaccine[8]. 
Economic analyses on vaccination against hepatitis B in different populations in the USA[17], 
Canada[18] and other countries have confirmed the cost-effectiveness of this approach[19-24]. In 
2004, WHO recommended that countries opt for vaccination schedules including a birth-dose. 
In some cases, this monovalent first dose given at birth comes in addition of three doses 
given later in the form of combination vaccine[25]. In 2009, 177 counties had integrated 
hepatitis B vaccine into routine immunization, and the coverage of timely hepatitis B vaccine 
birth dose (that is, given within 24 hours of birth) was recommended as a performance 
indicator for all immunization programmes[14]. 
In the Western Pacific Region, South Korea was one of the first countries to begin 
manufacturing hepatitis B vaccine. Several nations/areas including Brunei Darussalam and 
Hong Kong introduced the vaccine in 1983[26]. Most Pacific countries began using the 
vaccine by 1992, by which time the price had dropped significantly from 150 USD in 1980s 
to 15 USD in 1990s. In 2005, of the 25 of 37 countries in WPR reporting coverage data, 15 
reported coverage greater than 85%. Only 4 of these 25 countries (Philippines, Papua New 
Guinea, Vanuatu and Vietnam) reported coverage of less than 70%. Of the remaining 11 
countries/areas, one has chosen not to use the vaccine; four did not report progress and three 
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had only recently begun giving the vaccine. However, in 2005, WHO estimated that there 
were still around 3,824,000 infants in the Western Pacific Region each year not receiving full 
hepatitis B immunization, with nearly 66% of them living in China. In September 2005, 
Western Pacific became the first WHO Region to set a time-bound control goal for the 
reduction of chronic hepatitis B infection, hoping to reduce its prevalence to less than 2% 
among five-year-old children by 2012[27]. In 2010, WHO estimated that there were only 0.956 
million children not receiving hepatitis B vaccination in Western Pacific Region, with only 9% 
in China, indicating an impressive change (WPRO, unpublished data)[27].  
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Table 2: Milestones in prevention and control hepatitis B in China and in the world, 1975-2010 
Timeline 
Chinese milestones Key international 
milestones Burden of disease documentation 
Vaccine development  
and production 
Programme development  
and implementation 
Pre GAVI 
China 
years 
1975  Clinical trial of vaccine  Clinical trials of vaccines 
1979 First national 
sero-survey 
  Clinical trials of vaccines 
1981    Hepatitis B vaccines become available  
1982    Hepatitis B vaccine used in the United States  
1985  Plasma derived vaccine licensed    
1986   Pilot vaccination in partial counties Recombinant hepatitis B vaccine available 
1991 Hepatitis B reported 
by type in the national 
disease reporting 
system 
  EPI Global Advisory Board recommends inclusion of 
hepatitis B vaccine in national immunization 
programmes in high endemicity countries by 1995 and in 
all countries by 1997  
U.S. recommends universal vaccination of infants in 
1991.  
1992 Second national 
serosurvey 
Chinese Hamster Ovary vaccine 
licensed 
Universal vaccination recommended, but 
with cost incurred by parents 
World Health Assembly endorses EPI recommendation 
1993  Merck helps organizing a hepatitis 
B production line in China through 
technology transfer 
  
1994    World Health Organization sets goal of 80% reduction in 
the incidence of new HBV chronic infections among 
children by the year 2001  
1996  Yeast-derived vaccine available  First regional conference on prevention and control of 
hepatitis B in Central and Eastern Europe 
1997  HansenulaPolymorpha technology 
available in Dalian 
  
1998  Plasma derived vaccine production 
stopped 
  
2000  Plasma derived vaccine use 
stopped 
 GAVI alliance established to help improve delivery of 
traditional childhood vaccines and introduce new ones  
2001   China applied for GAVI support World Health Assembly resolution sets new goal of 90% 
coverage with three-dose regimen of hepatitis B vaccine 
for all children by 2015  
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Table 2: Milestones in prevention and control hepatitis B in China, 1975-2010 (Continued) 
Timeline 
Chinese milestones 
Key international milestones Burden of disease 
documentation 
Vaccine development  
and production 
Programme development  
and implementation 
GAVI China 
years 
2002   
GAVI China project launched, 
auto-disable syringes used 
 
2004   
National EPI review Third regional conference on prevention and control of 
hepatitis B in Central and Eastern Europe 
2005 Surveillance project in 18 counties 
 Free vaccination policy started Hepatitis B control goal voted by the WHO WPR regional 
committee  
2006 Third national sero-survey 
 National hepatitis B action plan  
2007   
EPI enlarged to include a total of 14 
vaccines (8 new antigens) 
 
Extension 
of 
GAVI China 
2008   
Extension of the GAVI China project, 
savings used for support to activities in 
under-performing areas 
 
2009   
Last year of the GAVI China project, 
catch-up campaign for children under 
15 
 
After GAVI 
China 2010   
Final evaluation of the GAVI China 
project  
New WHO resolution on comprehensive approaches to 
prevention and control of viral hepatitis  
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2. Hepatitis B and its prevention in China 
2.1 Progress in burden of disease documentation 
In 1979, China conducted a national serosurvey. Results indicated that the prevalence of 
HBsAg was 8.9% among persons 1-59 years of age. Prevalence of HBsAg was 9.2% among 
children under 5 and peaked among children 5-9 (10.6%). HBsAg prevalence clustered 
among families. Families with more than one case of HBsAg infection accounted for 27.3% 
of the total. Within families, the HBsAg status of the parents, especially the mother, was 
strongly associated with the status of the children. The prevalence of HBsAg among children 
was higher in mother-positive families than that in mother-negative families[28]. Although the 
HBsAg test used lacked sensitivity, HBsAg prevalence was higher in men than in women 
(10.3% among males versus 7.3% among females)[29]. Overall, this suggested that hepatitis B 
was widely endemic in China, with most infections occurring among the youngest age groups. 
Furthermore, perinatal transmission was a major mode of transmission, and the high 
prevalence of HBsAg among children also contributed to the high burden of disease[30,31].  
In 1992, a second sero-epidemiological investigation of viral hepatitis in the whole 
country reported that 57.6% of the population had evidence of past or present HBV infection 
(Anti-HBc). The prevalence of HBsAg was 9.8% in the general population[32]. The 
prevalence of HBsAg among children under 5 was as high as among persons above 15. This 
suggested a high frequency of perinatal transmission, in agreement with the results of the 
1979 sero-survey. Based on these prevalence estimates, China CDC estimated that 690 
million people had been infected with HBV in the country, and that among those, 120 million 
people were chronically infected [32]. HBsAg prevalence was higher in men than in women 
(11.3% among males versus 8.2% among female in 1992) (P<0.01). The prevalence of 
anti-HBs was also higher among men than among women (28.9% versus 27.5%, p<0.01) [29] .   
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In 2005, a study documented the rates of progression from chronic hepatitis B towards 
cirrhosis and from cirrhosis towards hepatocellular carcinoma among chronic HBV infection. 
These rates at five year were 9% and 5%, respectively. In addition, the study suggested that 
260,000 people died of hepatitis B related diseases each year in China [33], accounting for a 
third of global HBV-related deaths. Chinese studies also estimated that there were 30 million 
chronic hepatitis patients in the country, and about 250,000-300,000 persons dying of HBV 
infection-associated consequences each year. Among chronically infected patients in China, 
only a small number (0.6%-6.6% per year) become HBsAg negative each year [34]. Therefore, 
newborns constitute the priority group for hepatitis B prevention.  
In 2005, a study conducted by the Chinese Foundation for Hepatitis Prevention and 
Control estimated that the cost of outpatient and hospitalized patients was 17,988 RMB (USD 
2,500) each year for each case of chronic hepatitis B. Based on the estimated 20 million 
hepatitis patients in the country, the direct economic loss from hepatitis B is 360 billion USD 
each year, while Chen estimates the direct medial loss caused by hepatitis is up to 900 billion 
RMB (USD 128 billion) each year in China [35]. 
 
2.2 Progress in vaccine development 
2.2.1 The development of hepatitis B vaccine 
In 1975, China began the development of hepatitis B vaccines. In 1985, domestic plasma 
derived hepatitis B vaccine was licensed. In 1992, recombinant Chinese Hamster Ovary 
(CHO) cell Hepatitis B vaccine was developed and China imported a recombinant yeast 
hepatitis B production line from American Corporation Merck. In 1993, middle term testing 
was completed and in 1995, the State Food and Drug Administration (SFDA) allowed 
production for a yeast derived, recombination hepatitis B vaccine. In 1995, German 
Rheinland limited company developed the recombinant HansenulaPolymorpha Hepatitis B 
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vaccine, which improved the production capacity of vaccines. In 1996, China began 
producing hepatitis B vaccine using the technology transferred from Merck, and the 
production capacity rose to 60 million doses each year. In 1997, China developed and 
licensed recombinant Hansenula yeast engineered bacteria vaccine. Since then, recombinant 
Hansenula yeast engineering has been used widely in eastern China. In 1998, the Ministry of 
Health (MoH) stopped the production of haematogenous hepatitis B vaccine and in 2000, the 
MoH stopped using this plasma derived Hepatitis B vaccine. In 2010, Chinese hepatitis B 
vaccines produced in China included the recombinant hepatitis B vaccine from beer yeast, 
HansenulaPolymorpha and CHO cells [36]. 
 
2.2.2 Progress of hepatitis B vaccine introduction in China 
In 1978, China began the expanded programme on immunization (EPI), and provided 
bacillus Calmette-Guerin (BCG), oral poliomyelitis vaccine (OPV), diphtheria, tetanus, and 
pertussis vaccine (DTP) and measles vaccine (MV). When plasma-derived hepatitis B 
vaccine became available in 1986, vaccination was only implemented among high risk 
populations in urban areas. No recommendations from the MoH framed this use. Vaccination 
took place on a voluntary basis and was paid for by users. Its price included the cost of the 
vaccine, the syringes and the administration fee.  
In 1992, the China MoH recommended the introduction of Hepatitis B vaccine into 
routine immunization management. Although the national policy encouraged infant 
vaccination and timely birth dose, parents had to pay for the cost of the vaccine, which the 
government could not afford at that time. Because of the high cost, hepatitis B vaccination 
was only implemented among children living in rich and urban areas [37-39]. Coverage of three 
dose of hepatitis B vaccine reached 30% in 1992 [40,41]. Seven years later, in 1999, China 
conducted a national EPI review, which included a coverage survey. The EPI review also 
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addressed injection practices. Result indicated that hepatitis B coverage had increased to 70.7% 
overall (88.5% in urban areas and 62.7% in rural areas). The timely birth dose (TBD, the first 
dose given within 24 hours of birth) coverage was only 29% [42]. Coverage remained low 
overall, especially among children in the Western region and the poverty-affected counties of 
the Central region. Studies suggested that cost was one of the important factors that 
constrained vaccination. With respect to injection safety, grass root level clinics had 
comparatively high rates of unsafe injection practice. Disposable syringes were re-used and 
the level of knowledge about safe injection was poor [43]. Therefore, the Chinese government 
was eager to obtain funds to integrate hepatitis B vaccine into routine immunization and to 
improve injection safety. In 2002, following a Chinese application, the GAVI alliance 
provided the funds to pay for hepatitis B vaccine and injection devices in Western areas and 
in poverty-affected counties in the Central region. This provided the resources that were 
missing in China to fully integrate hepatitis B vaccine into routine immunization national 
wide. 
 
3. The GAVI China project 
3.1 Origins of the project 
Since most chronic HBV infections were acquired early in life, universal vaccination for 
infants and children was a priority for China. In 2002, with support from the GAVI alliance, 
the central government fully integrated hepatitis B vaccine into routine immunization and 
provided free vaccine and syringes for all infants in the Western region and in 
poverty-affected counties in the Central region. China received GAVI support because of (1) 
high prevalence of HBsAg, (2) low vaccine coverage in areas where economic status was 
poor, (3) a gross domestic product (GDP) per capita < $1,000 with a government that could 
not afford universal free vaccination and (4) political commitment to protect infants at risk. 
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3.2 The introduction of the GAVI China project 
According to memorandum of understanding (MOU) that framed the GAVI China 
project, GAVI China supported the 12 Western project provinces (2002 population: 367 
million). In addition, in the 10 middle provinces (2002 population: 507 million), GAVI China 
also supported 223 poverty-affected counties (2002 population: 107 million, 21% of the 
population of the middle provinces) (Table 3). 
 
Table 3: GAVI China project support by region, 2002 
Eastern (No GAVI fund) Central (Partially funded) Western (Fully funded) 
Beijing, Fujian, Guangdong, 
Jiangsu, Liaoning, Shandong, 
Shanghai, Tianjin, and 
Zhejiang. 
Anhui, Hainan, Hebei, 
Heilongjiang, Henan, Hubei, 
Hunan, Jiangxi, Jilin, and 
Shanxi. 
Chongqing, Gansu, Guangxi, 
Guizhou, Neimenggu (Inner 
Mongolia), Ningxia, Qinghai, 
Shaanxi, Sichuan, Tibet, 
Yunnan, and Xinjiang 
Source: China GAVI MOU 
 
In GAVI supported areas, the project supported provinces through provision of hepatitis 
B vaccine and auto-disable (AD) syringes for all childhood vaccinations. The project covered 
1,301 counties in 22 provinces for a total population of 470 million persons and an average 
birth cohort of 5.6 million each year. The goal of the project was to achieve universal infant 
hepatitis vaccination in GAVI project areas, reaching 85% coverage for three dose of 
hepatitis B vaccine and 75% for TBD at the county level. In addition, the project planned to 
introduce AD syringes to improve the safety of injection in all counties by the end of project. 
GAVI alliance and the Chinese government shared funding responsibilities for the 
GAVI China project. Of the total GAVI China project funds of 76 million USD, 50% came 
from the international GAVI alliance and 50% came from the Chinese government. The 
GAVI China project funds covered 100% of the cost of the hepatitis B vaccine itself and 100% 
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of the cost of the AD syringes used for hepatitis B vaccination. In addition, with respect to 
the cost of AD syringes for other vaccines included in the national immunization programme, 
it funded (1) 70% of the cost in Western areas and in the poverty-affected counties of 6 
Central provinces and (2) 50% of the cost in the poverty-affected counties of 4 other Central 
provinces. This additional support for injection safety over and beyond what was strictly 
necessary for hepatitis B vaccine was designed to facilitate transition from sterilizable 
syringes to AD syringes in the whole EPI system.  
The MoH took the responsibility making arrangements with the Ministry of Finance for 
the flow and the management of funds. MoH also took responsibility for centrally-managed 
procurement, and for the coordination and monitoring of the procurement conducted by the 
provinces. Activities supported by the government at all levels included the routine EPI work, 
including logistics, health care workers, and surveillance. Aside from GAVI China project 
funds, additional government funding contributed to support new training needs, information 
and communication, project management, supervision and monitoring. The government also 
agreed to work towards improving the EPI reporting system at the county level to improve 
monitoring. At the central level, MoH and GAVI alliance created a project office, which was 
a unique model for project management. The national manager and an international project 
co-manager/consultant ran the project office, were responsible for routine work and 
developed the project indicator: the HepB3/DTP3 ratio and the DTP1/HepB1OT (Hepatitis B 
first dose on time) ratio. Since children who received DTP3 should also received three dose 
of hepatitis B vaccine and since children receiving DTP1 should also receive hepatitis B first 
dose on time, GAVI China was able to use these ratios as process indicators of the 
progressive introduction of hepatitis B vaccine into the EPI system. An Operational Advisory 
Group (OAG) of the project was constituted of the MoH, China CDC, GAVI alliance 
representatives, UNICEF, and WHO. The OAG met every year and made all key decisions 
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relevant to the GAVI project. Overall, the managerial structure of the GAVI project provided 
a conduit for policy dialogue and technical exchanges while the Chinese Government had full 
responsibilities over the implementation.  
The government also ensured that the following inputs were available to the project:  
(a) Local counterpart professional staff and other services, including national 
counterparts to operational experts;  
(b) Land, buildings, training and other facilities available or produced within the 
country; 
(c) Equipment, materials and supplies available or produced within the country. 
 
3.3 The main project years (2002-2007) 
3.3.1 Implementation 
The investment: The scheduled investment of the GAVI China project amounted to 76 
million USD, paid 50% by GAVI alliance and 50% by the government of China (300 million 
RMB). The central and sub-national levels shared a common responsibility, provided the 
co-funding to the project, including cost for AD syringes and operational cost of training, 
supervision, surveillance and management.  Between 2002 and 2007, during project years, 
the central government invested 180 million RMB each year for hepatitis B vaccine and AD 
syringes in GAVI China project areas. Aside from the GAVI China contribution, the 
government invested a total of 227 million RMB for cold chain, surveillance, operational 
costs and Information, Education and Communication (IEC) costs during the project. The 
provincial governments in the Western and Central areas invested 96 million RMB for (1) 
co-funding for AD syringes and (2) operational cost of training, supervision, surveillance and 
management. Overall, from 2002 to 2007, the Chinese government invested an additional 203 
million RMB in the GAVI China project in addition to the original 300 million given as the 
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50% contribution of China to the GAVI China project. Using the GAVI China funds, 
between 2002 and 2007, the GAVI China project provided 29,282,364 person doses of 
hepatitis B vaccine (one person-dose=three doses, enough to fully vaccinate one person), 
206,649,679 auto-disable (AD) syringes, and 150,154 safety boxes (Table 4). 
Strategies: In collaboration with GAVI China, the Government of China implemented a 
number of activities, including (1) increasing awareness of the importance of TBD among 
providers and parents, (2) intensifying training for health care workers (HCWs), (3) 
monitoring and supervision of vaccination activities, (4) improving hospital delivery rates 
through provisions of subsidies for hospital deliveries, (5) building bridges between delivery 
service (maternal and child health, MCH) and vaccination service (EPI) and (6) subsidizing 
providers.  
Social mobilization: The GAVI China project developed IEC material and conducted 
social mobilization activities in 22 provinces. Data from 22 provinces between 2002 and 
2009 indicated that provinces invested 4.45 million RMB, 200 prefectures invested 8.28 
million RMB, and 1,301 counties invested 55.62 million RMB for social advocacy, media, 
posters, and banners to deliver information to the public.  
Training: Between 2002 and 2009, the GAVI China project office at the national level 
conducted 5 workshops and trained 540 participants from 22 provinces. 22 provinces 
conducted 328 workshops and trained 36,610 professionals. 200 prefectures conducted 2,754 
workshops, and trained 119,122 professionals. 1,301 counties conducted 25,671 workshops 
and trained 991,542 professionals. Finally, 23,047 townships conducted 114,358 workshops, 
and trained 5,350,879 village doctors. All HCWs at each level received at least one training 
during the project period (Table 5 and Table 6). 
During 8 years of project implementation, 193,000 health care workers in 118,316 
health care facilities participated in the project, mostly at the township hospitals level (55,051) 
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and in health community centers (104,547). In each county of the Western region, as a result 
of Government co-investment in EPI, EPI staff increased from an average 29 in 2002 to 66 in 
2009 number of workers. GAVI China project areas also benefitted from training, supervision 
and capacity building.  
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Table 4: Inputs of GAVI China project, from the GAVI Alliance and the Government of China, data are shown in RMB (2002-2007) 
  Items 2002 2003 2004 2005 2006 2007 2008 2009 2010 Total 
Funds 
disbursements 
in RMB 
Vaccine 56,103,663 45,198,130 35,999,817 36,000,000 20,780,322 1,241,600 
   
195,323,532 
AD syringes 10,890,337 26,471,593 12,910,952 13,381,463 9,678,134 24,047,643 
   
97,380,123 
Serosurvey     4,440,000 
    
4,440,000 
Catch-up campaign 
and Demonstration 
project to improve 
TBD 
      50,332,459  56,300,000 106,632,459 
Information system         53,550,000 53,550,000 
Commodities 
procured 
Vaccine* 7,099,340 6,325,925 5,038,488 5,142,858 5,355,753 320,000 
   
29,282,364 
AD syringes 21,298,022 49,419,810 24,958,904 31,718,178 18,258,244 60,996,521 
   
206,649,679 
Safety boxes  150,154 
       
150,154 
Needle cutters          0 
Input per live 
birth 
GAVI China project 
Birth cohort  5,843,662 5,680,529 5,481,887 5,406,975 5,422,372 
    27,835,425 
Vaccine doses/birth 1.21 1.11 0.92 0.95 0.99 
    
- 
AD syringes/birth  3.64 8.70 4.55 5.87 3.37 
    
- 
Government 
co-funding 
Province level 100,000 5,766,000 11,505,000 14,108,100 18,236,400 22,492,300 6,821,600 16,831,700 
 
95,861,100 
National level   17,260,000 24,610,000 40,400,000 25,970,000 43,921,213.2 37,414,366.8 37,414,366.8 226,989,947 
* 1 person dose= 3 doses 
# In 2002, AD syringes were procured for hepatitis B vaccine only, in 2003, AD were procured for two years. 
1 USD=7.28-8.28 RMB (2002-2007) 
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Table 5: Summary of the training sessions conducted during the implementation of the GAVI China project, 2002-2009 
Year 
Provincial Prefecture County Township 
# Training 
sessions 
# persons 
trained 
# Training 
sessions 
# persons 
trained 
# Training 
sessions 
# persons 
trained 
# Training 
sessions 
# persons 
trained 
2002 28 1,760 128 3,210 1,197 34,338 5,357 116,446 
2003 31 13,988 292 9,671 2,789 104,741 12,924 677,504 
2004 46 3,118 314 10,370 2,969 99,186 13,097 660,238 
2005 49 3,743 335 13,593 2,862 109,728 16,919 676,713 
2006 55 3,120 391 14,286 3,828 130,591 16,607 756,633 
2007 31 3,108 360 15,401 3,716 142,498 15,647 754,459 
2008 39 3,274 436 20,236 3,957 174,832 18,293 824,583 
2009 49 4,499 498 32,355 4,353 195,628 15,515 884,303 
Total 328 36,610 2,754 119,122 25,671 991,542 114,359 5,350,879 
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Table 6: Content of the training sessions and targeted participants, GAVI China 
project implementation, 2002-2009 
Year Training material Targeted participants 
2002 1. Project implementation and management 
2. Vaccine and AD management 
Project managers of 
provinces 
2003 1. Injection safety and improving training for use of AD syringes 
2. Hepatitis B vaccination and data reporting 
National training for 
provincial  project 
managers and enhanced 
training in Tibet, Qinghai , 
Ningxia and Chongqing 
2004 1. Evaluation of training on hepatitis B and injection safety 
2. Training of the Trainers (TOT)  to improve skills on 
immunization with hepatitis B vaccine and safe injections 
Provincial staff from CDC 
and health bureau 
2005 1. Training to update the knowledge of safe injection and to 
improve the practice of AD syringe use 
2. Meeting to exchange experiences 
3. Middle term evaluation 
Provincial staff 
2006 1. Safe injection training courses to update knowledge and 
improve the practice of AD syringe use.  
2. Data management 
Provincial staff 
2007 1. Experience regarding improving timely birth dose 
2. Data auditing and programme monitoring 
Provincial staff 
2008 Guideline for GAVI China savings utilization and evaluation Provincial staff 
2009 Guideline for GAVI China savings utilization and evaluation Provincial staff 
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3.3.2 Policy decisions 
In 2002, hepatitis B vaccine was integrated into China’s national immunization 
programme. Since then, hepatitis B vaccine and AD syringes for infants have been provided 
for free either though GAVI China project in Western region and poverty-affected counties in 
Central region, or by the provincial government in other counties in the Central region and 
Eastern regions. However, user fees (around 1 USD for three doses) were still charged until 
2005. The regulation on “Vaccine Circulation and Vaccination Management” issued in 2005 
by the Ministry of Health recommended recombinant yeast hepatitis B vaccine or 
recombinant CHO hepatitis B vaccine for use in China with an immunization schedule of ‘0, 
1, 6’, which required immunization of infants 24 hours after birth, 1 month after birth and 6 
months after birth, respectively.  
In 2005, the State Council issued the regulation on ”Vaccine Circulation and Vaccination 
Management," which required implementers to give all vaccines integrated into routine 
immunization at no cost [44]. Since June 1, 2005, a national policy banned the user fee and all 
hepatitis B vaccination has been provided to all newborns for free. This important document 
assured the sustainability of EPI and indicated that hepatitis B vaccination of infants was the 
responsibility of the government [45, 46].  
In 2006, to strengthen the prevention and treatment of hepatitis B, the MoH classified 
hepatitis B as one of the four key diseases (the others being AIDS, TB and schistosomiasis) 
and issued the 2006-2010 National Plan on Hepatitis B Prevention and Control (January 2006) 
[47]. The objectives of the plan were to (1) preferentially protect the neonates and the most 
susceptible populations through prevention, (2) reduce the incidence of hepatitis B, (3) 
decrease HBsAg prevalence in China and (4) reduce the mortality caused by cirrhosis and/or 
cancer of the liver resulting from hepatitis B by 2010. Multiple year guidelines were issued 
between 2006 and 2010.   
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Since 2006, in collaboration with the Ministry of Education, the MoH carried out regular 
school entrance immunization checks to provide a second opportunity for those who had 
missed vaccination at an earlier age.   
In 2007, the government of China integrated 14 vaccines into its national immunization 
programme and provided funding for all vaccines (including hepatitis B vaccine) and AD 
syringes for all provinces.  
In 2007, GAVI China planned a catch-up campaign for children under 5 years (born after 
GAVI China project) starting in 22 provinces, and completing it in 2008, immunizing 1 
million children (Table 7). 
 
3.3.3 Remaining problems: Need for programme activity funds 
According to the project memorandum of understanding, the GAVI China funds only 
paid for the cost of hepatitis B vaccine and the cost for AD syringes during the years of the 
project (i.e., equipment and supplies). However, because of imbalances in economic 
situations in the various areas of China, there was often a shortage of operational funds at the 
prefecture and county level that affected training, supervision and monitoring. The local 
health bureaus did not fully pay subsidies to HCWs and as a result, HCW did not have 
incentives to work on vaccination. Thus, limitations on the use of GAVI China funds for 
activities became a bottleneck for vaccination. Health departments needed enough program 
activity funds to ensure universal hepatitis B vaccination. 
During the project implementation, several reasons resulted in GAVI savings. Those 
included (1) smaller birth cohorts than originally estimated, (2) lower price of vaccine and 
AD syringes, and (3) the national government paying its full share from beginning. This left 
GAVI China funds unspent.Hence, from 2006 onwards, GAVI China savings were assigned 
to support operational costs in low performing areas with flexibility given for expenditure so 
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that human resources could also be covered. In 2006, as part of this GAVI China saving 
expenditure plan, 4.44 million RMB was used to conduct a national wide serosurvey to 
monitor the HBsAg prevalence among the population aged 1-59, and to evaluate the impact 
of vaccination for children born after 1992 (when hepatitis B vaccine was integrated into EPI 
management). The results of this serological survey are reported in Chapter 2, 3 and 4. 
 
3.4 The extension years (2008-2009) 
The original project duration was 5 years from 2002 to 2007, but because of savings 
accumulated during implementation, GAVI alliance and MoH made an agreement to expand 
the project to the end of 2009, which allowed China to spend all savings while focusing on 
strengthening programme activities. As a result, China went through four stages of hepatitis 
B vaccine integration into routine immunization. 
First, between 1992 and 2001, parents were charged the vaccine and the user fee. 
Second, between 2002 and 2005, parents were only charged the user fee. 
Third, between 2005 and 2007, all vaccination was provided for free. Policy support 
from the national government assured sustainable funding for hepatitis B vaccination, which 
not only provided for the cost of vaccines and syringes, but also the cost of the subsidies to 
the health care providers 
Fourth, from 2008 onwards, the Central government took over the cost of vaccine and 
AD syringes in the whole country. Hence, GAVI China project savings allowed the provision 
of operational funding to improve timely birth dose, catch-up campaign, and support hepatitis 
B vaccination relevant activities such as training and social mobilization(Box 1).  
In addition, GAVI China project office monitored immunization coverage by county 
using the indicators of HepB3/DTP3 and HepB1OT/DTP1, and provided specific activities in 
low performance prefectures and poverty-affected counties, including training, supervision, 
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and demonstration projects. In 2008, the GAVI China project allocated 50 million RMB in 
savings to all 666 national poverty-affected counties. This enhanced training and supervision 
for better performance in counties and provided special support to those low performance 
prefectures where it provided funds to improve the timely birth dose, train health 
professionals, conduct supervisions, and implement social mobilization. In additional, GAVI 
China provided 28 million in 666 poverty-affected counties to conduct the campaign among 
children born after 2002(Table 7).  
In 2009, the national government started to conduct catch-up immunization for children 
under 15 years of age, and GAVI China provided savings for operational costs in 22 
provinces. Altogether, 62 million children were targeted for vaccination in 2009, 2010 and 
2011 (Table 7). The costs for the vaccine and injection equipment were entirely covered by 
the MoH. 
 
3.5 The final extension year (2010) 
At the end of 2009, funds remained in the GAVI China account because (1) the Chinese 
government decided to cover the main costs of the catch up vaccination for children under 15 
years of age and because (2) the H1N1 pandemic slowed down use of the GAVI China funds 
in 2009. Hence, in 2010, another calendar year of extension was negotiated between GAVI 
alliance and MoH to spend left over funds. This allowed MoH to have one last year to use the 
GAVI China savings. A major component of the use of the GAVI China savings for the last 
year was an investment in the Chinese information management system (53.55 million RMB, 
43% of the final savings). In addition, other activities included project evaluation and other 
activities to facilitate a smooth closure of GAVI China and to spend the last of GAVI China 
project savings. Those included (1) pilot projects for timely birth dose administration, (2) IEC 
activities, and (3) operational funds for the catch up campaign in poor areas. These GAVI 
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China project savings also provided 32.7 million RMB to fund programme operations for the 
catch-up campaigns in 22 provinces (there was no need for vaccine and AD syringe funding 
since the Chinese government already paid these costs) and provided 23.6 million RMB for 
improving timely birth dose in 29 prefectures with timely birth dose <75% (Table 8).  
 
Table 7: Summary of the hepatitis B catch up vaccination activities among children in 
China, 2008-2011 
Year Location Objective Implementation 
strategy 
Target 
population 
Children 
reached 
Funding  
2002-7 
16 provinces  Improve 
coverage  
School entrance 
and routine 
immunization 
Children 
under five 
years of age 
8 million Government 
funds and cost 
recovery  
2008 
666 
poverty-affected 
counties in 
Western and 
Central areas 
(GAVI-supported 
areas) 
Immunize 
children 
born after 
project 
launch who 
had missed 
vaccination  
Catch-up 
campaign 
Children born 
between 2002 
and 2004 
(Under five 
years of age) 
1 million GAVI China 
(Vaccine, AD 
and subsidies) 
2009-11 
Nationwide Immunize 
all children 
under 15 
Catch-up 
campaign  
Children born 
between 1994 
and 2001 
62 million Government of 
China (Vaccine 
and AD) 
GAVI China 
savings 
(Operational 
costs in GAVI 
supported 
areas) 
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Box 1: Policy decisions relevant to hepatitis B vaccine introduction, China, 
1992-2008 
Year Key decisions 
Subsequent situation 
Progress Remaining issues 
1992 
Hepatitis B vaccine 
included in EPI 
management 
China government takes 
responsibility for 
administration of the 
vaccine and monitors 
coverage 
Parents charged the 
vaccine, the syringe and 
the user fee 
2002 
Hepatitis B vaccine fully 
integrated into EPI, with 
vaccine and syringes free 
of charge 
Vaccine and syringes 
provided for free 
Parents still charged a user 
fee 
2005 
Users fee abolished 
through provision of 
subsidies to vaccinators by 
the central government 
All vaccination provided for 
free 
Hepatitis B vaccine and 
syringes still funded though 
GAVI China in 
GAVI-supported areas 
2008- 
Central government took 
over the cost of vaccine 
and AD syringes in the 
whole country, provided 
operational funding and 
subsidies 
Sustainability ensured  Additional efforts needed 
to reach the unreached 
(e.g., remote, rural areas, 
migrant) 
 
 
Table 8: Funding envelopes from the GAVI China savings approved for use by the 
OAG (million RMB) 
 Sero- survey IEC 
Training 
and 
super- 
vision 
Activities for 
the catch up 
campaigns 
Birth 
dose 
pilot 
project 
Final 
evaluation 
End of 
project 
activities 
Information 
system Total 
2006 4.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.44 
2007 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2008 0.00 1.38 11.07 27.89 10.00 0.00 0.00 0.00 50.34 
2009 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2010 0.00 6.80 0.00 32.70 23.60 3.70 4.78 53.55 125.13 
Total 4.44 8.18 11.07 60.59 33.60 3.70 4.78 53.55 179.91 
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3.6 Wrapping up the GAVI China project 
In 2010, GAVI China office started to implement a package of activities to ensure a 
smooth closure of the project, according to the agreed upon goals. These activities included:  
 Conducting a final evaluation to evaluate the input, process, the output, outcome and 
impact of the GAVI China project. 
 Conducting a scientific review, bringing back the various stakeholders of the project 
to document achievements and provide vision in terms of the next challenges in viral 
hepatitis prevention and control in China.  
 Developing an advocacy package on the success of the GAVI China project, 
including a movie, calendar posters, and media advertisement.  
 Auditing the financial management of the project  
 Conducting an external evaluation before project closure. 
 Organizing a high level summary meeting for the project closure. 
  
3.7 Need of an evaluation 
A high quality evaluation of the GAVI China project was important for a number of 
reasons. First, GAVI China received a large investment from the GAVI alliance and from the 
Government. Second, the GAVI Alliance and the Government of China needed a good 
understanding of the relations between input, process, output, outcome and impact. This 
information regarding returns on investment could impact future commitment in the field of 
immunization. Third, documentation of the work in promoting timely birth dose could help 
WHO and other partners regaining support from the GAVI Alliance (As global support to this 
area of work has been minimal in the recent years). Fourth, China evaluations on timely birth 
dose and equity in immunization are relevant to many countries in the Western Pacific region 
that struggle to meet immunization targets largely due to challenges with reaching their 
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impoverished populations. Fifth, the Government of China wanted to seize the opportunity to 
generate a comprehensive evaluation for this large-scale programme. Such comprehensive 
evaluation for large-scale programmes are often not undertaken because of a lack of 
resources, a lack of time, or simply because interventions are assumed to be effective. 
However, the complexity and multiple simultaneous factors influencing outcome should not 
deter public health stakeholders from trying to document these situations in the best possible 
way.  
The various evaluation elements of the China GAVI project were brought together as a 
single piece of work. While some components of the GAVI evaluation were conducted in 
2006 (the serological survey), others were conducted in 2010 using the last portion of the 
GAVI savings. The overall objectives of the evaluation work were to measure the progress 
and to learn the achievements and challenges of the project. The evaluation included 
reviewing the project documents (including GAVI annual project reports), conducting field 
investigations, interviewing HCWs and parents and analyzing the vaccine coverage data 
available. This evaluation was organized according to a logic model (Box 2). 
Structural elements that were essential to the project included (1) its integration with 
the National Immunization Programme (NIP), (2) its cooperative management based on a 
national and international co-manager and an Operational Advisory Group (OAG) that made 
all the key decisions, (3) the domestic procurement and (4) the decentralized implementation 
at the provincial level and below.  
Elements of the GAVI China project included (1) hepatitis B immunization, including 
timely birth dose, (2) injection safety and (3) social mobilization and training. 
With respect to hepatitis B immunization, input included the GAVI China project 
funds to supply vaccine and the subsidies to the health care workers after 2005. These were 
used by the immunization services (process) to obtain programmatic outputs that included 
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timely administration of the first dose within 24 hours and completion of the three-dose series. 
The national immunization programme schedule was shown in box 3. Both of these resulted 
in immunity in the population (outcome).  
With respect to injection safety, input included the GAVI China project funds to supply 
auto-disable syringes, safety boxes and needle cutters. These were used by the immunization 
services (process) to administer safe injections (output), which resulted in the reduction of 
injection-associated infections (outcome).  
With respect to social mobilization and training, input included the resources assigned 
locally for Information, Education and Communication (IEC). Most of those were not 
directly funded by GAVI alliance but leveraged during the implementation of the project. 
These were used to train health care workers and produce material (process) that resulted in 
better knowledge but also in higher immunization coverage and safer injections (output).  
Ultimately, the output of the elements of the GAVI China project combined at the 
impact level to prevent HBV infections, which led to prevention of cirrhosis and 
hepatocellular carcinoma and ultimately to the prevention of early deaths and benefit in terms 
of disability-adjusted life years (DALYs).  
While the introduction of this dissertation reviews the input into the GAVI China project, 
chapters 1 to 7 will examine process, output and impact. In the report, we describe what the 
GAVI China project has done with respect to immunization, injection safety and social 
mobilization and the input, process, the output, outcome and impact of the GAVI China 
project to hepatitis B vaccination and safety injection in China (Box 2).  
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Box 2: Logic model of the GAVI China project, 2002-2009 
Structure 
- Integration within the National Immunization Programme 
- Management structure (Advisory Operational Group), national and 
international co-managers 
- National procurement 
- Decentralized management 
Elements Immunization against hepatitis B 
Social mobilization 
and training 
Injection safety 
Input 
- Funds for hepatitis B 
vaccine 
- Subsidies to health care 
workers (from 2005) 
- IEC material 
- Funds disbursed 
- Funds for AD syringes 
- Funds for safety boxes 
Process 
- Immunization services 
- Hospital deliveries  
- People trained - Use of AD in EPI  
- Use of safety boxes in 
EPI 
- Use of needle-cutters  
Output 
 
- Knowledge  
- Timely birth dose 
- Completion of three dose hepatitis B 
vaccine schedule 
- Safe injections 
Outcome - Immunity in the population - No injection associated infections 
Impact 
- Infections prevented  
- Cirrhosis/Hepatocellular carcinoma cases prevented  
- Deaths prevented 
- DALY averted 
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4. Goals and objectives 
The goal of this work was to review the process of hepatitis B introduction, develop an 
evidence base upon which countries could make decisions regarding national policies for the 
new vaccine introduction. The specific objectives included: 
1. Describe the progress in hepatitis B prevention through universal infant vaccination- 
China, 1997-2006 (Chapter 1) 
2. Evaluate the impact of hepatitis B vaccination among children born during 1992–
2005 in China (Chapter 2) 
3. Describe the prevalence of hepatitis B among general population aged 1-59, to 
describe the strength of the association between HBV prevalence and Hepatitis B vaccination 
(Chapter 3) 
4. Determine the factors associated with effectiveness of the first dose of hepatitis B 
vaccine in China -1992-2005 (Chapter 4) 
5. Evaluate the inequities in hepatitis B prevention: results from final evaluation of the 
GAVI China project (Chapter 5) 
6. Access the immunization injection safety in China, 2010: progress and residual 
challenges (Chapter 6) 
7. Examine the status of progress towards the elimination of mother to child 
transmission of hepatitis B virus in China (Chapter 7)  
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Box 3: Vaccination schedule for the National Immunization Programme, China, 2007 
Vaccine Age of Targets Number of doses Site of vaccination Vaccination route 
Dosage 
/dose 
Remark 
Hepatitis B vaccine 0, 1, 6 month 3 Upper arm deltoid Intramuscular injection 
Yeast vaccine 
5μg/0.5ml， 
CHO vaccine 10μg/1ml, 
20μg/1ml 
The first dose should be 
immunized within 24 hours after 
birth, the interval between the 
first dose and the second dose is 
not less than 28 days (Figure1) 
BCG At birth 1 
Lower part of the 
middle in upper arm 
deltoid 
Intra-dermal 
injection 0.1ml  
Poliovirus vaccine 
2, 3, 4 months,  
4 years old 
4  oral 1 granule 
The interval between the first and 
the second dose, the second and 
the third dose is not less than 28 
days 
Diphtheria- 
Tetanus -Pertussis- 
Vaccine ( DTaP) 
3, 4, 5 months 
18-24 months 
4 Deltoid in the lateral side of upper arm 
Intramuscular 
injection 0.5ml 
The interval between the first and 
the second dose, the second and 
the third dose is not less than 28 
days 
Diphtheria 
Tetanus vaccine 6 years 1 Upper arm deltoid 
Intramuscular 
injection 0.5ml  
Measles Rubella 
vaccine (MR) 8 months 1 
Attachment site of 
the lower border of 
lateral deltoid in 
upper arm 
Subcutaneous 
injection 0.5ml  
Measles Mumps 
and Rubella 
vaccine(MMR) 
18-24 months  1 
Attachment site of 
the lower border of 
lateral deltoid in 
upper arm 
Subcutaneous 
injection 0.5ml  
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Box 3: Vaccination schedule for the National Immunization Programme, China, 2007 (Continued) 
Vaccine Age of Targets Number of doses Site of vaccination Vaccination route 
Dosage 
/dose 
Remark 
Japanese 
encephalitis live 
attenuated 
vaccine 
8 months, 2 
years 2 
Attachment site of 
the lower border of 
lateral deltoid in 
upper arm 
Subcutaneous 
injection 0.5ml  
Inactivated 
Japanese B 
encephalitis 
vaccine 
8 months (2 
doses, 2 years, 
6 years 
4 
Attachment site of 
the lower border of 
lateral deltoid in 
upper arm 
Subcutaneous 
injection 0.5ml 
The interval between the first and 
the second dose is 7-10 days 
Epidemic 
cerebrospinal 
meningitis group A 
vaccine 
6-18 months 2 
Attachment site of 
lateral deltoid in 
upper arm 
Subcutaneous 
injection 30μg/0.5ml 
The interval between the first and 
the second dose is 3 months 
Epidemic 
cerebrospinal 
meningitis group A 
plus C vaccine 
3 years, 6 years 2 
Attachment site of 
lateral deltoid in 
upper arm 
Subcutaneous 
injection 100μg/0.5ml 
The interval of the two doses is not 
less than 3 years, the interval 
between the first and the second 
dose of epidemic cerebrospinal 
meningitis group A vaccine is not 
less than 12 years 
Live attenuated 
hepatitis A vaccine 18 months 1 
Attachment site of 
lateral deltoid in 
upper arm 
Subcutaneous 
injection 1ml  
Inactivated 
hepatitis A vaccine 
18 months, 
24-30 months 
2 Attachment site of deltoid in upper arm 
Intramuscular 
injection 0.5ml 
The interval between 2 doses is 
not less than 6 months 
Note: 1. The dosage of CHO vaccine used to prevent mother to child transmission is 20μg/ml. 
2. The vaccination site, route and dosage of vaccines which are not in pharmacopeia refer to the instructions of vaccines. 
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Figure 1: Healthcare provider vaccinating a new born against hepatitis B within 24 hours after 
birth, Gansu, 2005 
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Methods 
Methods used to achieve the objectives at each chapter: 
1. A review of national EPI reviews conducted in 1997, 1999 and 2004 and the present 
data to evaluate progress on hepatitis B introduction (Chapter 1); 
2. National serosurvey to evaluate the prevalence of HBV and the association between 
prevalence of HBsAg and hepatitis B vaccination (Chapter 2 and 3); 
3. Sub-group analysis of the serosurvey to evaluate the factors associated with 
effectiveness of timely birth dose (Chapter 4); 
4. A national evaluation to examine the equity of hepatitis B vaccination, the progress of 
safety injection and progress towards the elimination of mother to child transmission of 
hepatitis B virus in China (Chapter 5, Chapter 6, Chapter 7).  
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Box 4: Data collection methods, GAVI China project evaluation, 2002-2009 
 
Indicators Data collection methods 
Input 
- Funding support - Annual reports from the provinces 
- Field supervision 
Process 
- Birth cohort 
- People trained 
- Vaccine allocated  
- AD syringes allocated 
- Birth Registration 
- Annual report from the provincial GAVI China office 
- Final project report from the provincial GAVI China office 
- MoH/GAVI office 
Output 
- Vaccine coverage 
- HepB3 and TBD 
- Reported: GAVI China office 
- Estimated: GAVI China office 
- Surveyed: Final evaluation 
- AD syringes used  - Final evaluation survey 
Outcome 
- Anti-HBs Prevalence 
- HBsAg prevalence 
- National serological survey (2006) 
Impact 
- HBsAg prevalence  
- Morbidity from 
cirrhosis and HCC 
- National serological survey (2006) 
- Published data from China 
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Results 
1. Chapter 1: Progress in Hepatitis B Prevention Through Universal Infant Vaccination- 
China, 1997-2006. 
2. Chapter 2: Evaluation of the Impact of Hepatitis B Vaccination among Children Born 
during 1992–2005 in China 
3. Chapter 3: Epidemiological Serosurvey of Hepatitis B in China - Declining HBV 
Prevalence due to Hepatitis B Vaccination 
4. Chapter 4: Factors Associated with Effectiveness of the First Dose of Hepatitis B Vaccine 
in China -1992-2005 
5. Chapter 5: Reducing inequities in hepatitis B prevention: A final evaluation of the GAVI 
China Project 
6. Chapter 6: Immunization injection safety in China, 2010: Progress and residual challenges 
7. Chapter 7: Progress towards the elimination of mother to child transmission of hepatitis B 
virus in China: Results from GAVI China project Final evaluation (Table 9) 
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Table 9: Presentation of the results as per the larger evaluation plans 
Chapters Content  Relevance to evaluation plans 
Level of the logic model Intervention 
elements 
Chapter 1 Mid-term progress in 
coverage  
- Structure 
- Process 
- Output  
- Hepatitis B 
immunization 
Chapter 2 Serological survey 
among children 
targeted by 
vaccination  
- Outcome  
- Impact 
- Hepatitis B 
immunization 
Chapter 3 Serological survey in 
the whole population  
- Outcome  
- Impact 
- Hepatitis B 
immunization 
Chapter 4 Factors associated with 
effectiveness of birth 
dose 
- Process 
- Output 
- Outcome  
- Impact 
- Hepatitis B 
immunization, more 
specifically, 
prevention perinatal 
infections  
Chapter 5 Coverage progress in 
terms of equity  
- Output  - Hepatitis B 
immunization 
- Social mobilization 
and training   
Chapter 6 Injection safety 
assessment  
- Output - Injection safety  
Chapter 7 Progress in prevention 
of perinatal infections  
- Output - Hepatitis B 
immunization, more 
specifically, 
prevention perinatal 
infections 
- Social mobilization 
and training   
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Hepatitis B virus (HBV) infection is a leading cause of illness and death in China. 
Approximately 60% of the population has a history of HBV infection, and 9.8% of persons in 
China are chronically infected with HBV and at risk for premature death from liver disease[32]. 
Each year, an estimated 263,000 persons in China die from HBV-related liver cancer or 
cirrhosis, accounting for 37%–50% of HBV-related deaths worldwide [48]. Because most HBV 
infections occur during infancy or early childhood, when HBV infection is most likely to 
become chronic, vaccination of infants beginning at birth is the key strategy for preventing 
chronic HBV infection. This report describes China’s progress in increasing coverage among 
infants with hepatitis B vaccine and timely administration of the hepatitis B vaccine birth dose 
(i.e., within 24 hours of birth). Infant vaccination coverage with both the timely birth dose and 
the complete vaccine series was substantially higher among children born during 2003 than 
among those born during 1997; timely birth-dose coverage increased from 29.1% to 75.8%, and 
HepB series completion increased from 70.7% to 89.8%. Furthermore, in economically 
disadvantaged populations in western and middle provinces† targeted by the China-Global 
Alliance for Vaccines and Immunization (China-GAVI) project, reported coverage with timely 
HepB birth dose increased from 64% in 2004 to 81% in 2006, and coverage with the complete 
HepB series increased from 52% in 2001 to 92% in 2006. China has established a goal to 
reduce chronic HBV infection among children aged <5 years to <1% by 2010 [49]. Achieving 
this goal will require continued commitment to increasing vaccination coverage in 
impoverished regions and ensuring that infants born at home are vaccinated within 24 hours of 
birth. 
†
China-GAVI–funded western provinces: Chongqing, Gansu, Guangxi, Guizhou, Neimenggu (Inner Mongolia), Ningxia, Qinghai, 
Shaanxi, Sichuan, Tibet, Yunnan, and Xinjiang; middle provinces with GAVI funding in government-designated poor counties: Anhui, 
Hainan, Hebei, Heilongjiang, Henan, Hubei, Hunan, Jiangxi, Jilin, and Shanxi.  
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Hepatitis B Immunization Program 
HepB was first recommended for routine vaccination of infants in China in 1992, with the 
first dose to be administered within 24 hours of birth and subsequent doses at ages 1 and 6 
months. However, because of high vaccine prices and user fees charged to parents by local 
health departments for vaccine purchase and administration, until 2002, infant vaccination 
occurred primarily in large cities of the wealthier eastern provinces.‡ Beginning in 2002, infant 
hepatitis B vaccination was added to China’s National Immunization Programme. Also in 2002, 
the China Ministry of Health began a project with the GAVI Alliance§ (formerly known as the 
Global Alliance for Vaccines and Immunization) to ensure HepB availability in China’s poorest 
provinces and counties. The 5-year China-GAVI project provides free HepB, targeting 
approximately 5.6 million children born each year in 12 western provinces and in 
government-designated poor counties in 10 middle provinces, covering approximately 36% of 
China’s child population. In 2005, a new vaccination regulation abolished all charges and user 
fees for all nationally recommended vaccines, including hepatitis B; the vaccine is now free to 
all children in China. To estimate national 3-dose HepB coverage and timely (i.e., within 24 
hours of birth) HepB birth-dose coverage and to describe the effects of province and location of 
birth (e.g., home versus hospital) on vaccination coverage levels, data from two national 
vaccination coverage surveys conducted by the China Ministry of Health in 1999 and 2004 
were reviewed. In both 1999 and 2004, parents were interviewed in house-to-house surveys 
regarding the vaccination status of eligible children born during the study periods. Sampling of 
households in each province was conducted using the probability proportional to size (PPS) 
‡
Eastern provinces: Beijing, Fujian, Guangdong, Jiangsu, Liaoning, Shandong, Shanghai, Tianjin, and Zhejiang. §
Additional information regarding the GAVI Alliance is available at http://www.gavialliance.org. 
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method. In the 1999 survey, counties in each province were divided into four economic strata, 
and PPS sampling was conducted within each strata. In 2,173 counties in 31 provinces, parents 
of 25,878 children born during 1997 were interviewed [50]. In the 2004 survey, 273 counties 
were selected randomly from all counties throughout the country, including at least three 
counties in each province, and PPS sampling was conducted in each county; parents of 171,188 
children born during 2001–2003 were interviewed [51]. For both surveys, 3-dose HepB and 
timely HepB birth-dose coverage were measured by dividing the number of children receiving 
3-dose HepB and timely HepB birth dose, respectively, by the number of children surveyed, 
taking into account the PPS sampling design. To examine in more detail the impact of the 
China-GAVI project, routine immunization-reporting–system data from 2001 through 2006 for 
China-GAVI–funded provinces were reviewed. In this national reporting system, the numbers 
of children targeted for and receiving each dose of routinely recommended vaccines are 
compiled by each immunization clinic and reported monthly to provincial and national 
immunization programs. For this analysis, 3-dose HepB and timely HepB birth-dose coverage 
in China-GAVI–funded provinces were measured by comparing the ratio of the number of 
children receiving doses of HepB to the number of children targeted to receive doses of 
diphtheria, tetanus, pertussis (DTP) vaccine, because the latter represents the most accurate 
local estimate of the number of children requiring routine childhood vaccination. Timely HepB 
birth-dose coverage could only be analyzed from 2004 through 2006 since reporting of HepB 
birth-dose timing was not required by the China Ministry of Health until 2004. A mathematical 
model was used to calculate hepatitis B disease burden before inception of the vaccination 
program and to estimate the number of deaths prevented through vaccination [32, 48].  
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National Vaccination Coverage Survey 
Comparison of the two national vaccination coverage surveys indicated that estimated 
3-dose HepB coverage increased substantially overall, from 70.7% among children born in 
1997 to 89.8% among children born in 2003 (Figure 2). Timely HepB birth-dose coverage also 
increased, from 29.1% among children born in 1997 to 75.8% among children born in 2003 
(Figure 1). During 1997–2003, estimated national 3-dose DTP coverage remained level (93%). 
The difference between 3-dose HepB coverage and 3-dose DTP coverage was reduced from 20% 
in 1997 to 3% in 2003.  
In the 2004 survey, estimated coverage was substantially lower in western provinces (68.0% 
for 3 doses of HepB and 49.5% for timely birth dose) than in middle provinces (91.8% for 3 
doses of HepB and 72.7% for timely birth dose) or eastern provinces (94.1% for 3 doses of 
HepB and 81.9% for timely birth dose) (Figure 3). Timely birth-dose coverage among infants 
born at home during 2001–2003 was less than half that of those born in hospitals. Among 
children born in 2004, timely birth-dose coverage for infants born in township hospitals was 
only two thirds that of those born in county, provincial, or national hospitals. 
China-GAVI Project 
For the period 2003–2006, 3-dose HepB coverage and timely HepB birth-dose coverage 
increased in the 12 western provinces and in the counties in 10 middle provinces supported by 
the China-GAVI project. In 2006, the ratios of 3-dose HepB/3-dose DTP coverage and timely 
HepB birth dose/first-dose DTP coverage were 92% and 81%, respectively (Figure 4). During 
2003–2006, approximately 15.4 million children in China-GAVI project counties received the 
3-dose HepB series, preventing an estimated 1.47 million chronic HBV infections in children 
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and 265,000 future deaths attributable to chronic HBV infection.  
    China has made substantial progress in implementing universal, timely hepatitis B 
vaccination for infants and in reducing disparities in coverage between the poorest and 
wealthiest parts of the country. The support from the China-GAVI project has improved 
vaccination coverage and helped prevent chronic HBV infection in children. During 2003–2006, 
approximately 15 million children in China-GAVI–funded provinces and approximately 42 
million children nationwide received HepB. Since 2002, implementation of universal infant 
hepatitis B vaccination in China has focused particularly on improving timely administration of 
the birth dose. Approaches used to increase timely birth-dose coverage have included 1) 
increasing the percentage of births that occur in hospitals; 2) improving vaccine availability in 
hospitals and township health facilities; 3) building collaboration among delivery services (i.e., 
maternal and child health programs and obstetrics) and between vaccination services (i.e., 
immunization programs and pediatrics) in hospitals and township health centers; 4) increasing 
the awareness of the importance of timely birth dose administration among providers and 
parents; 5) intensifying training, supervision, and monitoring of county, township, and village 
health workers; and 6) providing subsidies to village doctors to provide vaccines. Disparities in 
vaccination coverage continue to exist by region and by location of birth. Despite the 
China-GAVI activities, during 1997–2006, children from eastern provinces had substantially 
higher coverage than those from middle or western provinces, as did children born in hospitals 
versus those born at home. Income levels continue to be highest in China’s eastern provinces 
and lowest in the western provinces; residents in eastern provinces generally have greater 
access to and ability to pay for health care, including hospital care for childbirth. Children born 
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in hospitals generally have better access to immunization services and can be vaccinated more 
easily within 24 hours of birth. In western China, children are more likely to live in remote, 
mountainous areas and have less access to hospital delivery and immunization services. The 
China Ministry of Health is implementing programs to increase births in hospitals nationwide 
by expanding and improving obstetric care in health-care facilities throughout China and 
providing incentives to give birth in hospitals. Prevention of chronic HBV infection in China is 
integral to global initiatives to reduce the burden of HBV infection. In 1992, the World Health 
Assembly passed resolution 45.17, which called for all World Health Organization (WHO) 
member states to integrate cost-effective new vaccines, including HepB, into national 
immunization programs where feasible. The same year, WHO recommended that HepB be 
included in routine vaccination schedules for all children in all countries [52]. During 2000–2006, 
the GAVI Alliance has provided support for HepB introduction to 51 less developed member 
states (i.e., countries with less than $1,000 per capita gross national income), and these 
countries have made substantial progress in introducing HepB into their vaccination schedules 
[53]. As of 2005, a total of 154 (80%) of 192 WHO member states reported having integrated 
HepB into their routine infant vaccination schedules; global coverage with 3-dose HepB had 
increased from 32% in 2001 to 55% in 2005, with 2005 coverage varying by WHO region 
(South-East Asia: 27%; Africa: 39%; Eastern Mediterranean: 74%: Europe: 76%; Americas: 
85%; Western Pacific: 87%) [54]. The advances in hepatitis B vaccination have led countries 
and WHO regions to set goals for the elimination of HBV transmission. The WHO Western 
Pacific Region has committed to reducing chronic HBV infection in children aged <5 years to 
<2% by 2012. The findings in this report are subject to at least two limitations. First, the design 
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of the national surveys conducted in 1999 and 2004 differed in how counties were stratified 
before PPS sampling, which might limit comparability of the two surveys. Second, for the 
analyses using data from the routine immunization reporting system, the precise number of 
children requiring vaccination at local levels is not known because some children might not be 
registered; hence, the use of children targeted to receive DTP vaccine as a surrogate for total 
number of children might result in overestimation of reported vaccination coverage. Despite 
China’s progress in increasing hepatitis B vaccination coverage and timely administration of 
the birth dose, challenges remain to reaching the national goal of <1% chronic HBV infection 
among children aged <5 years by 2010. Achieving this goal will require increasing 3-dose 
HepB coverage to the same level as 3-dose DTP coverage and increasing timely HepB 
birth-dose coverage to 90% in all provinces. The greatest challenge is to increase 
administration of the birth dose among children born at home. Three provinces (Guizhou, Tibet, 
and Yunnan) and 42% of China-GAVI project counties still have timely birth-dose coverage 
levels of <75% and are most in need of targeted interventions. Although most hospitals now are 
achieving >95% timely birth-dose coverage for infants born in hospitals, strategies are needed 
to ensure that false contraindications to vaccination, including low birth weight and unstable 
medical condition at birth [55], do not delay administration of the birth dose. Innovative 
measures also are needed to reach infants born at home, particularly through linking prenatal 
care and birthing-care providers with immunization program staff at township and village 
levels. With these improvements, China can reduce substantially the burden of hepatitis B.   
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Figure 2: Estimated infant vaccination coverage with 3 doses of hepatitis B vaccine (HepB3) 
and timely* administration of the HepB birth dose (HepB1), by year of birth- China, 1997 
and 2001-2003 
 
 
SOURCE: China Ministry of Health national vaccination coverage surveys, 1999 and 2004. 
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Figure 3: Estimated infant vaccination coverage with 3 doses of hepatitis B vaccine (HepB3) 
and timely* administration of the HepB birth dose (HepB1), by region — China, 2001–2003 
 
 
SOURCE: China Ministry of Health national vaccination coverage survey, 2004. 
*Within 24 hours of birth. 
†China-GAVI–funded western provinces: Chongqing, Gansu, Guangxi, Guizhou, Neimenggu (Inner Mongolia), Ningxia, Qinghai, Shaanxi, 
Sichuan, Tibet, Yunnan, and Xinjiang. (GAVI was formerly known as Global Alliance for Vaccines and Immunisation.) § Middle provinces 
with GAVI funding in government-designated poor counties: Anhui, Hainan, Hebei, Heilongjiang, Henan, Hubei, Hunan, Jiangxi, Jilin, and 
Shanxi.  ¶ Eastern provinces: Beijing, Fujian, Guangdong, Jiangsu, Liaoning, Shandong, Shanghai, Tianjin, and Zhejiang. 
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Figure 4: Estimated infant vaccination coverage with 3 doses of hepatitis B vaccine (HepB3)/3 
doses of DTP* vaccine (DTP3) and timely† administration of the HepB birth dose (HepB1)/first 
dose of DTP vaccine (DTP1), by year of birth — China-GAVI §–funded provinces and 
counties ,¶ China, 2001–2006 
 
SOURCE: Routine Immunization Reporting System, China Center for Disease Control and Prevention.  
* Diphtheria, tetanus, pertussis. 
† Within 24 hours of birth. 
§Formerly known as Global Alliance for Vaccines and Immunisation. 
¶ China-GAVI–funded western provinces: Chongqing, Gansu, Guangxi, Guizhou, Neimenggu (Inner Mongolia), Ningxia, Qinghai, 
Shaanxi, Sichuan, Tibet, Yunnan, and Xinjiang; middle provinces with GAVI funding in government-designated poor counties: 
Anhui, Hainan, Hebei, Heilongjiang, Henan, Hubei, Hunan, Jiangxi, Jilin, and Shanxi. 
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Abstract 
Background: Endemic hepatitis B virus (HBV) infection is a serious health problem in 
China. Hepatitis B vaccination of infants was introduced in 1992 and was progressively 
expanded during the subsequent 15 years. 
Methods: We conducted a national serosurvey, with participants selected by 
multiple-stage random sampling. Demographic characteristics and hepatitis B vaccination 
history were collected by a questionnaire and a review of vaccination records, and serum 
specimens were tested for hepatitis B surface antigen, antibody to hepatitis B core antigen, and 
hepatitis B surface antibody by enzyme-linked immunosorbent assay. 
Results: Hepatitis B vaccine coverage (3 doses) increased from 30.0% for children born in 
1992 to 93.4% for children born in 2005. Receipt of a timely birth dose increased from 22.2% 
to 82.6% for children born during this interval. Multivariate analysis showed that older age, 
western and rural residence, birth at home, and certain ethnicities were risk factors for under 
vaccination with both full vaccine series and timely birth dose. The prevalence of hepatitis B 
surface antigen was reduced to 2.1% among all children and 1.0% among children born after 
1999. The efficacy of hepatitis B vaccination with a timely birth dose was 88.3%. 
Conclusions: Hepatitis B vaccine has been successfully integrated into routine infant 
immunization in China, now reaching most infants within 24 h after birth, and the prevalence 
of hepatitis B surface antigen has been greatly reduced among children born after 1992. 
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Background 
Endemic hepatitis B virus (HBV) infection is a serious health problem in China, causing a 
substantial burden of acute and chronic liver disease [33]. A national serosurvey from 1992 
revealed that the prevalence of hepatitis B surface antigen (HBsAg) was 9.8% in the general 
population, and that 9%–12% of children aged <5 years carried HBV [32]. The duration of 
hepatitis B carriage is almost lifelong, and current antiviral treatment is costly and has limited 
effectiveness in resolving chronic HBV infection [56-58]. Perinatal transmission is a major mode 
of HBV transmission in China. Therefore, China has made strong efforts to establish universal 
infant immunization. The recommended schedule involves administration of the first dose 
within 24 h after birth and administration of subsequent doses at ages 1 and 6 months-a 
schedule shown to be 70%–95% effective in preventing transmission from mother to infant [50]. 
In 1992, the Ministry of Health recommended routine immunization with the hepatitis B 
vaccine for routine immunization of infants. At this time, parents could be charged for the cost 
of hepatitis B vaccine and its administration. Data from national Expanded Programme on 
Immunization reviews showed that the rate of immunization coverage with the 3-dose series 
was 70.7% for children born in 1997 and was highest in urban and eastern areas [59]. In 2002, 
China fully integrated hepatitis B vaccine into the routine immunization program, providing 
free vaccine, although parents could still be charged a user fee. A collaborative project between 
the China Ministry of Health and the Global Alliance for Vaccines and Immunization assured 
that free vaccine would be available for all children born in poorer western provinces and 
impoverished areas of the central provinces beginning in 2003 [50]. In 2004, a review by the 
National Expanded Programme on Immunization reported that, for children born during 2001–
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2003, the rate of 3-dose vaccine coverage reached 85.5% nationally; the rate was 94.1% in the 
eastern provinces but only 68.0% in western provinces [51]. In 2005, the State Council issued 
the “Regulation on Vaccine Circulation and Immunization Management,” which eliminated all 
vaccination-associated charges, so that infants born after 1 June 2005 would be provided with 
hepatitis B vaccine for free [49]. 
In 2006, the Chinese government conducted a national serosurvey to evaluate the progress 
in the prevention of hepatitis B. This article describes the immunization coverage for children 
who were born after hepatitis B vaccine had been integrated into routine immunization, 
identifies risk factors for under-immunization, and evaluates the impact of hepatitis B 
vaccination on the seroprevalence of HBV markers among children born during 1992–2005.  
Methods 
Study population. The target population was children born during the period 1 January 
1992 through 31 December 2005 in each of 160 national Disease Surveillance Points (DSP) in 
31 provinces, which were selected by the Chinese Center for Disease Control and Prevention 
(CDC) to be representative of the population of China. Each DSP consists of 1 county; in total, 
73 million persons live in these counties, with a birth rate of 12.09 births per thousand 
inhabitants. Demographic characteristics and economic conditions in these points are not 
statistically different from those for whole country [60-62]. 
These sites were divided into 6 major regional groups (eastern urban, eastern rural, central 
urban, central rural, western urban, and western rural) for sampling. Western provinces 
included Chongqing, Gansu, Guangxi, Guizhou, Inner Mongolia, Ningxia, Qinghai, Shaanxi, 
Sichuan, Tibet, Yunnan, and Xinjiang. Central provinces included Anhui, Hainan, Hebei, 
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Heilongjiang, Henan, Hubei, Hunan, Jiangxi, Jilin, and Shanxi. Eastern provinces included 
Beijing, Fujian, Guangdong, Jiangsu, Liaoning, Shandong, Shanghai, Tianjin, and Zhejiang. 
Children aged 1–14 years and adults aged 15–59 years who had resided in the DSP for 16 
months at the survey visit were selected for the study; the complete selection methods are 
described elsewhere [40]. 
Sampling method. With use of the expected prevalence of HBsAg for different age 
groups in the study (1% for age 1–4 years, 4% for age 5–14 years, and 9% for age 15–59 years), 
the desired sample size was 79,129 children, including 15,213 children aged <5 years and 
23,416 children aged 5–14 years. First, 369 townships were identified from 160 counties (1–4 
townships per county) by simple random selection; second, one village was randomly selected 
from each township; and third, the populations of children aged 1–4 and 5–14 years were 
enumerated and selected on the basis of systematic interval from a list of village residents. 
Average sampling proportions for each age group at village were 1:1 for children aged <5 years 
and 1:7 for children aged 5–14 years.  
Investigation. A house-to-house investigation was completed by trained staff on the basis 
of the sampled name list. Basic information, including sex, birth date, ethnicity, place of birth, 
and immunization history, was compiled through parent interview. Immunization status was 
recorded from the child’s home immunization certificate or, if not available, by a review of the 
child’s immunization card at the township immunization clinic; if neither was available, the 
village doctor’s registry was reviewed. Otherwise, the immunization information was recorded 
as unvaccinated or unknown. Full vaccination was defined as receipt of 3 doses of hepatitis B 
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vaccine within 12 months, as documented by any immunization record. Timely birth-dose 
coverage was defined as receipt of the first dose of hepatitis B vaccine within 1 day after birth.  
Specimen collection. Blood samples were obtained from each study participant (4 ml for 
children aged ≥2 years and 2 ml for children aged <2 years). Serum was separated in county 
laboratories, transported, and stored at -20℃ , initially at provincial laboratories and 
subsequently at the National Hepatitis Laboratory, Chinese CDC (Beijing).  
Laboratory testing. All serum specimens were tested in the National Hepatitis Laboratory, 
Institute for Viral Disease Control and Prevention (IVDC) at the Chinese CDC. A detailed 
laboratory testing protocol was used that included retesting of specimens with inconsistent 
results. Testing reagents were selected on the basis of an evaluation of available enzyme-linked 
immunosorbent assay (ELISA) kits in China and were compared with use of Abbott enzyme 
immunoassay reagents using a panel of 153 reference serum specimens. ELISA reagents for 
HBsAg and hepatitis B surface antibody (anti-HBs) testing were purchased from Xiamen 
Xinchuang Production Company, utilizing a single lot of each test kit (batch number 
2006071301 for HBsAg, 2006071401 for anti-HBs, and 20060705 for hepatitis B core antigen 
(anti-HBc)). Anti-HBc detection reagents were purchased from the Shanghai Kehua Company. 
For specimens with inconsistent results, Abbott radioimmunoassay or ELISA reagents were 
used for reconfirmation testing, with neutralization method for final HBsAg confirmation. Data 
analysis. All data were double-inputted using EPI Data software, version 3.02 (The EpiData 
Association), and were checked for consistency. After verification of the accuracy of the data 
set, it was analyzed at the Chinese CDC with SAS software, version 9.13 (SAS Institute). 
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Appropriate sampling weights were constructed for national sample data set. The weight for 
person i  can be expressed as follows:  
| | ,kji k j k i k j adjw w w w w= × × × , 
where, 
kw is the reciprocal of the inclusion probability of township k ; 
|j kw is the reciprocal of the conditional inclusion probability of village j  within the selected 
township k ; 
| ,i k jw is the reciprocal of the conditional inclusion probability of person i  within the selected 
village j ; 
adjw is an adjustment factor for person i  such that the sum of the weights equals the actual size 
of the Chinese population. 
The Taylor series linearization methods were applied for variance estimation. We used 
survey freq procedure of SAS software for computation. The weighted prevalence rates of 
hepatitis B vaccination and HBV biomarkers include the point estimates and their estimated 
95%CIs [63-67]. Multivariable logistic regression (forward method) was used to identify the 
predictors for high risk of under-vaccination. Vaccine effectiveness was calculated using the 
formula VE = (ARuv –ARv) / ARuv, where ARuv is prevalence in unvaccinated and ARv is 
prevalence in vaccinated children. 
7. Quality control: National specialist groups were convened to guide statistical design, 
epidemiological investigation, laboratory testing and logistic services, training and data 
analysis. Two field pilots were conducted before the survey. Appropriate visiting time was 
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considered to ensure high response rate. Trained County CDC staffs were responsible for 
administering the questionnaire, and collecting, storing and transporting the blood specimens.  
8．Ethical Issues: The survey was approved by the China CDC Ethics Committee, and all 
study work done according to the national Ethics regulations. Study participants were informed 
of the study purpose and their right to keep information confidential.   
Results 
1. Characteristics of study population 
During the investigation, 87,454 persons (1~59 years old) were enumerated; among these, 
5,376 were excluded due to absence or refusal, 82,078 interviewed, and 82,008 blood samples 
were taken. Overall, 40,129 children born between 1992 and 2005 participated. The study 
population was predominantly Han (86.4%), balanced by sex and among regions and 
urban/rural status; 40.8% were 1-4 years while 59.2% were 5-14 years; 75% had been born in 
county or above (47.7%) or township (28.1%) hospitals, while 21.5% were born at home.  
2. Immunization coverage of HepB for children born between 1992 and 2005 
Among the study population, 32,732 (81.6%) had received hepatitis B vaccination (any 
doses), 3,755 (9.4%) had not received HepB vaccine, and 3,642 (9.1%) had unknown 
vaccination history.  
For children born between 1992 and 2001, weighted 3 dose and timely birth dose coverage 
of HepB were 50.6% and 35.1%. For children born between 2002 and 2005, weighted 3 dose 
and timely birth dose coverage of HepB had increased to 89.4% and 73.4%, respectively, and 
reached 93.4% and 82.6%, respectively, for children born in 2005 (Table 10). 
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In both time periods, weighted coverage for 3 dose and timely birth dose of HepB were 
significantly higher among Han, Mongolian, and Hui children than among all other ethnic 
groups (Table 10). Vaccine coverage did not differ by gender.  
3. Hepatitis B immunization coverage trends in different regions  
For children born between 1992 and 2001, both 3 dose and timely birth dose HepB 
coverage were highest in the eastern region, intermediate in central region, and lowest in the 
western region, and were significantly higher in urban than rural areas in each region (Table 11, 
Figures 5, Figure 6). For children born between 2002 and 2005, regional and urban/rural 
vaccine coverage differences had decreased but remained significant. Increases in coverage 
were seen in all 6 sub-regions, and were most dramatic in areas that had lowest coverage in 
1992-2001 birth cohorts (western urban and all rural areas). Timely birth dose coverage in 
Western rural regions, however, reached only 58% in 2002-2005.  
4．Relationship of birth place and hepatitis B Immunization coverage  
The proportion of births occurring in hospitals increased substantially during the study 
period. Among children born between 1992 and 2001, 70.9% of were delivered at hospitals, 
and 27.4% were delivered at home, while among children born between 2002 and 2005, 85.1% 
were delivered at hospitals, and only 13.9% were delivered at home (p<0.05).  
Timely birth dose coverage increased substantially among children born in 2002-2005 
compared to those born between 1992-2001 in all settings (Table 10). Coverage was highest 
among children born in county hospital and above (84% in 2002-2005), and was slightly lower 
among children born in township hospitals. Coverage among children born at home improved, 
but remained low (31.4%) for children born between 2002 and 2005.  
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5. Prevalence of HBV among children born between 1992 and 2005 by year  
Weighted prevalence of HBsAg for children born between 1992 and 2005 was 2.1%, with 
highest prevalence in oldest children and decreasing steadily with decreasing age (Table 12). 
Among children born in 1992, the HBsAg prevalence was 5.5%, decreasing to 1.8% among 
children born between 1993 and 1998. Among children born after 1998, HBsAg prevalence 
was approximately 1%. Prevalence of anti-HBc, also decreased monotonically with age, from 
16.5% in the oldest to 3.3% in the youngest children. Conversely, the weighted prevalence of 
anti-HBs decreased steadily with earlier birth year, reaching a plateau of about 55% for 
children born before 2002 (Table 12). 
6．Weighted prevalence of HBsAg and other HBV markers and immunization history 
Weighted prevalence of HBsAg was significantly lower among children who were fully 
vaccinated than among unvaccinated children and those with unknown immunization status. 
HBsAg prevalence among children who received the full 3 dose immunization series and 
timely birth dose were 1.0% and 0.7% among children born between 1992-2001 and 2002-2005, 
respectively (Table 13). HBsAg prevalence among children receiving a birth dose between 2 
and 7 days after birth was 0.4-0.5%, lower than that of children receiving a birth dose on time, 
but this difference was not statistically significant. However, children receiving the birth dose 
after 1 week of age had higher HBsAg prevalence (1.3-1.8%), significant for children born 
2002-2005. Among children with no immunization, HBsAg prevalence was 5.5-5.6%, 
approximately 60% that observed among children in this age group in the 1992 hepatitis B 
serosurvey2. Based on these results, the effectiveness of HepB for full and on-time immunized 
infants compared with non-immunized infants is estimated to be 88%. The weighted prevalence 
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of anti-HBs was higher among fully immunized children (63.2% and 74.3% in children born in 
1992-2001 and 2002-2005, respectively) than among not immunized (34.8% and 21.1%) 
children in both time periods. Anti-HBc prevalence was significantly lower for fully 
immunized children (3.7-5.6%) than in unimmunized children (10.6-17.8%). 
7．Multivariable regression analysis on risk of low immunization coverage 
Multivariable analysis was used to examine risk factors for not being fully immunized for 
HepB, with vaccination status as the dependent variable, and age, gender, ethnicity, type of 
residence, region, and birthplace as covariates. Risk factors for low 3 dose immunization 
coverage included being born before 2001; Tibetan, Uigur, and other ethnicity compared to 
Han ethnicity; and living in western region and rural location. In addition, full immunization 
was lower among children born at home or in other settings than for children born at hospital 
(Table 14).  
Results for low timely birth dose coverage were almost identical to those for full 
immunization series, although odds ratios were higher for most factors. Thus birth before 2001; 
Tibetan, Uigur, Zhuang, and other ethnicity; living in western region and rural location; and 
birth in township hospital or at home, were strong predictors of low timely birth dose (Table 
15). 
Discussion 
Before wide availability of hepatitis B vaccination in China, HBV infection was acquired 
rapidly by perinatal and infant transmission among children aged 1-4 years, with the HBsAg 
prevalence reaching 9.8%, and remaining consistently high in older age groups. Among the 
global deaths attributed to hepatitis B, about 40% occur in China [10]. Therefore, control of 
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hepatitis B is among the highest priorities in China. Policies currently being implemented to 
control hepatitis B include universal infant immunization, HBsAg screening of blood for 
transfusion, control of blood exposure in medical settings, and management and treatment of 
hepatitis B infected persons [68]. 
    Vaccination is considered the most cost-effective way to control hepatitis B, and 
immunization of newborns is necessary to prevent perinatal HBV transmission [50,69]. HepB was 
fully integrated into the National Immunization Program in 2002, and since 2005, all 
vaccination of infants has been provided for free, providing equal opportunity for all 
socioeconomic classes. Since 2002, multiple approaches have been implemented to increase 
timely birth doses, with strongest emphasis on increasing the proportion of births in hospitals, 
building collaboration between Maternal Child Health (MCH) and EPI departments, and 
assuring timely birth doses for children born in hospitals. Assuring safe childbirth has been a 
national priority since 2000; in addition to training and upgrading hospital facilities, the 
government provides subsidies to pregnant women to deliver in hospitals, through national 
rural health reform cooperation policy, reducing or eliminating the hospital charges. This has 
increased the percentage of births that occur in hospitals to over 85% nationally. Regular 
communication between MCH and EPI has been mandated by provincial and local Health 
Bureaus to ensure collaboration to deliver vaccination. In 2002, national guidelines were 
established to require obstetrical nurses who deliver the baby to give the hepB birth dose within 
24 hours after birth; with strong training, systematic recordkeeping, and regular monitoring, the 
policy has been well implemented [70], with coverage now exceeding 90% in most hospitals. 
Timely birth doses for births at home may be provided by village doctors, who coordinate with 
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MCH staff/midwives to track pregnancies and to facilitate having hepB vaccine available in 
village at time of childbirth. 
The successful introduction of HepB into the national immunization program has brought 
great impact in reducing the prevalence of HBsAg among population aged 1 to 14 years. The 
results affirm that universal vaccination of infants contributed directly to the reduction of 
HBsAg prevalence; vaccination with full series and timely birth dose was 88% effective 
compared to unvaccinated children among both recently born and older children. Interestingly, 
un-immunized children tested in 2006 had lower HBsAg prevalence compared with same age 
group tested in the 1992 serosurvey (5.6% vs. 9.8%) [32]. This is likely due to several factors: a 
modest decrease in HBsAg prevalence among women (15~59 yrs), from 8.1% in 1992 to 6.7% 
in 2006; reduced size of families due to the one-child per family policy and therefore reduced 
transmission risk among children; improvement of safe injection practices [50, 59], and herd 
immunity due to high rates of vaccination. 
   Hepatitis B vaccination of infants and children has been demonstrated to reduce the 
prevalence of HBsAg in many different populations that previously experienced high HBV 
endemicity[71]. Previous studies have shown marked reduction in prevalence in both urban and 
rural areas of China (Shanghai, LongAn County, Beijing, etc), Africa (eg. Gambia and Senegal), 
and all other populations with high HBV endemicity [72-79]. This study reaffirms the 
effectiveness of infant vaccination for the national Chinese population, and demonstrates the 
importance of timely birth doses for greatest reduction of risk. Delayed delivery of timely birth 
dose, but within one week, also appeared to reduce the prevalence of infection in infants. This 
is reassuring for programs where challenges remain to achieving timely birth doses within 24 
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hours. However, this finding is based on observations in a relatively small number of infected 
infants, and will require confirmation in a larger study to be sufficient to consider modifying 
current HepB birth dose recommendations. Available controlled trials show that timely birth 
dose within 24 hours is highly effective for hepB prevention among children born to highly 
infectious HBsAg, HBeAg positive mothers or those with high HBV DNA, and it is strongly 
recommended that hepB vaccination programs provide the birth dose within 24 hours if 
possible.  
Although China has greatly improved infant hepatitis B vaccination coverage and reduced 
HBsAg prevalence in young children, this study shows that certain groups remain at high risk 
of not receiving timely birth dose or full immunization. Due to uneven development among 
regions, immunization coverage remains low in rural areas and in the western region, and 
among several ethnic minority groups. Finally, children born at home remain at very high risk 
of not receiving timely birth dose or full immunization. Because a high proportion of women of 
child-bearing age remain HBsAg and HBeAg positive (6.7% HBsAg +; 30% of these HBeAg 
positive), to achieve further gains in reducing hepatitis B risk among children, the national 
program must continue to improve immunization, and particularly timely birth doses, in these 
risk groups [80].  
In addition, efforts still need to focus on assuring high timely birth dose coverage (>95%) 
among children born in hospitals. Field studies in China indicate that birth doses are often 
delayed due to false contraindications, including low birth weight (< 2500 gms), prematurity, 
and unstable infant condition [70]. HepB vaccine has been shown to be safe when given to 
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infants of any age, and prematurity or low birth weight should not delay the administration of 
timely birth doses [81].    
This study has several limitations. First, because the target population was children living 
in village more than 6 months, some floating (migrant) children as well as children born outside 
the birth control plan (unregistered children) were excluded from the study. Therefore, this 
study may overestimate immunization coverage. The floating population represents only a 
small proportion in this age group (3%), but the number of unregistered children is not known. 
Secondly, effectiveness of timely birth dose vaccination may be overestimated, since in urban 
areas, many pregnant women are screened for HBsAg and infants born to HBsAg positive 
mothers given not only HepB but also HBIG at birth. In this survey, the proportion of infants 
who were reported by parents to have received HBIG was relatively small (<1%), and 
exclusion from the analysis did not change the results. One other limitation is that because all 
children were tested during 2006, the children who were less than 5 years (born 2002-2005) 
may still be at risk for horizontal transmission of HBV. 
China has made great achievement in integrating HepB into routine immunization 
programs, achieving very high full immunization coverage and timely birth dose, and has 
demonstrated dramatic impact in reducing the prevalence of HBsAg among young children. In 
particular, the collaborative approach to achieve uniform vaccination of infants at birth should 
serve as a guide to other countries with high HBV endemicity to achieve rapid reduction in 
perinatal HBV transmission. Prevalence of HBsAg for children under 7 years is now about 1% 
indicating achievement of the national goal of 1% HBsAg prevalence among children by 2010, 
and of the WHO Western Pacific Regional Office (WPRO) hepatitis B reduction goal. WPRO 
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is the first WHO region to set a time-bound goal of reducing chronic HBV infection rates to 
less than 2% among five-year-old children by 2012. To further reduce the prevalence of 
HBsAg, accelerate progress toward further reducing hepatitis B transmission, and assure high 
levels of protection for the Chinese population, the national program will need to focus 
strongest efforts on improving timely birth doses among disadvantaged minority populations 
and the Western rural areas where many births still occur at home, and among floating and 
unregistered children. In addition, China should continue to focus on protecting all children 
through providing vaccination to previously unvaccinated children < age 5 years, and to 
expanding coverage to all children < 15 years, and to high risk populations.  
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Table 10: Immunization coverage of hepatitis B vaccine for children born during 
the period 1992–2005. 
Year No.  Investigated 
3 dose   Timely Birth dose 
Weighted  
Coverage (%) 95% CI  
Weighted 
 Coverage (%) 95% CI 
1992 1,724 30.0  22.7~37.2   22.2 14.7~29.7 
1993 2,285 34.3 29.4~39.2  23.7 19.2~28.2 
1994 2,415 38.1 33.3~43.0  22.5 19.2~25.7 
1995 2,773 39.7 35.8~43.6  27.1 21.2~32.9 
1996 2,647 45.2 40.8~49.6  28.2 24.7~31.8 
1997 2,578 55.9 47.4~64.4  39.4 31.6~47.3 
1998 2,434 56.8 52.2~61.3  39.1 34.1~44.0 
1999 2,326 61.2 57.3~65.1  43.7 39.8~47.6 
2000 2,356 76.6 71.3~82.0  54.1 49.9~58.2 
2001 2,215 83.0 78.7~87.3  64.4 59.8~68.9 
2002 4,175 84.3 82.0~86.5   66.1 62.7~69.6 
2003 4,412 87.7 86.3~89.2  68.9 65.9~71.9 
2004 4,153 92.4 90.9~93.9  76.8 74.5~79.1 
2005 3,636 93.4 92.1~94.7  82.6 80.2~85.0 
Total 40,129 59.6 57.3~61.8    43.9 41.6~46.2 
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Table 11: Weighted hepatitis B immunization coverage among children born 
between 1992 and 2005 by characteristics of study population 
  Category Frequency 
1992~2001   2002~2005 
3 doses  
 
Timely  
  
 
3 doses 
 
Timely  
  Gender Male a 20,960 51.8 35.5 
 
89.6 73.2 
 Female 19,169 49.2 34.6  89.2 73.6 
Ethnicity Han a 34,668 53.6 37.7  92.9 78.0 
 Mongolian  336 70.2* 26.2*  97.1 75.3 
 Tibetan 1,138 6.4** 3.9**  38.5** 8.4** 
 Uigur 599 2.0** 2.0**  55.7** 15.1** 
 Zhuang 244 19.0** 11.3**  65.6** 37.4** 
 Hui (Muslim)  583 50.6 45.5  79.6 70.5 
 Others 2,561 25.0** 13.2**  61.8** 41.0** 
Urban/Rura
l 
Urban a 19,999 68.6 58.7  93.4 81.5 
 Rural 20,130 45.5** 28.4**  88.0** 69.5** 
Region Eastern a 13,530 64.2 45.2  96.8 85.5 
 Central 13,336 60.7* 41.9  91.9** 75.9** 
 Western 13,263 33.5** 22.8**  78.8** 57.7** 
Birth Place County Hospital
 
a 
19,156 60.6 49.5  94.9 84.5 
 Township 
Hospital 
11,266 72.7 41.2*  94.4 78.0** 
 At home 8,631 27.0** 11.6**  62.5** 31.4** 
 Others 1,076 35.1** 18.4**  91.1 64.5** 
aReference  * P<0.05  ** P<0.01  
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Table 12: HBV markers among children born between 1992 and 2005 by birth year 
Year 
No.  
Investigated 
HBsAg   Anti-HBc   Anti-HBs 
Weighted 
 
 
95%CI   Weighted 
 
 
95%CI   Weighted  
 
 
95%CI 
1992 1,724 5.5 3.7~7.4 
 
16.5 13.7~19.2 
 
50.5 46.8~54.1  
1993 2,285 3.4 2.5~4.2  
 
13.3 10.8~15.7  
 
57.9 54.2~61.7 
1994 2,415 2.9 1.9~4.0  
 
10.5 8.3~12.7  
 
53.4 46.1~60.8  
1995 2,773 3.0 1.8~4.1  
 
8.7 6.6~10.9  
 
61.6 56.4~66.9  
1996 2,647 2.1 1.1~3.1 
 
7.1 5.4~8.7  
 
60.5 57.1~63.9 
1997 2,578 2.3 1.8~2.9  
 
7.5 5.9~9.1  
 
55.7 50.8~60.5  
1998 2,434 1.8 1.4~2.1  
 
6.1 4.8~7.5  
 
54.2 49.8~58.6  
1999 2,326 1.0  0.4~1.6 
 
5.3 3.5~7.1  
 
54.8 51.0~58.5  
2000 2,356 0.9 0.4~1.5  
 
3.7 2.0~5.4  
 
56.9 50.4~63.5  
2001 2,215 1.1 0.4~1.8  
 
4.8 3.3~6.4 
 
55.8 45.6~65.9  
2002 4,175 1.2 0.8~1.6  
 
4.2 3.3~5.1 
 
63.5 60.9~66.0 
2003 4,412 0.9 0.5~1.3  
 
4.5 3.4~5.6  
 
65.7 63.4~67.9  
2004 4,153 0.9 0.4~1.3  
 
4.2 3.1~5.4 
 
72.9 70.6~75.1  
2005 3,636 0.9 0.4~1.3 
 
3.3 2.3~4.4 
 
84.5 82.4~86.7 
Total 40,129 2.1 1.78~2.38 7.4  6.8~8.0    60.0 58.4~61.5 
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Table 13: Immunization status and prevalence of HBsAg 
Status of 
Immunization 
1992-2001 2002-2005 
Investigated 
Weighted 
prevalence 
(%) 
95% CI Investigated 
Weighted 
prevalence 
(%) 
95% CI 
Full,-Birth dose 
 
11,103 1.0  0.7~1.4 12,024 0.7 0.5~0.8 
Full,-BD within 1 
week 
887 0.4 0~0.8 671 0.5 0.1~1.0  
Full, BD after 1 
week  
5,026 1.8 1.2~2.3 2,614 1.3 0.7~1.8 
Not immunized 3,274 5.5  3.4~7.7 481 5.6 3.5~7.6  
Unknown 3,222 3.7  2.9~4.5  420 3.2  1.6~4.8  
Legend: 
  Full, Birth Dose OT: Full HepB series with birth dose within 24 hours of birth 
  Full, BD within one week: Full series, with birth dose given between 2-7 days after birth 
  Full, BD after 1 week: Full series with birth dose given > 7 days after birth 
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Table 14: Multivariable regression analysis on risk of low full immunization 
coverage (HepB3) 
Category Frequency OR 95.0% CI P value 
Age  1~4* 16,376 1.0 
  
5~14 23,753 10.0 8.6~11.8 <0.01 
Sex Male* 20,960 1.0 
  
Female 19,169 1.1 0.8~1.5 0.5 
Ethnicity# 
Han* 34,668 1.0 
  
Mongolian  336 0.3 0.1~0.8 <0.05 
Tibetan 1,138 5.9 3.5~9.9 <0.01 
Uigur 599 5.3 3.7~7.5 <0.01 
Zhuang 244 1.5 0.9~2.5 0.09 
Hui 583 1.1 0.7~1.8 0.67 
Others 2,561 2.2 1.6~3.1 <0.01 
Urban/Rural Urban* 19,999 1.0    
Rural 20,130 1.9 1.4~2.6 <0.01 
Region 
Eastern* 13,530 1.0 
  
Central 13,336 1.0 0.7~1.5 0.85 
Western 13,263 3.1 2.2~4.3 <0.01 
Birth Place 
County Hospital* 19,156 1.0 
  
Township Hospital  11,266 1.2 1~1.5 0.15 
Home 8,631 4.4 3.5~5.7 <0.01 
Others 1,076 3.2 1.7~6.0 <0.01 
     * Reference  
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Table 15:  Multivariable regression analysis on high risk of low timely birth dose 
coverage 
  Category Frequency OR 95.0% CI P value 
Age  1~4* 16,376 1.0 
  
5~14 23,753 5.5 4.8~6.3 <0.01 
Sex Male* 20,960 1.0 
  
Female 19,169 1.0 0.9~1.2 0.79 
Ethnicity# 
Han* 34,668 1.0 
  
Mongolian 336 1.2 0.5~3.0 0.69 
Tibetan 1,138 9.1 5.2~16.2 <0.01 
Uigur 599 7.7 4.3~13.6 <0.01 
Zhuang 244 1.7 1.2~2.6 <0.01 
Hui 583 0.9 0.6~1.3 0.53 
Others 2,561 2.3 1.8~2.8 <0.01 
Urban/Rural Urban* 19,999 1.0    
Rural 20,130 2.6 2.1~3.3 <0.01 
Region 
Eastern* 13,530 1.0 
  
Central 13,336 1.1 0.8~1.4 0.66 
Western 13,263 2.4 1.8~3.1 <0.01 
Birth Place 
County Hospital* 19,156 1.0 
  
Township Hospital  11,266 1.7 1.3~2.1 <0.01 
Home 8,631 7.6 5.7~10.2 <0.01 
Others 1,076 4.3 2.5~7.5 <0.01 
    * Reference  
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Figure 5:  Hepatitis B Immunization coverage of 3 doses for children born between 1992 
and 2005 in different regions 
 
 
 
 
  
Urban Rural 
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Figure 6: Timely birth dose coverage for children born between 1992 and 2005 by 
different regions 
 
 
Urban Rural 
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Abstract 
Objective: To determine the prevalence of hepatitis B surface antigen (HBsAg), hepatitis B 
surface antibody (anti-HBs), and hepatitis B core anti-body (anti-HBc) in a representative 
population in China fourteen years after introduction of hepatitis B vaccination of infants.  
Methods: National serosurvey, with participants selected by multi-stage random sampling. 
Demographics and hepatitis B vaccination history collected by questionnaire and review of 
vaccination records, and serum tested for hepatitis B surface antigen (HBsAg), antibody to 
hepatitis B core antigen (anti-HBc) and hepatitis B surface antibody (anti-HBs) by ELISA. 
Findings: The weighted prevalence of HBsAg, anti-HBs and anti-HBc for Chinese population 
aged 1-59 years were 7.2%, 50.1%, 34.1% respectively. HBsAg prevalence was greatly 
diminished among those age < 15 years compared to that found in the 1992 national serosurvey, 
and among children age < 5 years was only 1.0% (90% reduction). Reduced HBsAg prevalence 
was strongly associated with vaccination among all age groups. HBsAg risk in adults was 
associated with male sex, Western region, and certain ethnic groups and occupations while risk 
in children included birth at home or smaller hospitals, older age, and certain ethnic groups 
(Zhuang and other).   
Conclusions: China has already reached the national goal of reducing HBsAg prevalence to 
less than 1% among children under 5 years and has prevented an estimated 16-20 million HBV 
chronic infections through hepatitis B vaccination of infants. Immunization program should be 
further strengthened to reach those remaining at highest risk.  
Key Words: Hepatitis B, Serosurvey, immunization
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Background 
In 1992, the China national hepatitis seroepidemiological survey found that the prevalence 
of HBsAg for population aged 1-59 years was 9.8%. Based on this survey, it has been 
estimated that in China, 120 million people carry HBsAg [32, 82, 83], 20 million suffer from 
chronic hepatitis B, and almost 300,000 die annually from chronic consequences of HBV 
infection. Both liver cancer and cirrhosis are among the 10 most common causes of mortality in 
China; for both, hepatitis B virus causes the majority of deaths [33, 84, 85].  
To control hepatitis B, the Chinese government has implemented infant vaccination with 
hepatitis B vaccine as the highest priority. In 1992, the Ministry of Health recommended 
hepatitis B vaccine for routine immunization of infants but parents had to pay for the vaccine, 
therefore vaccine coverage was higher in urban and high socioeconomic areas and lower in 
rural and lower socioeconomic areas. In 1999, a National Expanded Programme on 
Immunization (EPI) review showed that, the immunization coverage with 3 doses of hepatitis B 
vaccine was 70.7%, but varied from 99% in Beijing to only 7.8%% in Tibet [42]. A follow-up 
survey showed immunization coverage among children born in 2001 had reached 82.4 %, but 
with continued disparities in western provinces and rural counties [51]. In 2002, China integrated 
hepatitis B vaccine into EPI, with emphasis on providing a timely birth dose (within 24 hours 
of birth). The cost of vaccine was paid by the government, but vaccine administration fees of 
up to $1.10 per dose were still allowed as a charge to parents. In addition, the China/Global 
Alliance on Vaccine and Immunization (GAVI) project provided $76 million funding to 
purchase hepatitis B vaccine and autodisable syringes for all children born in western provinces 
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and poverty counties in middle provinces [50]. In May 2005, the government required that all 
infant vaccinations be given at no charge to parents. 
To accelerate the control of hepatitis B, the Ministry of Health developed the "2006 ~ 
2010 National guidelines for hepatitis B prevention and treatment", establishing national goals 
of achieving HBsAg prevalence less than 7% by 2010 for whole population and less than 1% 
for children under five years [86].   
The vaccination program in China has been regarded as a success story in preventing 
hepatitis B through universal infant vaccination [53]. To measure the prevalence of hepatitis B 
markers among population aged 1-59 years, ongoing risk factors for hepatitis B infection, and 
to evaluate the impact of the hepatitis B vaccination programme since 1992, the China 
government conducted the national hepatitis serosurvey in 2006. 
Methods 
Planning for this study was started in December 2005 and data analysis completed in 
December 2007. All field work was conducted between September and October 2006.  
1. Study population: The target population was local residents aged 1 to 59 years living in 160 
disease surveillance points (DSP) in 31 provinces which have been selected by Chinese Center 
for Disease Control and Prevention (China CDC) to be representative of the population of 
China. Demographic, economic conditions and the situation of the population in these sites are 
not statistically different compared to whole country [60, 61, 87]. For the serosurvey, these sites 
were divided into 6 major regional groups -- urban eastern, rural eastern, central urban, central 
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rural, western urban and western rural -- for further sampling**. Persons aged 1-59 years 
resident for more than 6 months at the survey visit were selected.  
2. Sampling Method: Using the expected HBsAg prevalence for different age groups in the 
study (1% for age 1-4 yrs., 4% for age 5-14 yrs., 9% for age 15-59 yrs), the desired sample size 
was 79129, and included 15,213 children < 5 yrs and 23,416 children 5-14 years.  
First, 369 townships were identified from 160 counties (1-4 per county) by simple random 
selection; secondly, one village was randomly selected from each township; third, the 
population aged 1-4, 5-14, and 15-59 years, respectively, were enumerated and selected based 
on the systematic interval from a list of village residents. Average sampling proportions for 
each age group at village were 1:1 for children < 5 years, 1:7 for children 5-14 years, and 1:8 
for population aged 15-59 years.  
3. Investigation: House to house investigation was completed by trained staff based on the 
sampled name list. A standard questionnaire was used to compile the basic information 
including gender, birth date, education, occupation, ethnicity, place of birth, and immunization 
history through face to face interview with the study subject or parent (if child < 15 years). For 
children under 15 years, immunization status was recorded from the child’s immunization 
certificate kept by the parents or by review of the child’s immunization card kept at the 
township hospital immunization clinic; if neither were available, the village doctor’s registry 
was reviewed. If none of these sources were available, the vaccination status was recorded as 
unvaccinated (if parent denied vaccination) or as unknown. Because there are no personal 
**Western provinces include: Chongqing, Gansu, Guangxi, Guizhou, Inner Mongolia, Ningxia, Qinghai, Shaanxi, 
Sichuan, Tibet, Yunnan, and Xinjiang. Central provinces include: Anhui, Hainan, Hebei, Heilongjiang, Henan, 
Hubei, Hunan, Jiangxi, Jilin, and Shanxi. Eastern provinces include: Beijing, Fujian, Guangdong, Jiangsu, 
Liaoning, Shandong, Shanghai, Tianjin, and Zhejiang. Urban counties are defined as that counties which are 
capital in prefecture; rural counties are those counties which are not capital of the prefecture.   
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immunization records for adults, the immunization information for adults was based on 
memory (vaccinated, unvaccinated, unknown). Definitions of education and occupation are 
according to the Chinese social classification criteria, and only applicable to population aged 
15~59 years. Occupation of public service worker is defined as a person who works in hotel, 
hospital, barber, transportation center, etc, and who has high frequency of contact with the 
public.  
4. Specimen collection: Blood samples collected for each study participant included 4ml for 
population above 2 years, and 2ml for children age 2 years or less. Serum was separated in 
county laboratories, transported and stored at –20℃ at provincial laboratories, and submitted to 
National Hepatitis laboratory of Institute for Viral Disease Control and Prevention (IVDC) at 
China CDC in Beijing.   
5. Laboratory testing: All serum specimens were tested in the National Hepatitis laboratory at 
IVDC, China CDC. A detailed laboratory testing protocol was established before testing, 
including retesting of specimens with inconsistent results. Testing reagents were selected 
based on evaluation of available ELISA kits from 5 companies in China compared to Abbott 
EIA reagents using a panel of 153 standard reference sera. ELISA reagents for HBsAg, 
anti-HBs, HBeAg and anti-HBe testing were purchased from Xiamen Xinchuang Production 
Company, utilizing a single lot of each test kit for all specimens††. Anti-HBc detection 
reagents were purchased from the Shanghai Kehua company. For specimens with inconsistent 
†† Batch number 2006071301 for HBsAg, 2006071401 for anti-HBs, 2006095312 for HBeAg, 2006071801 for 
anti-HBe; anti-HBc batch number 20060705 
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results, Abbott EIA reagents were used for reconfirmation testing, with neutralization method 
for final confirmation of HBsAg. 
6. Statistical analysis: All data was double inputted into an EPI Data 3.02 software database, 
and checked for consistency with provinces. After verifying accuracy, the data was analyzed at 
China CDC, with SAS 9.13 software.  
Appropriate sampling weights were constructed for national sample data set. The weight 
components computed for this design, which involves 160 county strata, 369 township and 
village clusters and 81,775 persons, consisted of factors reflecting township selection 
probability, village selection probability within the selected township, age-specific person 
selection probability within the selected village and post-stratification adjustments to adjust to 
the sex and age of the entire Chinese population. The weight for each person i  can be 
expressed as follows:  
| | ,kji k j k i k j adjw w w w w= × × × , 
where, 
kw is the reciprocal of the inclusion probability of township k ; 
|j kw is the reciprocal of the conditional inclusion probability of village j  within the selected 
township k ; 
| ,i k jw is the reciprocal of the conditional inclusion probability of person i  within the selected 
village j ; 
adjw is an adjustment factor for person i  such that the sum of the weights equals the actual size 
of the Chinese population. 
The Taylor series linearization methods were applied for variance estimation. The prevalence 
rates of HBV sero-markers include the point estimates and their estimated 95%CIs [10, 63-67]. 95% 
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confidence intervals (95% CI) were compared for HBV marker prevalence of each variable; 95% 
CI which did not overlap were considered as statistically significant. Multivariate analysis 
(forward multinomial logistic regression analysis) of weighted data was used to identify the 
predictors for high risk of prevalence of HBsAg among the study population.  
7. Comparison with 1992 national serosurvey 
The prevalence of HBsAg found in the 2006 national survey was compared with that of 
the 1992 national serosurvey, standardized to national census data in 2000. The target 
population of the 1992 serosurvey was persons aged 1 to 59 years residing in the same disease 
surveillance points (counties) in 31 provinces [32]. Based on the desired sample sizes, first, 3 
villages were identified from each county by systematic random selection; secondly, families 
were randomly selected according the sample size for each village; thirdly, all family members 
in selected families were investigated and blood were taken for testing for hepatitis B markers.   
The mathematical model developed by Goldstein [10] was used to estimate hepatitis B 
disease outcomes in China, and HBV chronic infections and deaths prevented by vaccination, 
using data from the 1992 and 2006 national serosurveys. Key data inputs included birth cohorts 
(from China national census data and projections), HBsAg and HBeAg prevalence among 
women of childbearing age, anti-HBc prevalence at 5 and 30 years of age, and proportions of 
children completing the three-dose vaccination series. 
8. Quality control: National specialist groups were convened to guide statistical design, 
epidemiological investigation, laboratory testing, training and analysis. Two field pilots were 
conducted before the survey. All the villages were selected at the national level. Appropriate 
visiting time was considered to ensure high response rate. Trained County CDC staffs were 
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responsible for administering the questionnaire, collecting the blood specimens, and separating, 
storing and transporting the serum specimens. 227 of 378 inconsistent laboratory results were 
confirmed by testing with Abbott reagents, and 151 were tested by neutralization method for 
final confirmation. 
9．Ethical Issues: The survey was approved by the China CDC Ethics Committee, and all 
study components done according the national ethics regulations. Study participants were 
informed of the study purpose and the right to keep information confidential.  
Results 
Overall, the survey investigated 82,078 persons, from whom 82,008 blood samples were 
collected, and 81,963 with both investigation and blood sample available. Among houses 
visited, in 93.5% the occupants participated in the survey. Among these, 81,775 (99.6%) were 
eligible for data analysis; 178 persons were excluded due to being outside the study age range, 
and for 10 persons serum samples were insufficient.    
1. Characteristics of study population 
The characteristics of study population are shown in table 16. Among the study population, 
20.0% were age 1-4 years, 29.1% age 5-14 years and 50.9% age 15-59 years. The male to 
female ratio is 0.91:1, and 86.6% were Han ethnicity. The proportions of persons reporting any 
hepatitis B vaccination were 13.8% among persons age 15-59 years; 72.7% among children age 
5-14 years, and 94.5% among children <5 years old (Table 16). 
2. Results of HBV testing and distribution of HBV serological markers by age 
Among the eligible study population, 4,150 persons were positive for HBsAg (5.1%); 
44,928 positive for anti-HBs (54.9%) and 20,163 positive for anti-HBc (24.7%). The weighted 
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prevalence adjusted to represent the Chinese population age 1-59 years were HBsAg 7.2%; 
anti-HBs 50.1%, and anti-HBc 34.1%. The major differences between unweighted and 
weighted prevalences were due to age standardization.   
Prevalence of HBsAg varied markedly by age group, increasing steadily from 0.96% 
among children age 1-4 years, to 8-12% among persons age 20 years and older (Table 17). 
Differences in prevalence were highly significant for each 5 year age group through age 20 
years, after which they did not vary significantly. The trend of prevalence of anti-HBc was 
similar to that of HBsAg, but continued to increase among adults to reach 50.0% among those 
age 50-59 years. The prevalence of anti-HBs was inverse to that of HBsAg, decreasing with 
increasing age from 72% among children age < 5 years, to 45-50% among 15-59 year olds 
(Table 17). 
3. Prevalence of HBsAg by other demographic characteristics 
HBsAg prevalence was significantly higher for males (8.6%) than females (5.7%, p<0.01) 
(Table 18). Persons of the Zhuang minority had the highest weighted HBsAg prevalence 
(13.4%), followed by Uigur (8.2%) and Han (7.2%) ethnic groups. HBsAg prevalence was 
significantly lower among Mongolian (2.1%), Hui (3.1%) and Tibetan (5.0%) ethnic groups. 
Among persons >15 years, the HBsAg prevalence decreased with increasing education level. 
The highest prevalence was in the illiterate population (9.7%), and was significantly lower in 
persons with undergraduate degrees (3.1%). Among occupation groups, HBsAg prevalence was 
lowest in health care workers and students, and highest in public service workers (22.9%) 
(Table 18). 
86 
Results – Chapter 3 
 
The HBsAg prevalence among persons living in western regions (8.3%) was higher than 
the eastern region (6.5%, p<0.05). The prevalence of anti-HBs was slightly higher in urban 
(52.6%) than in rural areas (49.3%. p<0.05), and in the western region (53.0%) than eastern 
region (46.8%. p <0.05).   
4. Relationship between hepatitis B immunization and prevalence of HBsAg 
The prevalence of HBsAg among vaccinated persons was only 2.1%, compared to 9.4% 
among unvaccinated persons (p<0.001). Similarly, prevalence of anti-HBc was lower among 
vaccinated (8.5%) than unvaccinated persons (41.1%), while the prevalence of anti-HBs was 
higher among vaccinated persons (68.2% vs. 42.6% respectively). Among all age groups, the 
immunized population had a much lower prevalence of HBsAg than un-immunized population; 
this difference was proportionally greatest in children < 5 years (Figure 7).  
5. Comparison with results of the 1992 national hepatitis serosurvey 
Compared with the national serosurvey conducted in 1992, the prevalence of HBsAg 
among children age 1-14 years born after hepatitis B vaccine was recommended for routine 
childhood immunization was much lower than same age groups in 1992 (Figure 8). In 
particular, among children < 5 years, prevalence was only 1.0%, 90% lower than in 1992 
(9.8%). For persons age 15-19 years, HBsAg prevalence was also moderately lower (P < 0.05), 
but for population aged 20 to 59 years, the prevalence of HBsAg was high in both surveys. In 
the 2006 survey, the prevalence of anti-HBc was consistently lower than in the 1992 survey, 
especially in younger age groups (Figure 9). 
Among children age 1-14 years, assuming that the force of infection remained the same as 
in 1992, and using the mathematical model to estimate hepatitis B disease outcomes, an 
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estimated 16-20 million HBV chronic infections and 2.8-3.5 million future HBV related deaths 
have been prevented [10]. 
6. HBeAg status among HBsAg positive persons 
Among HBsAg positive children <15 yrs, the proportion positive for HBeAg was high 
(>68%).  HBeAg decreased with age to 15% among persons age 40-59 years. The prevalence 
of HBeAg among HBsAg positive childbearing women was 30.0%, similar to that measured in 
1992 (Table 19).  
7. Multivariable analysis of HBsAg status for adults and children  
To identify factors that affected the prevalence of HBsAg for population aged 15 to 59 
years, a multivariable logistic regression was used, the dependent variable being the weighted 
prevalence of HBsAg; independent variables included gender, location of community (urban vs. 
rural), region, ethnicity, occupation, education, and immunization history. Results show that 
male sex (O.R= 1.7), living in the western region (O.R. 1.2), and unvaccinated persons or with 
vaccination status unknown (OR=2.5, 2.3) had higher likelihood of HBsAg positivity than 
females, persons living in Eastern region and vaccinated populations, respectively (p<0.01) 
(Table 20). Among the different ethnic groups, Inner Mongolian, Tibetan and Hui had lower 
HBsAg prevalence than Han (p<0.05), while Zhuang had borderline significantly higher 
prevalence. Public workers and others were found to have higher HBsAg prevalence than 
farmers, while students were found to have lower HBsAg prevalence (P<0.01).  
Among children aged 1 to 14 years, multivariate analysis showed the strongest predictors 
of HBsAg status were vaccination status (unvaccinated or vaccination status unknown, OR=2.5, 
2.0), and place of birth (Table 21). Children born in hospital had the lowest prevalence, while 
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those born in smaller township hospitals or at home had successively higher risk. Children aged 
10 to 14 years have higher prevalence than children aged 1 to 4 years (OR=1.9) (P<0.01). 
Among the different ethnic groups, Zhuang (OR=3.5, p<0.01) have higher prevalence than Han 
ethnicity, and other ethnic groups (mainly from southern China) had borderline significant 
higher risk (O.R = 1.5, p=0.08).  
Discussion  
Hepatitis B is among the most important infectious diseases in China. Based on the 
national serosurvey in 1992, Chinese population’s prevalence of HBsAg was about 10% for all 
age groups, including young children. The national serosurvey in 2006 shows that for 
population aged 1 to 59 years, the prevalence of HBsAg has decreased from 9.8% to 7.2%, and 
for children under 5 years is now only 1.0%. The findings from this survey indicate that the 
HBsAg prevalence in the whole population is now close to the national goal (less than 7% by 
2010), and that the prevalence for children under 5 has already reached both the national goal 
of less than 1% by 2010, and the WHO Western Pacific Regional goal of less than 2% by 2012.  
The most dramatic finding is the decrease in HBV infection risk and HBsAg prevalence 
among children born after hepatitis B vaccine was recommended for infant routine 
immunization in 1992, and especially for children born after hepatitis B vaccine was fully 
integrated into infant routine immunization in 2002. The HBsAg prevalence among children 
aged 1-4 years has decreased by 90%; in addition, HBsAg prevalence among children aged 5-9 
and 10-14 years have decreased by 86% and 72%, respectively. In these cohorts, an estimated 
16-20 million HBV chronic infections and 2.8-3.5 million future HBV related deaths have been 
prevented [10].  
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Conversely, the prevalence of anti-HBs for population aged 1-59 years has increased from 
27.4% in 1992 before hepatitis B vaccine was recommended, to 50.1% in 2006, with a four fold 
increase among children 1 to 4 years (from 15.8% to 72.3%).  
These data are consistent with many studies globally and in China which show that after 
introduction of hepatitis B vaccination programs, the prevalence of HBsAg has declined 
significantly [73, 74, 76-79, 88]. The decline of HBsAg among children in China can be attributed 
primarily to impact of hepatitis B vaccination [40], and will not only bring the decreased 
prevalence of HBsAg, but will decrease the future incidence of cirrhosis and hepatocellular 
carcinoma [71]. Other factors such as the single child policy which reduces horizontal (child to 
child) transmission in the home, and possibly safer injection practices that reduce nosocomial 
transmission may have also contributed to this decline, but their precise impact cannot be 
evaluated in this survey.  
The multivariate analysis provided useful insights into risk factors for HBsAg positivity 
among both the adult and child population, in addition to showing the clear effect of hepatitis B 
immunization. Among adults, risk factors included male sex, living in Western provinces, 
belonging to specific ethnic groups (Zhuang), and certain work professions. We found a 
relatively low HBsAg prevalence among health care workers, but also that public service 
workers had a high prevalence of HBsAg. Health care workers are in high socio-economic 
status, have better access to public health services, and some are already protected by 
vaccination, but high prevalence of HBsAg for social workers in public places is of concern, 
particularly for risk of long term disease and of discrimination. On detailed review, the high 
prevalence for public service workers was found in a single cluster of workers with high 
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prevalence of HBsAg in one large community; outside of this community prevalence among 
public workers was similar to that of other workers. 
Among children, the main risk factors for HBsAg positivity, in addition to lack of 
vaccination, included birthplace – a predictor of health care and immunization access; age, 
region and ethnicity. Infants born in hospitals are much more likely to receive a birth dose of 
HepB than those born at home; in addition, in larger hospitals mothers may be screened for 
HBsAg, and infants of those found positive may also be given HBIG (1.9% of infants born in 
larger hospitals between 2002-2005 were given HBIG). The reason for low risk in the western 
region may be greater recent improvement in vaccination status. While certain northern China 
groups (Mongolian, Hui) consistently have lower risk, risk is consistently elevated in the 
Zhuang and others mainly in southern China [32]. For these groups, particularly the Zhuang, the 
risk of developing chronic HBV infection remains high among children, in part due to lower 
accessibility to hepatitis B vaccine before incorporation in routine EPI and removal of financial 
barriers to infant immunization. 
Despite the substantial progress in preventing hepatitis B infection in children, this study 
confirms the ongoing high prevalence of active HBV infection among adults, and its 
consequent high risks of HBV transmission and chronic sequelae. The continued high 
prevalence of HBsAg and HBeAg positive women of child bearing age -- who have a 90% 
chance of infecting their newborns unless the newborns are treated with vaccine or vaccine plus 
HBIG soon after birth -- reaffirms the need to further strengthen infant immunization programs, 
including assuring timely birth doses are given to all children in the poorest areas and to 
underserved ethnic groups. In addition, expanded vaccination is needed to prevent HBV 
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infection in older children and adults, among whom 40%-50% remain susceptible to HBV 
infection. Catch-up vaccination is now planned for children less than 15 years, and 
immunization is recommended for adults at high risk. Finally, programs to prevent the 
long-term consequences of HBV infection, through screening and antiviral drug treatment, 
need to be developed and expanded to reach those at risk of developing cirrhosis and liver 
cancer. The China government has greatly expanded funding to evaluate strategies for 
prevention of hepatitis B, and for identifying and treating those persons at highest risk for 
developing cirrhosis and liver cancer [86].    
One study limitation is that study participation was limited to persons resident in the 
villages for 6 months or more, and excluded the short-term floating population, who are 
estimated to comprise 3% of the total population in China (higher in some urban areas) [68], and 
unregistered children born outside of family planning. As the majority of these persons come 
from poorer, rural areas, they may have a relatively high prevalence of HBsAg and lower 
likelihood of hepatitis B vaccination, therefore, underestimating overall HBsAg prevalence. In 
addition, 6.5% of the interviewees were not present during the visits.  
In conclusion, China has successfully integrated hepatitis B vaccine into routine 
immunization programs and has achieved very significant impact on decreasing the HBV 
chronic infection rate among children born after 1992. The national goal of reducing HBsAg 
prevalence to less than 1% by 2010 among children less than 5 years old will certainly be 
reached if current immunization programs can be sustained. To achieve the national goal for 
whole population in decreasing the prevalence of HBsAg to less than 7%, free immunization of 
infants should be maintained and timely birth dose should be targeted to reach all newborn 
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infants in the coming years. In addition, expanded vaccination is needed to prevent HBV 
infection in older children and adults. 
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Table 16: Characteristics of study population 
 Category    Frequency Proportion (%) 
Age (years) 1~4 16,376 20.0 
 
5~14 23,753 29.1 
 
15~59 41,646 50.9 
Gender Male  38,895 47.6 
 
Female 42,880 52.4 
Education Illiterate 3,993 9.6 
(15~59 years) Primary school 10,125 24.3 
 
Middle school 16,615 39.9 
 
High school 7,581 18.2 
 
Junior College 2,248 5.4 
 
Undergraduate Degree 1,068 2.6 
Occupation Student  2,232 5.4  
(15~59 years) Farmer 24,144 58.0  
 
Worker 5,352 12.9  
 
Cadre 2,443 5.9  
 
Health care worker 640 1.5  
 
Public place 1,336 3.2  
 
Others 5,499 13.2  
Ethnicity Han 70,815 86.6 
 
Mongolian  566 0.7 
 
Tibetan 1,211 1.5 
 
Uigur 1,165 1.4 
 
Zhuang 525 0.6 
 
Hui 2,441 3.0 
 
Others 5,052 6.2 
Urban/Rural Urban 40,840 49.9 
 
Rural 40,935 50.1 
Region Eastern 27,457 33.6 
 
Central 27,218 33.3 
 
Western 27,100 33.1 
Immunization  Yes 5,744 13.8 
15~59 years No 28,642 68.8 
 
Unknown 7,260 17.4 
 
Yes 17,257 72.7 
5~14 years No 3,274 13.8 
 
Unknown 3,222 13.6 
 
Yes 15,475 94.5 
1-4 years No 481 2.9 
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Unknown 420 2.6 
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Table 17: Age Distribution of HBV markers among population aged 1-59 years 
Age  
Group 
(Year) 
Sample 
Tested 
HBsAg   Anti-HBs   Anti-HBc 
 Prevalence* 
95%CI 
  Prevalence* 
95%CI 
  Prevalence* 
95%CI 
 (%)   (%)   (%) 
1~ 16,376 
 
1.0 0.8~1.2 
  
71.2 69.8~72.7 
  
4.1 3.5~4.7  
5~ 11,909 
 
1.4 1.2~1.7 
  
55.5 52.4~58.5 
  
5.5 4.7~6.3  
10~ 11,844 
 
3.2 2.6~3.8 
  
57.5 55.4~59.5 
  
10.7 9.7~11.7  
15~ 2,942 
 
5.4 4.4~6.4 
  
50.3 44.4~56.2 
  
25.0  22.3~27.7  
20~ 6,778 
 
10.5 8.2~12.7 
  
45.6  42.9~48.4  
  
38.9 36.6~41.3  
30~ 13,164 
 
8.6 7.5~9.6 
  
46.4 44.1~48.7  
  
41.8 39.3~44.3 
40~ 10,477 
 
8.5 7.4~9.6 
  
46.0 43.5~48.5  
  
45.1 42.7~47.5  
50~59 8,285 
 
8.9 7.1~10.7 
  
50.3 47.2~53.5 
  
50.0 46.6~53.4 
Total 81,775 
 
7.2 6.7~7.7   
 
50.1 48.8~51.3   
 
34.1 32.8~35.5 
 
* Weighted prevalence – see text 
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Table 18: Prevalence of HBsAg by gender, occupation, education, nationality, 
geographic, vaccine status 
    Investigated 
 
Prevalence* % 95% CI 
Gender Male  38,895 
 
8.6 7.8~9.4 
 
Female 42,880 
 
5.7 4.9~6.6 
Education Illiterate 3,993 
 
9.7  7.6~11.7  
(15~59) Primary school 10,125 
 
8.8  7.9~9.7 
 
Middle school 16,615 
 
9.1 8.1~10.1 
 
High school 7,581 
 
8.3 7.2~9.3  
 
Junior college 2,248 
 
5.9  4.2~7.7 
 
Undergraduate 1,068 
 
3.1  1.4~4.9 
Occupation Student  2,232 
 
4.0 3.0~5.0 
(15~59) Farmer 24,144 
 
8.5 7.8~9.3  
 
Worker 5,352 
 
8.9 7.7~10.1 
 
Cadre 2,443 
 
6.5 2.2~10.8 
 
Health care worker 640 
 
2.7 1.2~4.2  
 
Public worker 1,336 
 
22.9 17.4~28.4 
 
Others 5,499 
 
10.0 8.1~12.0 
Ethnicity Han 70,815 
 
7.2  6.9~7.8 
 
Mongolian  566 
 
2.1  0.8~3.3  
 
Tibetan 1,211 
 
5.0  4.1~6.0 
 
Uigur 1,165 
 
8.2  6.0~10.5  
 
Zhuang 525 
 
13.4  7.4~19.4  
 
Hui 2,441 
 
3.1  1.2~5.1  
 
Others 5,052 
 
7.0  5.6~8.4  
Region Eastern 27,457 
 
6.5 5.7~7.3 
 
Middle 27,218 
 
6.7 5.6~7.8 
 
Western 27,100 
 
8.3 7.6~8.9 
City Urban 40,840 
 
6.8 5.8~7.8 
 
Rural 40,935 
 
7.3 6.7~7.9 
Vaccinated Yes 38,476 
 
2.1 1.8~2.4 
 
No 32,397 
 
9.4 8.4~10.3 
 
Unknown 10,902 
 
7.8 5.0~10.6 
    * Weighted prevalence – see text 
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Table 19: Proportion of HBeAg among HBsAg positive person by gender 
Age 
Groups 
(Year) 
Male  Female 
HBsAg 
Positive 
Prevalence* 
(%) 
95％CI  
HBsAg 
Positive 
Prevalence* 
 (%) 
95％CI 
  
1~4 
106 76.4 65.5~87.2 
 
71 74.1 58.9~89.3 
5~14 
341 69.4 61.4~77.4 
 
249 67.6 56.4~78.7 
15~39 
962 38.4 29.6~47.2 
 
874 30.0 25.9~34.1 
40~59 814 15.7 11.8~19.6   733 15.0 11.4~18.5 
* Weighted prevalence – see text 
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Table 20: Multinomial logistic regression analysis of HBsAg prevalence among 
population aged 15 to 59 years 
Variable Category Frequency OR 
95.0% C.I. for OR 
P value 
Lower Upper 
Gender Female* 23,637 1.0 
   
 
Male 17,883 1.7 1.5 2.0 <0.01 
Urban Urban * 20,785 1.0 
   
 
Rural 20,735 1.0 0.8 1.2 0.96 
Region Eastern* 13,887 1.0 
  
  
  Central 13,833 1.1 0.8 1.3 0.70 
  Western 13,800 1.4 1.2 1.6 <0.01 
Ethnicity Han* 36,041 1.0 
     Mongolian 230 0.3 0.2 0.6 <0.01 
  Tibetan 1,296 0.5 0.3 0.7 <0.01 
 
Uigur 608 0.7 0.3 1.6 0.38 
 
Zhuang 281 1.5 0.9 2.5 0.08 
  Hui 580 0.4 0.2 0.7 <0.01 
 
Others 2,480 0.9 0.7 1.1 0.32 
Occupation Student 2,117 0.6 0.5 0.9 <0.01 
  Farmer* 24,136 1.0 
   
 
Worker 5,352 1.1 0.9 1.3 0.36 
 
Cadre 2,442 1.2 0.4 3.7 0.71 
 
Health worker 639 0.5 0.2 1.2 0.12 
  Public worker 1,335 3.8 2.9 4.8 <0.001 
 
Others  5,499 1.4 1.1 1.8 <0.01 
Education Illiterate 3,972 2.8 0.9 8.7 0.07 
 
Primary School 10,097 2.4 0.8 6.3 0.11 
 
Middle School 16,574 2.4 0.9 5.6 0.08 
 
High School 
  
 
7,564 2.2 0.9 4.6 0.76 
 
Junior College 2,246 1.4 0.8 2.5 0.21 
 
Undergraduate * 1,067 1.0 
   Immunization 
History 
Yes* 5,730 1.0 
  
  
No 28,557 2.5 1.9 3.2 <0.01 
Unknown 7,233 2.3 1.5 3.6 <0.01 
*Reference category 
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Table 21: Multinomial logistic regression analysis of HBsAg prevalence among 
population aged 1 to 14 years 
Variable Category Frequency OR 
95% C.I. for OR 
P value 
Lower Upper 
Gender Female * 19,169 1.0 
   
 
Male 20,960 1.3 0.9 1.9 0.20 
City Urban * 19,999 1.0 
   
 
Rural 20,130 1.1 0.8 1.4 0.65 
Region Eastern* 13,530 1.0 
  
  
  Central 13,336 1.0  0.7  1.3  0.23  
  Western 13,263 0.6 0.4 0.8 <0.01 
Age group 1-4* 16,376 1.0 
   
 (yrs) 5-9 11,909 1.1  0.9  1.4  0.41 
  10-14 11,844 1.9 1.3  2.7  <0.01 
Ethnicity Han* 34,668 1.0 
   
 
Inn Mongolia 336 0.2 0.0  1.2 0.08 
  Tibetan 1,138 1.0  0.6 1.7  0.98 
 
Uigur 599 1.9 0.5  7.4  0.35 
 
Zhuang 244 3.5  1.8  6.9 <0.01 
 
Muslim 583 0.9 0.3  2.5 0.89 
 
Others 2,561 1.5  0.9 2.4 0.08 
Immunization 
History 
Yes* 32,732 1.0 
  
  
No 3,755 2.5  1.5  4.1 <0.01 
Unknown 3,642 2.0 1.4 3.0 <0.01 
Birth Place County Hospital 19,156 1.0 
   
 
Township hospital 11,266 2.1 1.5 3.5 <0.01 
 
Home 8,631 4.0 2.7 6.0 <0.01 
 
Others 1,076 3.5 2.0 6.3 <0.01 
*Reference category 
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Figure 7: Relationship between immunization and prevalence of HBsAg, by age 
 
 
  
P<0.001 
P<0.001 
P<0.001 
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Figure 8: Comparison of Prevalence of HBsAg in 1992 and 2006 
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Figure 9: Comparison of Prevalence of anti-HBc in 1992 and 2006 
 
 
 
 
 
0
20
40
60
80
Pr
ev
al
en
ce
 o
f A
nt
i-H
Bc
 (%
) 
Age (Year) 
1992 2006
103 
Results – Chapter 4 
 
4. Chapter 4: Factors Associated with Effectiveness of the First Dose of Hepatitis B 
Vaccine in China -1992-2005£ 
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Background: In China, the prevalence of chronic hepatitis B infection was high because of 
perinatal and early childhood transmission. A three-dose hepatitis B vaccine schedule with a 
first dose as soon as possible after birth was introduced in 1992 and generalized in 2002 in the 
Expanded Programme of Immunization (EPI). In 2006, a serological survey evaluated the 
effectiveness of vaccination. 
Methods: We conducted a restricted analysis of the national serological survey that sampled 
children and collected information on demographic characteristics, birth history, hepatitis B 
vaccination and hepatitis B surface antigen (HBsAg) status as determined by ELISA testing. 
We compared children who received the first dose in a timely way (i.e., within 24 hours of birth) 
with others in terms of HBsAg status, stratified by birth cohort and place of birth. 
Results: Three-dose hepatitis B vaccine coverage increased from 60.8% for children born in 
1992 -1997 to 93.2% for children born in 2002 - 2005. Meanwhile, timely birth dose coverage 
increased from 38.7% to 74.4%. Among 29,410 children born in 1992-2005 who had received 
three vaccine doses and no hepatitis B immune globulin, factors associated with being HBsAg 
negative in multivariate analysis included receiving a timely birth dose (p=0.04), birth after 
1998 (p<0.001), living in an urban setting (p=0.008) and hospital birth (p=0.001). The relative 
prevalence of HBsAg among children receiving the timely birth dose was lower for children 
born in county or larger hospitals (0.39), intermediate in township hospitals (0.73) and highest 
at home (0.87). 
Conclusions: Hospital birth and receiving a timely birth dose are the main determinants of the 
field effectiveness of the first dose of hepatitis B vaccine. Efforts to increase the proportion of 
hospital deliveries are key to increasing timely birth dose coverage and its effectiveness.  
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Background 
Hepatitis B virus (HBV) infection is more likely to become chronic among persons 
infected as infants or young children [89] leading to a substantial burden of chronic liver disease 
in settings where perinatal transmission is common [32]. HBV is most efficiently transmitted 
from the mother to the child during delivery, but also is frequently transmitted among young 
children in low socioeconomic or poor hygienic conditions. Chronically infected persons are at 
increased lifetime risk for cirrhosis and hepatocellular carcinoma (HCC) and serve as the main 
reservoir for continued HBV transmission. Current anti-viral treatment is costly and has limited 
effectiveness in resolving chronic HBV infection [33, 83]. Thus, hepatitis B vaccination of infants 
is the most effective measure to prevent HBV infection and its consequences [14, 
90]. Recommendations advise that vaccination should occur as soon as possible after birth 
[14].  In practice, a "timely" birth dose of hepatitis B vaccine is one that is administered in the 
first 24 hours of life. WHO recommends improving the system to deliver the timely birth dose 
of hepatitis B vaccine as a priority to eliminate hepatitis B virus transmission in high 
endemicityregions. However, availability of epidemiological data on the actual field 
effectiveness of the timely birth dose in the Expanded Programme of Immunization (EPI) is 
limited.  
China has made strong efforts to establish hepatitis B immunization with universal infant 
immunization [42, 50]. The recommended schedule includes a first dose within 24 hours of birth 
and subsequent doses at one and six months of age. This schedule was reported to be 70-95% 
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effective in preventing transmission from mother to infant. In 1992, the Ministry of Health 
(MOH) recommended routine immunization of infants against hepatitis B. In 2002, China fully 
integrated Hepatitis B vaccine into the routine immunization program with support from the 
Global Alliance on Vaccines and Immunization (GAVI). As a result, three-dose immunization 
coverage reached high levels (93.4% in 2005) in all areas, including Western provinces [50]. In 
2006, a serological survey documented the impact of the introduction of hepatitis B vaccine on 
the prevalence of chronic infection among Chinese children [80].   
In remote areas, giving hepatitis B vaccine within 24 hours of birth can be difficult 
logistically, particularly for home deliveries as cold-chain infrastructure is limited in villages 
[91]. Children born at home represented 14% of the birth cohort, or 2.2 million children, in 2005. 
In 1999 a survey indicated that the coverage of the timely birth dose among these children was 
only 17% [42]. These findings resulted in the development and implementation of a strategy to 
improve timely birth dose coverage. The strategy included (1) increasing the percentage of 
hospital births, (2) improving vaccine availability in health facilities, (3) promoting a hospital 
policy by which “whoever delivers the infant gives the hepatitis B birth dose”, and (4) 
increasing awareness among providers and parents. Following the implementation of this 
strategy, the coverage of the timely birth dose increased from 35% among children born in 
1992–2001 to 83% among children born in 2005 [50].  However, the actual health impact of 
improved coverage has not been estimated.  Hence, we conducted a restricted analysis of the 
2006 serological survey to examine in detail the association between the circumstances of 
administration of the first dose of hepatitis B vaccine and hepatitis B surface antigen (HBsAg) 
prevalence in infants [40].  
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Methods 
1. Study population and design: The study population consisted of children born 
between 1992 and 2005 who were included in the 2006 national serological survey in 160 
national Disease Surveillance Points (DSP) in 31 provinces. These were selected by China 
Center for Disease Control and Prevention (CDC) to be representative of the population of 
China. We restricted our study sample to children who had received three doses of hepatitis B 
vaccine. Among those, we compared the HBsAg prevalence among those with and without 
timely birth dose. To adjust for confounders, we stratified by birth cohort and place of delivery. 
In addition, we excluded the small proportion (1.3%) of children who had received hepatitis B 
immune globulin (HBIG) at birth. Although the national programme does not finance HBsAg 
screening of pregnant women and HBIG delivery in those who are HBsAg positive, this 
practice occurs in selected settings, particularly larger, urban hospitals. Information was not 
available for this study about whether the mother had been screened for HBsAg; however, 
information was available regarding whether the infant received HBIG. Because of concerns 
that these children might not be comparable to those who received hepatitis B vaccine alone, 
we excluded children who received both HBIG and hepatitis B vaccine from our study. 
2. Sampling method: The detailed sampling methods are reported elsewhere [40, 80]. 
Briefly, 369 townships were first identified from 160 counties by simple random selection. 
Second, one village was randomly selected from each township. Third, the population aged 1-4 
and 5-14 years was enumerated and selected with a systematic interval from a list of village 
residents.  
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3. Investigations: House to house investigations were conducted by trained staff based on 
the sampled name list. Basic information including gender, birth date, ethnicity, place of birth 
and immunization history was compiled through parent interview. Immunization status was 
recorded from the child’s home immunization certificate or, if not available, through a review 
of the child’s immunization card at the township immunization clinic. If neither were available, 
the village doctor’s registry was reviewed. In the absence of any information, the child's 
immunization status was recorded as "unvaccinated" or "unknown". "Full vaccination" was 
defined as having received three doses of hepatitis B vaccine within 12 months, documented by 
any immunization record. Timely birth dose vaccination was defined as receiving the first dose 
of hepatitis B vaccine within 24 hours of birth.  
4. Specimen collection and testing: Blood specimens were collected for each study 
participant, and serum tested at the National Hepatitis Laboratory at the Chinese Centers for 
Disease Control and Prevention in Beijing. The laboratory used a single lot ‡‡  of 
Enzyme-linked immunosorbent assay (ELISA) reagents for HBsAg and antibody to the 
hepatitis B surface antigen (anti-HBs) testing from Xinchuang Production Company (Xiamen).  
Reagents to detect antibodies against hepatitis B core antigen (Anti-HBc) were procured from 
the Kehua Company (Shanghai). For specimens with inconsistent results, ELISA reagents 
(Abbott) were used for reconfirmation testing. The neutralization method was used for final 
HBsAg confirmation. 
5. Data analysis: All data were entered twice in the computer using EPI Data 3.02 
software. After consistency check and accuracy verification, the data was analyzed with SAS 
‡‡ Batch numbers 2006071301 (HBsAg), 2006071401(anti-HBs), and 20060705(anti-HBc)  
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9.13 software. The weighted prevalence rates of hepatitis B vaccination and hepatitis B virus 
(HBV) serological markers included the point estimates and their estimated 95% confidence 
intervals (CI) [63, 80]. Multivariate forward logistic regression was used to identify the factors 
independently associated with positive HBsAg status.  
6. Quality control: National specialist groups were convened to guide statistical design, 
epidemiological investigations, laboratory testing, logistic services, training plans and data 
analysis. Two field pilot studies were conducted before the survey. Appropriate time was 
allotted to visit houses on multiple occasions at different times to ensure a high response 
proportion. Trained county CDC staff conducted all aspects of the local field work.  
7．Ethical issues: Study participants were informed of the study purpose and their right to 
keep information confidential. The survey was approved by the China CDC Ethical Committee. 
All procedures were conducted according to the national ethics regulations.  
Results 
1. Vaccination status and HBsAg prevalence among children born in 1992-2005 
Three-dose hepatitis B coverage increased from 60.8% among the 11,844 children born in 
1992-1997 to 79.8% among the 11,909 children born in 1998-2001 and to 93.2% among the 
16,376 children born in 2002-2005. Meanwhile, timely birth dose coverage increased from 38.7% 
to 56.8% and 74.4% in these cohorts. HBIG use was reported to be 0.4%, 0.7% and 1.4% of 
children born in 1992-1997, 1998-2001 and 2002-2005, respectively. Among the 352 children 
who received HBIG, 266 (75.6%) were born at hospitals at the county level or above, 70 
(19.9%) were born at township hospitals, 14 (4.0%) were born at home, and 2 (0.5%) were 
born in other settings. Among children born between 1992 and 2005, the prevalence of HBsAg 
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was 1.3% among fully immunized children, 2.9% for children receiving an incomplete vaccine 
series and 5.0% for children not immunized. The prevalence of HBsAg was lower among 
children who received a timely birth dose or were born in hospital(Table 22). The remainder of 
the analysis was based upon the 29,420 children born in 1992-2005 who had received three 
hepatitis B vaccine doses without HBIG. These accounted for 55.9% of children born in 
1992-1997 （N=6,624）, 73.7% of children born in 1998-2001 (N=8,780) and 85.6% of children 
born in 2002-2005 (N=14,016) 
2. Timely birth dose and prevalence of HBsAg among fully immunized children with no 
HBIG  
Among children fully vaccinated but who did not receive HBIG, 73% of infants received a 
timely birth dose. Others received hepatitis B vaccine 2 -7 days after birth (4.7%), and 8 -27 
days after birth (4.3%), and more than 27 days after birth (18%). The prevalence of HBsAg was 
0.97% among children fully vaccinated with a timely birth dose, 0.41% for children fully 
vaccinated who received the first dose after 24 hours but before seven days and 1.4%-2.7% 
among children fully vaccinated who received the first dose eight days or later (Table 23).  
3. Timely birth dose and prevalence of HBsAg among fully immunized children with no 
HBIG, by birth cohort 
For all birth cohorts of children fully vaccinated without HBIG, the HBsAg prevalence 
tended to be lower among those who had received a timely birth dose.  Overall, the later the 
birth dose, the higher the prevalence of HBsAg. However, a delay of seven days after birth was 
not associated with higher HBsAg prevalence (Table 24). 
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4. Timely birth dose and prevalence of HBsAg among fully immunized children with no 
HBIG, by birth place 
Among children born between 1992 and 2005 fully immunized without HBIG, 73% had 
received the first dose on time and 55% were born at a hospital at the county level or above 
(Table 25). Regardless of birth setting, the prevalence of HBsAg was significantly lower 
among children who had received a timely birth dose. However, there was a trend for this 
difference to be larger in hospitals at the county level or above (prevalence ratio: 0.39), 
intermediate in the township hospital (prevalence ratio: 0.73) and less marked in homes and 
other settings, (prevalence ratio: 0.87 and 0.84, respectively). A global chi-square test 
suggested that these prevalences were heterogeneous (χ2=27.78, p<0.001).  
5. Multivariate regression analysis  
The multiple logistic regression examined the effect of the timing of first dose (within one 
day, after one day but within seven days, eight-14 days, 15-27 days, 28-180 days, 181 days 
above) stratified stepwise by ethnicity (Han versus others), region (East, Central, West), setting 
(urban versus rural) and birthplace. Overall, the most important factor was the location of birth, 
with the lowest prevalence of HBsAg among children born in hospitals at the county level or 
above and the highest among those born at home. Residing in an urban setting was also 
independently associated with lower HBsAg prevalence. Children who had received the first 
dose within seven days of birth had an HBsAg prevalence that was lower than those who had 
received it within 24 hours. However, this difference was not statistically significant. Children 
who had received the birth dose after seven days had higher HBsAg prevalence, but this 
difference was significant only for those who received the birth dose after 181 days (Table 26).  
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Discussion 
With respect to the factors associated with HBsAg prevalence among children fully 
vaccinated but who did not receive HBIG, the timing of the first dose of vaccine and the 
birthplace played the greatest roles. In addition, the effect of the timing of the birth dose varied 
according to birthplace. 
Children born in hospitals had a lower HBsAg prevalence than those born at home. In 
China, mothers who give birth in hospitals usually have more education and higher family 
income than mothers who give birth at home. They may have better acceptance of medical and 
preventive health care [92, 93], and thus be more willing for their babies to be vaccinated early. In 
addition, it is logistically easier to give a child born in hospital a timely first dose of hepatitis 
vaccine as opposed to a child born at home. Taking these factors into account, it is not 
surprising that timely birth dose coverage was higher among children born in hospitals. 
However, our data suggested that birth in hospital per se was associated with lower HBsAg 
status independently of the higher birth dose coverage in hospitals.  
The HBsAg prevalence was lower among children who received the first dose within 24 
hours than among those who received it more than 7 days after birth. This suggests that 
providing the first dose of hepatitis B vaccine within 24 hours of delivery provides additional 
protection.  Published studies suggest that hepatitis B vaccine should be given within 24 hours 
after birth [94, 95] to provide early protection [1]. Most countries have strategies to deliver timely 
birth doses [77, 96].  
While vaccine delivered more than seven days after birth resulted in a higher prevalence of 
HBsAg, in our study we failed to detect a major difference of HBsAg prevalence between 
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children who received the first dose within 24 hours and those who received it within seven 
days of birth. Delays of the birth dose within seven days did not seem to be associated with 
substantially lower protection in each birth cohort. A number of factors may explain this 
finding. First, vaccine given within one week may still be effective since the incubation period 
of the virus may be six months or longer [14, 89, 97]. Second, as a result of the sustained efforts for 
hepatitis B control in China, the prevalence of HBsAg among childbearing women was lower 
in 2006 (6.7%) than in 1992 (9.8%) [80]. Therefore, vertical transmission may play less of a role 
than in the past [32, 96]. 
The results of our analysis also indicate that the effectiveness of the birth dose differed by 
birth setting. Four factors may have had an impact. First, caliber of staff and equipment may be 
better at larger hospitals (county and above). In these settings, professionals may be better 
trained and more skilled, resulting in better vaccination technique. The quality of cold chain 
equipment may have been better in larger hospitals. At peripheral levels in China, cold chain 
equipment is limited and the vaccine could have been exposed to freezing which could have 
affected potency [88]. Second, the quality of data at lower levels may be less good. As a result, 
some children recorded as being vaccinated within 24 hours after birth may in fact have been 
vaccinated later than this. Third, screening mothers for HBsAg to provide HBIG to infants is a 
practice that is more common in larger, better equipped, urban hospitals. We excluded children 
who received HBIG from our study, and may thus have decreased the risk of perinatal 
transmission in the hospital-born babies included in the study relative to those born in lower 
level facilities. Finally, while doctors are instructed to give both hospital and home-born 
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children a dose of vaccine at the first opportunity, this opportunity may occur later for children 
born at home.  
This study was subject to some limitations. First, as already discussed, some children may 
have been misreported as being vaccinated with 24 hours when they were not. Second, we had 
no data on pre-natal screening. Babies of mothers identified as HBsAg positive may have 
preferentially received timely birth doses leaving a pool of babies of HBsAg-negative mothers 
who would be less affected in terms of HBsAg status by delays in receiving the first dose of 
vaccine. Third, we excluded children who had received HBIG. This exclusion of some children 
at high risk of perinatal transmission may have led to an underestimation of the relative effect 
of the timely birth dose in this population. 
In conclusion, controlled trials indicate that receiving a dose of vaccine within 24 hours of 
birth is highly effective for hepatitis B prevention among children born to infectious 
HBsAg-positive, and HBeAg-positive mothers. Hence, this remains the gold standard, and 
hepatitis B vaccination programmes should provide the birth dose as soon as possible, within 
24 hours if feasible. While our field data suggest that delayed delivery of the first dose within 
one week is not associated with high HBsAg prevalence, these findings should be confirmed by 
further studies before forming the basis of programmatic recommendations. However, these 
findings do support that there is still a benefit in administering the first dose as soon as possible 
if the first 24 hour deadline has passed. Finally, our data suggest that, in China, pregnant 
women should give birth in hospital.  In these settings (1) the birth dose coverage is at its 
highest and (2) the birth dose has maximum effectiveness. Increasing hospital births is not only 
the most effective programmatic way to increase the coverage of the hepatitis B birth dose, it 
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also results in reduction of neonatal and maternal mortality and promotion of neonatal tetanus 
elimination.  
 
  
116 
Results – Chapter 4 
 
Table 22: Prevalence of HBsAg according to selected characteristics, 1992-2005 
birth cohorts, China 
Factors No. 
tested 
HBsAg prevalence 
Un-weighted Weighted 
No. % % 95% CI 
Birth cohort 
        1992-1997 11,844 399 3.4 3.69 3.68-3.71 
   1998-2001 11,909 191 1.6 1.63 1.62-1.65 
   2002-2005 16,376 177 1.1 0.95 0.94-0.96 
Number of vaccine doses 
     
0 7,397 393 5.3 4.98 4.96-5.01 
  1-2 759 16 2.1 2.94 2.88-3.00 
3 31,973 358 1.1 1.29 1.28-1.30 
HBIG received 
     
   Yes 352 8 2.3 1.34 1.24-1.44 
  No 36,330 667 1.8 2.19 2.19-2.20 
Unknown 2,929 62 2.1 2.75 2.71-2.79 
Timely birth dose  
     
   Yes 23,535 212 0.9 1.01 1.00-1.02 
   No 16,594 555 3.3 3.33 3.32-3.35 
Place of birth 
     
   County hospital  
 b  
19,156 178 0.9 1.09 1.08-1.10 
  Township hospital 11,266 184 1.6 1.75 1.73-1.76 
  Home 8,631 356 4.1 4.52 4.49-4.54 
  Other 603 22 3.6 3.62 3.53-3.70 
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Table 23: Prevalence of HBsAg among children fully vaccinated against hepatitis B 
according to the timing of the first dose, 1992-2005 birth cohorts, China* 
First dose of 
hepatitis B vaccine 
No. Tested HBsAg Un-weighted 
 
HBsAg weighted 
No. positive % 
 
% 95% CI 
Within 1 day 21,529 193 0.90 
 
0.97  0.96-0.98 
1-7 days 1,375 8 0.58 
 
0.41  0.39-0.43 
8-14 days 547 10 1.83 
 
2.33  2.25-2.41 
15-27 days 722 12 1.66 
 
1.40  1.35-1.45 
28-180 days 3,220 57 1.77 
 
1.50  1.43-1.62 
181 Days+ 2,027 49 2.53 
 
2.71  2.68-2.74 
Total 29,420 329 1.12   1.31 1.30-1.32 
*Excluding infants who received HBIG 
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Table 24: Prevalence of HBsAg among children fully vaccinated against hepatitis B 
according to the timing of the first dose, by age cohorts, 1992-2005 birth cohorts, 
China 
Birth 
Cohort 
Timing of 
first dose 
No. 
tested 
HBsAg Prevalence 
Un-weighted   Weighted 
No. 
 
%   % 95% CI 
1992-1997 Within 1 day 4,164 67 1.61 
 
2.18  2.15-2.21 
1-7 days 314 2 0.64 
 
0.37  0.33-0.41 
8-14 days 146 3 2.05 
 
1.29  1.19-1.40 
15-27 days 185 5 2.7 
 
2.77  2.64-2.91 
28-180 days 879 11 1.25 
 
1.27  1.23-1.31 
181 days+ 936 35 3.74 
 
3.95  3.91-4.00 
Total 6,624 123 1.86   2.46  2.44-2.48 
1998-2001 Within 1 day 6,194 43 0.69 
 
0.60  0.59-0.61 
1-7 days 480 2 0.42 
 
0.36  0.33-0.38 
8-14 days 176 6 3.41 
 
4.41  4.24-4.58 
15-27 days 215 1 0.47 
 
0.24  0.21-0.28 
28-180 days 1,074 20 1.86 
 
1.65  1.59-1.67 
181 days+ 641 8 1.25 
 
0.94  0.91-0.97 
Total 8,780 80 0.91   0.85  0.85-0.86 
2002-2005 Within 1 day 11,171 83 0.74 
 
0.65  0.64-0.67 
1-7 days 581 4 0.69 
 
0.56  0.51-0.62 
8-14 days 225 1 0.44 
 
0.14  0.10-0.18 
15-27 days 322 6 1.86 
 
1.53  1.43-1.64 
28-180 days 1,267 26 2.05 
 
1.57  1.51-1.62 
181 days+ 450 6 1.33 
 
1.32  1.24-1.40 
Total 14,016 126 0.90    0.77  0.76-0.79 
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Table 25: Prevalence of HBsAg among children fully vaccinated against hepatitis B 
according to the timing of the first dose, by birth place, 1992-2005 birth cohorts, 
China 
Place of birth 
Timing of  
first dose 
No.  
tested 
HBsAg 
 
Relative 
prevalence* 
(95% CI) 
Crude  Weighted 
No. 
positive %  % 95% CI 
County 
above 
Within  
24 hours 13,531 94 0.69  
0.65 0.64-0.66 
 
0.39 (0.36-0.39) 
After  
24hours 2,692 21 0.78   1.70 1.68-1.73     
Township 
Within  
24 hours 6,381 68 1.07  
1.19 1.17-1.20 
 
0.73 (0.71-0.75) 
After  
24 hours 2,564 44 1.72   1.62 1.60-1.65     
Home 
Within  
24 hours 1,472 29 1.97  
1.99 1.95-2.03 
 
0.87 (0.84-0.90) 
After  
24 hours 2,482 69 2.78   2.28 2.25-2.32     
Others 
Within  
24 hours 141 2 1.42 
 
2.30 2.15-2.44 
 
0.84 (0.75-0.95) 
After  
24 hours 147 2 1.36   2.71 2.58-2.85     
Total 
Within  
24 hours 21,525 193 0.90 
 
0.97 0.96-0.98 
 
0.52 (0.51-0.53) 
After  
24 hours 7,885 136 1.72   1.86 1.85-1.88     
*Relative prevalence is ratio of weighted HBsAg among infants receiving birth dose within 24 
hours to that among after 24 hours 
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Table 26: Factors associated with HBsAg positive status in multivariable regression 
analysis, 1992-2005 birth cohorts, China 
Variables Categories Frequency Odds ratio 95% CI  P value 
Timing of the first 
dose 
Within 1 day* 21,525 1.00 
  2-7 days 1,371 0.54 0.27-1.11 0.093
8-14 days  545 1.53 0.80-2.92 0.200 
15-27 days 722 1.26 0.69-2.30 0.445 
28-180 days 3,220 1.31 0.95-1.81 0.102 
181 days+ 2,027 1.54 1.10-2.20 0.017 
Birth cohort 1992-1997* 6,624 1.00 
  1998-2001 8,771 0.52 0.39-0.70 <0.001
2002-2005 14,015 0.55 0.42-0.72 <0.001 
Ethnicity Han* 26,689 1.00 
  Others 2,721 0.95 0.65-1.39 0.781
Setting Urban 15,707 1.00 
  Rural 13,703 1.39 1.09-1.77 0.008
Region Eastern* 10,533 1.00 
  Central 10,599 1.23 0.95-1.60 0.124
Western 8,278 1.06 0.79-1.43 0.698 
Place of birth County* 16,223 1.00 
  Township 8,945 1.54 1.17-2.03 0.002
At home 3,954 2.52 1.86-3.43 <0.001 
Others 288 1.51 0.55-4.14 0.427 
Constant -4.731 -     
* Reference categories 
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Background 
In 1992, a World Health Assembly resolution called for all countries to integrate hepatitis 
B vaccination into their routine childhood immunization programmes by 1997 [16]. In 2010, 
WHO estimated that each year, 500,000-700,000 deaths were caused by hepatitis B [98], many 
of those in Asia[98]. Use of hepatitis B vaccine in routine immunization has been shown to be 
cost effective [14]. However, it may represent an investment that is too large for national 
governments to pay. The risk then is of selective introduction among those who can afford it, 
which results in inequities [99]. Inequities in viral hepatitis burden and poverty mutually 
aggravate each other while equity in preventive health services breaks this cycle [100,101-103]. 
Thus, immunization must be accessible to all[104]. Donors, lenders and partners, including the 
Global Alliance for Vaccine and Immunization (GAVI), invest funds to help national 
governments introduce new vaccines free of cost in the entire population. Overall, 
immunization services, including mass immunization campaigns have a documented track 
record of working against inequities [101, 105,106]. Studying these inequities in disease burden or 
access to vaccine may help reducing them through adapted intervention, including free, 
universal immunization. 
In 1985, Chinese manufacturers initiated domestic production of hepatitis B vaccine which 
resulted in local introduction on the Chinese market. In 1992, use of the vaccine in the absence 
of any national guidelines already resulted in a three-dose vaccine coverage of 30% among 
infants, while hepatitis B timely birth dose (TBD: within 24 hours of birth) coverage reached 
22%[40]. The same year, the Ministry of Health first recommended hepatitis B vaccine for 
routine vaccination of infants because of the high prevalence of hepatitis B virus infection and 
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the large disease burden. However, local health departments charged parents for the vaccine 
and administrative costs. As a result, infant vaccination occurred primarily in large cities of 
wealthier Eastern provinces [107]. In 1999, three-dose coverage of hepatitis B vaccine reached 71% 
[42], but was 26% higher in urban than in rural populations[108] and 1.5 higher in males than in 
females [109, 110].  Moreover, surveys indicated that the TBD coverage was only 44%. Two 
years later, in 2002, the three dose coverage had increased to 84% but remained 38% higher 
among children of higher socio-economic status than among others [68, 111]. The cost of 
vaccination was one of the reasons of the slow progress [112,113]. Thus, identifying a financial 
mechanism to reach all infants became a priority[32]. 
In 2002, China collaborated with GAVI to implement a five-year project to provide free 
hepatitis B vaccine and Auto-Disable syringes (AD) for all infants in China[107]. This was 
planned through GAVI support of the Western region and 223 poverty-affected counties of the 
Central region. China received GAVI support because of (1) high prevalence of hepatitis B, (2) 
low vaccine coverage in poorer areas, (3) a national annual Gross Domestic Product (GDP) per 
capita < $1,000 with a government that could not afford universal, free vaccination and (4) 
political commitment to protect infants at risk. The 76 million USD project was funded 50% by 
GAVI and 50% by the Government of China. Central and sub-national levels shared a common 
responsibility and clarified each other role and responsibilities. GAVI support was used for the 
purchase of vaccine and injection devices. In addition, the government of China implemented a 
strategy that included (1) increasing awareness of the importance of TBD among providers and 
parents, (2) intensifying training for health care worker (HCW), (3) improving hospital delivery 
rate through provisions of subsidies, (4) building bridges between maternal and child health 
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(MCH) and immunization services and (5) subsidizing providers. Monitoring and supervision 
mechanisms were also built into the project. A national coverage survey in 2004 already 
showed progress, with a three-dose hepatitis B coverage of 94% in the East, 92% in the Centre 
and 68% in the West [51]. In 2005, the Government decided to abolish user's fees and all 
hepatitis B vaccination were provided for free. Overall, from 2002 to 2007, the GAVI China 
project provided doses of hepatitis B vaccine for 29,282,364 children, along with 206,649,679 
AD syringes. In 2008, the project was extended for two years. In 2010, we conducted a final 
evaluation to measure hepatitis B coverage and progress in equity with respect to protection 
against hepatitis B. 
Methods 
We reviewed routinely reported coverage data and conducted a national stratified, 
validation, cross-sectional survey in October 2010. 
Definitions 
We defined a timely birth dose of hepatitis B vaccine (TBD) as a dose of hepatitis B 
vaccine received by a surviving infant within 24 hours after birth. The targets of the GAVI 
project were to increase (1) three dose coverage of hepatitis B vaccine (HepB3) in children 
under 12 months to 85% and (2) to increase TBD coverage to 75%. These two targets had to be 
achieved at the county level. We defined the urban and rural setting according to the 
geographic location and the national statistical bureau definition. We defined regions as Eastern 
(Beijing, Tianjin, Liaoning, Shandong, Jiangsu, Shanghai, Zhejiang, Fujian, and Guangdong), 
Central (Hebei, Shanxi, Heilongjiang, Jilin, Henan, Anhui, Hubei, Hunan, Jiangxi, and Hainan) 
and Western (Inner Mongolia, Guangxi, Chongqing, Sichuan, Guizhou, Yunnan, Tibet, 
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Shaanxi, Gansu, Ningxia, Qinghai, and Xinjiang,) according to national classification by 
geographic location and economic status [80, 107]. 
Sampling methodology 
We used the methods recommended by WHO to select a cluster sample of health care 
facilities for the purpose of injection safety assessments (The final GAVI evaluation included 
an injection safety assessment, see chapter 6)[114]. The injection safety assessment component 
of the final evaluation of the GAVI project was used to design the sampling strategy as its 
required confidence intervals that needed to the calculated using the WHO reference guidelines. 
First, we stratified the country into Eastern, Central and Western regions. Second, in each 
region, we selected eight counties using the probability proportional to population size (PPS) 
methods. Third, in each selected county, we selected 10 townships at random from the list and 
the county-level hospital. Fourth, in each selected township, we investigated the township 
hospital that maintained all immunization records. In each region, the sample size was eight 
clusters of 10 facilities, for a total of 80 facilities as per the WHO guidelines [114]. 
In addition, we reviewed each of the county hospitals, for timely birth dose evaluation. 
Finally, we collected timely birth dose data from the county level hospital that accounted for a 
large proportion of the deliveries in each county.  
Data collection 
We constituted a national team by recruiting 40 health professional working in EPI from 
national and provincial CDCs, trained them using the same standard protocol for data collection, 
and then divided eight groups who each visited 24 counties from 12th to 30th October 2010. 
Provincial staff recruited did not go to their own provinces. Teams collected birth cohort, DTP 
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and hepatitis B vaccine coverage data, including TBD and full series, in each township 
hospital.  
Data analysis 
Coverage 
Ratios: We calculated the ratio of the number of three doses of hepatitis B vaccine 
administered/the number of infants targeted for DTP3 as an indicator of the progressive 
introduction of hepatitis B vaccine into routine EPI. We calculated the ratio of TBD 
administered/infants targeted for DTP1 as an indicator of the progress in TBD coverage from 
2004 onwards (TBD coverage was not routinely reported before 2004). These indicators were 
only calculated in the GAVI supported areas.  
Reported coverage: Each calendar year, the various level of the CDC system (county, 
prefecture, provincial and national) reported coverage calculated by dividing the number of 
doses administered by the number of children registered for vaccination in health care facilities. 
This data was available for the whole of China. 
Estimated coverage: Because the number of children registered for vaccination differed 
from the National Bureau of Statistics figures, we calculated estimated coverage using 
denominators from the National Statistical Yearbook [115]. As studies reported that the some 
townships that did not report vaccination status of children to county level [116], we adjusted 
numerators to take this underreporting into consideration, according to China-specific WHO 
recommendations [117, 118]. In this adjustment, the numerator consisted of those recorded as 
vaccinated plus half of the difference between the estimated National Bureau of Statistics birth 
cohort as drawn from the National Statistical Yearbook and the birth cohort as estimated by the 
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EPI. Since 2005, China has used this adjustment method to officially report vaccine coverage 
estimates through the WHO and UNICEF Joint Reporting Form (JRF). Estimated coverage 
data were available for the whole of China. 
Surveyed coverage: We calculated survey coverage estimates by dividing the number of 
doses administered by the number of children registered on the birth cohort at the township 
level hospital. This data was available for the sample of townships investigated as part of the 
2010 final evaluation. 
Equity indicators 
We used coverage and ratios to measure inequities and gaps. We compared coverage 
among males and females, as well as among urban and rural area. We obtained data regarding 
the 2009 GDP per capita for each county (which was estimated based on the reported data of 
previous year) from in our sample from the Internet site of the county government. We 
compared the ratio of vaccine coverage across counties regrouped in GDP quintiles. We used 
the Contraction Index (CI) to measure the equity of coverage among regions, we considered 
CI<0 as pro-rich, 0 was equity, >0 was considered as pro-poor [106]. CI was defined as the 
following: 
,  
Where, X was proportion of accumulated population by GDP rank, Y was the accumulated 
coverage by the rank, Y0=0, X0=0 [119]. 
We used SPSS and Excel software for data analysis. 
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Results 
1. Vaccine coverage by year 
Progress in hepatitis B vaccine introduction in GAVI supported areas: Overall, in the 
GAVI supported areas, the HepB3/DTP3 ratio increased from 57% in 2002 to 94% in 2009; a 
37% increase in seven years; with the most dramatic increase between 2002 and 2005. The 
TBD/DTP1 ratio increased from 64% in 2004 to 88% in 2009; a 25% increase in five years 
(Figure 10).  
National surveyed coverage: We visited 244 townships as part of the final evaluation (71 
in the East, 86 in the Centre and 87 in the West). Overall, in these 244 townships, surveyed 
TBD coverage increased from 60% in 2002 to 91% in 2009 and surveyed three dose of 
hepatitis B vaccine coverage increased from 71% in 2002 to 93% in 2009 (Table 27, Figure 
11).  
2. Regional and gender differences 
Three dose of hepatitis B vaccine: In Eastern areas, surveyed coverage of three dose 
hepatitis B vaccine increased from 89% in 2002 to 92% in 2009 (+3%). In Central areas, during 
the same time, it increased from 65% to 96% (+31%), bringing the Central/Eastern coverage 
ratio from 0.73 to 1.04. In Western areas, it increased from 47% to 90% (+43%), bringing the 
Western/Eastern coverage ratio from 0.53 to 0.98 (Table 27).  
TBD: In Eastern areas, surveyed TBD coverage increased from 82% in 2002 to 96% in 
2009 (+14%). In Central areas, it increased from 51% to 86% (+35%), bringing the Central / 
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Eastern coverage ratio from 0.63 to 0.90. In Western areas, it increased from 26% to 86% 
(+60%), bringing the Western/ Eastern coverage ratio from 0.3 to 0.9. 
On the basis of the 2010 survey data, the concentration index for three dose of hepatitis B 
vaccine decreased from 0.12 in 2002, to 0.02 in 2005 and to 0 in 2008 and 2009. 
3. Vaccination coverage according to GDP per capital  
From 2002 to 2009, the surveyed three dose of hepatitis B vaccine coverage increased 
from 71% to 93% overall. In the 1st quintile, it increased from 80% to 98% while in the 5th 
quintile, it increased from 53% to 93%. The ratio of 5th to 1st quintile coverage increased from 
0.66 in 2002 to 0.95 in 2009 (Table 28). Reported coverage and estimated coverage showed 
less progress in terms of the 5th to 1st quintile coverage ratio from 2002 to 2009, from 0.95 to 1, 
and from 0.85 to 0.97, respectively (The baseline 2002 values were already higher). Although 
the ratio was higher between 2nd and 4th quintile than ration between 5th and 1st in 2002, but all 
ratios reached up to 1 in 2009.  
From 2002 to 2009, the surveyed TBD coverage increased from 60% to 91% overall. In 
the 1st quintile, it increased from 76% to 97% while in the 5th quintile, it increased from 27% to 
85%, for as ratio of 5th to 1st quintile coverage ratio that increased from 0.35 in 2002 to 0.88 in 
2009 (Table 29). Reported coverage and estimated coverage showed less progress in terms of 
the 5th to 1st quintile coverage ratio from 0.62 in 2004 to 0.90 in 2009, from 0.72 in 2002 to 
0.94 in 2009, respectively. The ratio trends were similar as trend of three dose of hepatitis B 
vaccine.  
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4. Proportion of counties having reached GAVI targets (Reported coverage)  
As of 2009, with respect to the three doses of hepatitis B vaccine criteria (hepB3/DTP3 
ratio), among 22 GAVI project provinces, 16 provinces had reached the GAVI China target in 
all counties and five additional provinces had reached it in 85% of counties. One province, 
Tibet had only reached the target in 76% of counties. Overall, 98% of the GAVI-supported 
counties reached the three dose of hepatitis B vaccine goal. These accounted for 99% of the 
population in the GAVI-supported areas. 
As of 2009, with respect to the TBD criteria, among 22 GAVI project provinces, 11 
provinces met the target in all counties, six provinces had met the target 85% of counties, and 
only five (Tibet, Gansu, Yunnan, Guizhou, and Sichuan) had reached target in less than 85% of 
counties (Figure 12). Overall, 80% of the GAVI-supported counties reached the TBD goal. 
These accounted for 79% of the population in the GAVI-supported areas. 
In terms of both targets, 80% of the GAVI-supported counties reached both the three dose 
of hepatitis B vaccine and TBD goals. These accounted for 79% of the population of the 
GAVI-supported areas. 
5. Validation of reported and estimated coverage 
Overall, the reported three dose of hepatitis B vaccine coverage increased minimally from 
95% in 2002 to 99% in 2009 (+4% in 7 years). According to these reported data, the Western/ 
Eastern coverage ratio only progressed from 0.92 to 0.99 between 2002 and 2009. Estimated 
three dose of hepatitis B vaccine coverage increased more from 74% in 2002 to 96% in 2009 
(+22% in 7 years). The Western/Eastern estimated coverage ratio progressed more from 0.85 to 
0.94 between 2002 and 2009. Surveyed three dose of hepatitis B vaccine coverage showed the 
132 
Results – Chapter 5 
 
largest increase, from 71% in 2002 to 93% in 2009 (+22% in 7 years). Surveyed coverage 
showed the largest progress in terms of the Western/Eastern coverage ratio, from 0.53 to 0.98 
between 2002 and 2009. 
Discussion 
From 2002 to 2009, following GAVI support to the hepatitis B vaccination programme, 
the national coverage of three dose of hepatitis B vaccine increased dramatically, from 71% to 
93% as per survey data. Overall, the 2002 coverage gap that affected Western and Central 
provinces was closed in 2009, with West/East coverage ratio that increased from 0.53 to 0.98 
and a Centre/East coverage ratio that increased from 0.74 to 1.0. Several factors may explain 
this improvement. First, GAVI provided the hepatitis B vaccine and AD syringes to Western 
provinces and national poverty counties in the Central region, lifting the cost barrier to infant 
vaccination. The evolution of the estimated ratios of three dose of hepatitis B vaccine expressed 
in dose administered/DTP3 targeted indicated that in GAVI-supported areas, the project was 
effective at integrating hepatitis B vaccine in routine EPI. Second, government of China 
support of new policy was a major co-factor. In 2002, the HepB3/Targeted DPT3 ratio was 
0.72 when the vaccine was free but with user-fees; by 2005, it had increased to 0.91 when 
services fees were abolished. Third, the government of China trained health care providers to 
increase their awareness. Fourth, social mobilization and supervision in 2002-2009 improved 
awareness of parents, who sought vaccination more actively. Finally, the government of China 
allocated funds to each province to improve universal vaccination among infant[117]. 
The final evaluation survey provided the most reliable estimates of coverage. Even though 
our survey may have suffered from biases, it generated the best estimate available. The 2004 
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national population-based EPI coverage survey validated our final survey estimates for children 
born in 2003 (89.8% three dose of hepatitis B vaccine coverage in the 2004 survey versus 84.0% 
in our survey). The 2006 national population-based serological survey also validated our final 
survey estimates for children born in 2005 (93.4% three dose of hepatitis B vaccine coverage in 
the 2006 serological survey versus 90.28% in our survey). In contrast, reported and estimated 
coverage differed from those obtained from the final evaluation survey. According to the 
reported three dose of hepatitis B vaccine coverage, coverage ratio between West and the 1st 
quintile only progressed from 0.95 to 1.0. A number of factors may explain this difference. 
First, the reported coverage is based upon a list of registered children that may not represent the 
real target population [120]. For example, migrant children and children born out of plan may not 
be registered on the target lists. This could underestimate the denominator. Second, local CDCs 
may overestimate their performance while reporting coverage data. This could over-estimate 
the numerator. Third, grass root level may make mistakes when handling and reporting data 
through the reporting system. This could under or over-estimate the reported coverage. As a 
result, the reported coverage is consistently higher than surveyed coverage and tends to 
over-estimate performance [118]. More specifically, this misrepresentation may hide inequities. 
Hence, reported coverage data need validations before they can be used to guide efforts to 
reduce inequities[120]. Estimated coverage provided a somewhat intermediate figure that still 
suffered from limitations since it was based upon ad-hoc adjustments in the numerators and 
denominators. China used this adjustments method since 2004 to report vaccination coverage 
but the methods used have not been validated or evaluated using sensitivity analyses. Although 
there was a difference among reported, estimated and surveyed data, the surveyed data that 
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were more reliable pointed to the largest coverage increase and inequities reductions between 
2002 and 2009. 
In China, between 1992 and 2009, the GDP per capita increased from 2,311(USD 
419)[121]to 25,575 RMB (USD 3,744)[122], (a 8.94 times increase, 4.6 times if corrected for the 
value of the currency). In the same time interval, surveyed TBD coverage increased from 22% 
to 91% (4.1 times) while surveyed three dose of hepatitis B vaccine coverage increased from 30% 
to 96% (3.2 times). Thus, increasing coverage, follows the same trend as GDP. From 2004 to 
2009, the Western/Eastern three dose of hepatitis B vaccine coverage ratios improved from 
0.72 to 0.98 while the Rural to Urban coverage ratio improved from 0.91 to 1.0 [123,40]. This 
indicated that once free hepatitis B vaccine was provided, children in Western and rural areas 
received the same opportunity to receive the vaccine without paying out of pocket. As a result, 
the 2009 three dose of hepatitis B vaccine coverage reached universally high levels. The 2006 
national serological survey also documented the absence of difference in the three dose of 
hepatitis B vaccine coverage in terms of gender and urban /rural residence. The concentration 
index that reached 0 in 2009 also suggested that equity had been reached. Experience from 
other countries also suggests that immunization systems can decrease inequities when designed 
with this objective. Approaches used in immunization to improve equity also include 
supplemental immunization activities [106] and specific strategies to reach every district [124].  
Our study suffered from some limitations. First, as this was an internal EPI evaluation, 
hepatitis B vaccination coverage could be overestimated. However, we used staff that was 
external to each province for data collection so that this source of bias could be minimized. 
Second, while we audited data during the evaluation, recall bias or misreporting may have 
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existed. This, however, is unlikely to have affected the trends observed. Third, the increase of 
coverage observed can be attributed to not only to the GAVI China project, but also to the 
general improvement of the Chinese immunization system. Fourth, although we sampled health 
care facilities to measure coverage, we did not use statistical analysis because our objectives 
were limited to documenting progress in reductions of inequities and did not include any 
reference to testing differences in coverage across different strata. Finally, this data analysis 
used an ecological approach conducted with the objective of evaluating a programme. Hence, it 
cannot be used to draw inferences regarding causality. 
On the basis of this evaluation, we formulated a number of conclusions. First, the pro-poor 
GAVI approach was an effective way to reduce inequity among children through provision of 
free vaccination. When vaccine and AD syringes were provided for free, they closed the gap 
between Eastern and Western regions and between the rich and the poor. Second, reported and 
estimated data only partially reflected inequities in immunization coverage. Third, pockets of 
low coverage persisted in the population living in GAVI-supported areas. In 2009, one percent 
infants lived in counties that had not reached the 85% three dose of hepatitis B vaccine 
coverage target and 21% lived in counties that had not reached the 75% TBD coverage target. 
On the basis of these conclusions, we formulated a number of recommendations. First, new 
vaccines should be introduced in China in a way that takes into account the lessons learned 
from the introduction of hepatitis B vaccine and the GAVI China collaboration project. Hence, 
this should consider (1) burden of disease, (2) cost-effectiveness, (3) willingness to pay, (4) 
availability of operational funds, (5) improved delivery system (human resource and technical 
capacity) and (6) equitable financing. Availability of domestically-produced vaccines will be 
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key issue because of the lower price and convenient transportation. Second, we must conduct 
regular surveys to validate reported and estimated coverage estimates so that inequities can be 
measured and addressed. Third, persisting pockets of low coverage need to be subject to more 
focused plans. As reduction of inequities is a key function of the government, the government 
must show leadership by introducing new vaccines in a comprehensive, equitable approach. 
Through GAVI, China benefited from externally funded, pro-poor mechanisms to reduce 
inequities with respect to hepatitis B. In 2011, newer vaccines, such as those against rotavirus, 
Hib and pneumococcal diseases were still used in China with an inequitable cost recovery 
system but were being considered for introduction into free, government-supported routine 
immunization services. As the China annual GDP per capita now exceeds 1,000 USD, China is 
no longer eligible for GAVI support. Hence, China could consider developing its own, national 
financial mechanism to support new vaccine introduction and reduce inequities with respect to 
other diseases in the same way it did for hepatitis B. To this effect, a mechanism based on 
individual social economic status (e.g., demand-side subsidies, conditional cash transfer) rather 
than geographic area of residence, may be more adapted to the China’s heterogeneity. Such 
inequity-reduction strategies may be more effective at increasing vaccine access for the poor 
wherever they live, including migrants in larger cities of the East. However, policy dialogue 
with GAVI and international partners will remain instrumental so that creative equitable 
solutions are identified. 
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Figure 10: Coverage of the hepatitis B third dose 8 and timely birth dose expressed as a ratio of the target populations,9,10 
GAVI China project counties, 2002-2009 
 
 
8 Calculated by dividing HepB3 doses administered by the size of the target groups for DTP3 vaccination 
9 Calculated by dividing HepBOT doses administered by the size of the target groups for DTP1 vaccination 
10 Reported TBD data was only available since 2004 
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Figure 11: Coverage of hepatitis B timely birth dose in the Western, Central and Eastern areas as per the 2010 final evaluation 
survey, by Region, China, 
2002-2009 
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Figure 12: Proportion of counties having reached the GAVI targets (HepB3> 85% and HepBOT>75), reported coverage, by 
province, China, 2009 
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Table 27: Hepatitis B third dose coverage by region, China, 2002-2009 
 
Region Year 
2002 2003 2004 2005 2006 2007 2008 2009 
Reported 11 
Eastern 98.54 99.11 98.86 98.92 98.64 98.92 99.00 99.19 
Central 96.08 97.47 98.91 99.24 99.26 99.27 99.34 99.40 
Western 91.06 93.24 96.79 97.16 97.12 97.69 98.32 98.66 
Overall 95.61 96.68 98.23 98.89 98.47 98.77 98.95 99.13 
 Western/Eastern Ratio 0.92 0.94 0.98 0.98 0.98 0.99 0.99 0.99 
Estimated 12 
Eastern 81.88  82.76  86.56  90.95  92.98  96.53  97.64  99.17  
Central 75.66  80.92  76.67  85.43  89.28  90.65  95.27  96.25  
Western 69.55  73.39  77.40  82.80  84.68  87.27  91.31  93.40  
Overall 74.11  78.78  78.07  85.20  89.05  91.46  94.82  96.30  
 Western/Eastern Ratio 0.85  0.89  0.89  0.91  0.91  0.90  0.94  0.94  
Surveyed 13 
Eastern 88.80 85.51 87.59 92.19 95.80 91.72 88.69 92.09 
Central 65.51 81.27 85.85 90.02 87.96 92.03 93.21 96.27 
Western 46.89 67.39 76.45 80.96 84.81 86.19 88.75 90.21 
 
Overall 71.73  84.01  86.75  90.18  91.36  91.39  91.35  93.19  
 Western/Eastern Ratio 0.53  0.79  0.87  0.88  0.89  0.94  1.00  0.98 
11National data as reported by the CDC system 
12 National data adjusted by denominator according to the methods used for official reports to WHO and UNICEF 
13Data from the 244 counties surveyed in 2010 
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Table 28: HepB3 coverage by quintile of county 2009 GDP per capita, China, 2002-2009 
  GDP (per capital)* Year 
 
Quintile 2002 2003 2004 2005 2006 2007 2008 2009 
Reported 14 1st Quintile 97.80 98.98 98.48 98.56 98.16 98.59 98.69 98.92 
2nd Quintile 99.07 99.29 99.44 99.5 99.52 99.57 99.53 99.55 
3rd Quintile 97.35 98.10 98.42 99.08 99.12 99.10 99.25 99.38 
4th Quintile 88.86 91.51 97.89 97.98 98.10 98.68 98.85 99.14 
5th Quintile 93.39 94.54 96.76 97.19 97.23 97.49 98.24 98.51 
Overall 95.61 96.68 98.24 98.89 98.47 98.77 98.95 99.13 
5th /1st Quintile ratio 0.95 0.96 0.98 0.99 0.99 0.99 1.0 1.0 
Estimated 15 1st Quintile 90.16  96.03  95.50  97.60  96.96  97.34  99.20  99.19  
2nd Quintile 88.65  95.22  97.18  94.75  96.72  96.05  97.67  98.10  
3rd Quintile 88.38  90.25  91.18  92.33  94.14  94.19  94.95  96.27  
4th Quintile 75.22  81.10  90.08  93.51  92.56  95.30  96.19  98.80  
5th Quintile 76.56  90.64  93.16  94.57  95.53  99.52  98.00  96.71  
Overall  85.86  92.01  93.88  95.09  95.68  96.70  97.68  98.10  
5th /1st Quintile ratio 0.85  0.94  0.98  0.97  0.99  1.02  0.99  0.97  
Surveyed 16 1st Quintile 80.33 92.06 91 95.19 93.92 94.68 98.4 98.39 
2nd Quintile 77.30 90.45 94.35 89.49 93.43 92.1 95.35 96.2 
3rd Quintile 76.77  80.49  82.37  84.67  88.28  88.38  89.91  92.53  
4th Quintile 50.44  62.21  80.16  87.03  85.11  90.61  90.38  92.60  
5th Quintile 53.12 81.29 86.33 89.15 91.05 99.05 95.99 93.42 
Overall 71.73  84.01  86.75  90.18  91.36  91.39  91.35  93.19  
5th /1st Quintile ratio 0.66 0.88 0.95 0.94 0.97 1.05 0.98 0.95 
 
14National data as reported by the CDC system 
15 National data adjusted by denominator according to the methods used for official reports to WHO and UNICEF 
16Data from the 244 counties surveyed in 2010 
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Table 29: TBD coverage by quintile of county 2009 GDP per capita, China, 2002-2009 
  GDP (per capital)* Year 
 
Quintile 2002 2003 2004 2005 2006 2007 2008 2009 
Reported 17 1st Quintile 
  
86.26  88.26  89.42  91.69  92.94  93.48  
2nd Quintile 
  
81.26  95.63  96.18  96.88  97.33  97.66  
3rd Quintile 
  
79.39  88.84  91.76  94.35  95.03  95.80  
4th Quintile 
  
82.71  98.34  80.17  90.35  91.56  92.35  
5th Quintile     53.35  64.79  74.00  76.28  81.93  84.22  
Overall     75.91  86.95  86.84  90.79  92.07  92.95  
5th/1st Quintile 
 
0.72  0.86  0.62  0.73  0.83  0.83  0.88  0.90  
Estimated 18 1st Quintile 87.86  92.60  93.60  94.72  97.61  96.05  97.84  98.64  
2nd Quintile 85.41  92.27  93.40  93.21  93.98  93.79  93.98  94.69  
3rd Quintile 84.23  88.42  90.07  94.62  95.38  95.48  96.55  96.49  
4th Quintile 65.88  77.12  81.33  86.76  88.23  90.22  91.23  91.41  
5th Quintile 63.26  80.04  89.76  89.97  89.92  91.82  93.45  92.63  
Overall  80.54  87.55  90.73  92.72  94.29  94.28  95.56  95.87  
5th /1st Quintile 
 
    0.96  0.95  0.92  0.96  0.96  0.94  
Surveyed19 1st Quintile 75.72  85.19  87.19  89.43  95.22  92.10  95.69  97.28  
2nd Quintile 70.82  84.53  86.79  86.42  87.96  87.58  87.96  89.38  
3rd Quintile 68.45  76.83  80.14  89.23  90.76  90.96  93.10  92.99  
4th Quintile 31.75  54.24  62.66  73.53  76.46  80.45  82.45  82.81  
5th Quintile 26.52  60.09  79.53  79.94  79.84  83.63  86.90  85.26  
Overall 60.41  73.43  78.95  83.64  85.98  90.46  91.40  91.18  
5th/1st Quintile 
 
0.35 0.71 0.91 0.89 0.84 0.91 0.91 0.88 
 
17National data as reported by the CDC system，available since 2004 
18 National data adjusted by denominator according to the methods used for official reports to WHO and UNICEF 
19Data from the 244 counties surveyed in 2010 
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Introduction 
Vaccines prevent diseases, avoiding human suffering and disability [125]. As 
vaccine-preventable diseases are less and less common, immunization safety becomes more 
and more important. Immunization safety includes quality of vaccine production, 
circumstances of shipment, delivery system, cold-chain and administration. As most vaccines 
are still administered through the percutaneous route, immunization injections need to be safe. 
A safe injection is defined as one that does not harm the recipient, the health care worker, or 
the community [126, 127]. In 2000, WHO estimated that of the 16 billion injections given 
annually worldwide in developing and transitional countries, 39.3% were given with syringes 
and/or needles reused in the absence of sterilization[128]. Even though immunization activities 
account for a minority of injections worldwide, the safety of immunization injections is a high 
priority to vaccine recipients, immunization providers, communities and policy makers in 
charge of the Expanded Programme on Immunization (EPI). In the late 1990s, a number of 
determinants led to poor injection practices in the specific context of immunization services. 
Those included short supplies of injection devices, challenges in ensuring adequate 
re-sterilization procedures for sterilizable devices, lack of knowledge among health care 
workers and community, and lack of systems to manage sharps waste [129]. In 1999, to 
eliminate unsafe administration of immunization injections, WHO, UNICEF and UNFPA 
called for the exclusive use of auto-disable (AD) syringes (disposable syringes that inactivate 
themselves automatically after one use to prevent re-use) in immunization services by 2003. In 
addition, the statement called for donors and lenders to include the cost of auto-disable 
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injection equipment and safety boxes when providing financial assistance to supply vaccines 
[130]. 
In 1995, the Chinese World Bank VII infectious disease control project introduced the 
"one needle, one syringe, one shot" policy for the first time in China. However, the choice of 
type of injection devices to be used in EPI was left to the provinces. Between 1999 and 2000, 
China, conducted a number of injection safety assessments [131-133]. The proportion of health 
care facilities using glass syringes ranged between 43% and 55%. The proportion of health 
care facilities reusing syringes and/or needles without sterilization ranged between 5% and 
51%. In 2000, China passed a regulation banning the reuse of medical devices labeled for 
single use. In 2003 another regulation required health institutions to sort health care waste and 
to collect sharps waste in puncture- and leak-proof containers. In 2002-2007, the 
implementation of the China project of the Global Alliance for Vaccine and Immunization 
(GAVI) provided support to immunization injections safety. In Western areas and in national 
poverty-affected counties of the Central areas (223 of the 1,087 countries in Central areas, 20% 
of the population), GAVI provided funds for auto-disable (AD) syringes for all hepatitis B 
vaccine and for 50%-70% of other EPI vaccines (provinces paid for the differences)[44] . For 
these GAVI supported areas, financing and procurement took place at central level. For areas 
not supported by GAVI in the Central and Eastern areas, procurement and financing took 
place at provincial level. In 2005, the Chinese Medical Association published clinical 
guidelines for injections and other skin-piercing procedures. In 2006, the Ministry of Health 
hepatitis B control plan called for exclusive use of disposable syringes in health services and 
for use of AD syringes for EPI. In 2007, this requirement for AD syringes in immunization 
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was taken into account for the national budget and currently in 2011, the price difference 
between AD and disposable syringes is minimal.  
In 2007, the GAVI project stopped providing financial support for injection equipment 
before it finally closed in 2010. By that time, injection safety interventions in China had 
largely introduced AD syringes in immunization services. A pilot injection safety assessment 
conducted in 2009 by the Chinese Field Epidemiology Training Programme (CFETP) pointed 
to major improvements in injection practices [134]. We decided to gather more evidence to 
quantify progress and document the current national situation. In October 2010, three years 
after the discontinuation of the GAVI financial support, we assessed immunization injection 
safety in three different areas of China (Western, Central and Eastern). The results of the 
evaluation describes injection practices in China in the post GAVI project era and can guide 
policy makers to update national standard for injection practices and further improve 
vaccination services. 
Methods 
Type of evaluation 
We conducted a cross-sectional evaluation in health care facilities using a tool adapted on 
the basis of the Tool C–Revised of the World Health Organization (WHO) [135]. This was 
based upon the WHO definition of a safe injection [128] and included (1) observations of health 
care facilities, (2) observations of practices from injection providers and (3) interviews of 
injection providers. 
Sampling method 
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We used the WHO recommended methods to select a cluster sample of health care 
facilities [135]. First, we stratified the country into three regions (Eastern, Central and Western) 
reflecting three levels of socio-economic development level in China[115].Second, in each 
region, we selected eight counties using a probability proportional to population size (PPS) 
method. Third, in each selected county, we selected 10 townships at random among the list of 
townships of the county. Fourth, in each selected township we investigated one immunization 
delivery site. If all immunizations were given at the township hospital, we investigated the 
township hospital. If immunizations were given at the township hospital and in village clinics, 
we selected one vaccine delivery site at random. In each of the three regions, the sample size 
was eight clusters of 10 facilities (80) as per the WHO guidelines [135], for a total of 240 for the 
country. 
Data collection 
EPI staff from China CDC (central level) or other provinces coordinated data collection 
in collaboration with the local EPI staff. We first conducted structured observations using a 
standardized instrument to collect information on the facility. Second, we observed providers 
while giving vaccination injections using a checklist. Third, we interviewed vaccination 
injection providers using a standardized questionnaire to collect information regarding 
knowledge regarding diseases acquired from unsafe injections, training experiences and 
occurrence of needle-stick injuries. 
Data analysis 
For each stratum, we estimated the frequency of specific findings through calculation of 
proportions using the relevant sample size as denominator. Then, we calculated China national 
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estimates through an average of the regional values weighted for the population size. For each 
of the indicators we calculated, the best estimate and a95% of confidence interval (CI) 
generated by software of Statistical Package for the Social Sciences (Version 13) that took into 
account the complex sampling design (Clustering and weighting). 
Quality assurance 
We designed and adapted the instruments through consultation of the WHO guidelines 
and experience recovery from two 2009 CFETP injection safety assessments [134]. We then 
pilot tested the instruments in the Banyan county of Guizhou province in July 2010 and 
subsequently revised the tools. We finally conducted a training workshop for all national 
assessment teams prior to the evaluation. 
Results 
Overall, we visited 231 facilities in the three regions. In the Western region, we visited 80 
facilities that benefited from the GAVI China project. In the Central region, we visited 77 
facilities (Three could not be visited as two counties had less than 10 townships). Of these 77 
facilities, 20 (26%) benefited from GAVI support. In the Eastern region, we visited 74 
facilities, none of which received GAVI support (Six could not be visited as three counties had 
less than 10 townships). 
Risks observed through structured observations of health care facilities 
With respect to the risk to the patient (Table 30), we never observed open injection 
equipment lying around or needles left in the septum of multi-dose vials. The proportion of 
facilities missing first aid medicine for anaphylaxis ranged from 1% to 5%. One facility 
presented evidence of attempts to re-sterilize disposable injection equipment in the Eastern 
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region. Six to eight percent of facilities prepared handmade cotton balls. The proportion of 
facilities that did not have water and soap for hand washing was 24% in the Eastern region, 46% 
in the Western region and 55% in the Central region. 
With respect to the risk to health care workers, the proportion of health care facilities 
without sharps containers was 15% in Eastern areas, 21% in Western areas and 44% percent in 
Central areas. Only two facilities presented evidence of overfilled or pierced containers in 
Central areas. The proportion of sharps in open containers was 8% in Eastern areas, 10% in 
Western areas and 18% in Central areas. 
With respect to the risk to the community, presence of sharps around health care facilities 
was uncommon, but highest (6%) in Western areas (Table 30). 
Safe practices observed through structured observations of injections 
We never observed sterilizable injection devices syringes in any of the facilities (Table 
30). The proportion of facilities using AD syringes was 78% in Western areas, 73% in Central 
areas and 25% in Eastern areas. Standard disposable syringes were still in use, but more in the 
East (90%) than in the Centre (49%) and in the West (39%). 
With respect to practices before injection, almost all providers took out injection devices 
from a new, sterile package. 92% to 99% of providers prepared injection in a clean, dedicated 
area. 97% of providers prepared the skin with antiseptic in all regions. The proportion of 
providers who did not touch the injection site after disinfection ranged from 90% to 95%. 
With respect to practices after giving injections, most providers (82% to 88%) abstained 
from removing the needle by hand and from two-hand recapping (81% to 89%). The 
proportion of providers who placed used devices directly into a sharp container was 29% in 
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the West, 36% in the Centre and 50% in the East. One provider presented evidence of attempts 
to re-sterilize disposable devices in Central areas (Table 31). 
Waste collection and management 
The proportion of facilities using sharps containers was highest in the East (85%), 
intermediate in the West (79%) and lowest in the Centre (56 %). 21% to 39% of facilities used 
needle cutters or destroyers. The proportion of facilities using open containers to collect sharps 
ranged from eight percent in the East to 10% in the West and 18% in the Centre. 
With respect to methods used to manage waste, only one facility in Central area dumped 
sharps waste in the open field. Burying waste shallowly was uncommon, highest (4%) in the 
West. The proportion of facilities that burnt and buried sharps waste ranged from 31% in the 
east to 69% in the centre. 14% to 25% of facilities disinfected sharps waste before further 
management. Three percent to 10% of facilities had small-scale incinerators. 26% to 53% of 
facilities transported the waste to the referral centers (Table 32). 
Health care workers interviews 
With respect to health care workers knowledge, the proportion who knew that unsafe 
injections could transmit viral hepatitis viruses ranged from 80% in the centre to 91% in the 
East. A lower proportion knew unsafe injections could transmit HIV (66% to 83%) or cause 
abscesses (61% to 74%). The proportion of health care workers who received at least three 
doses of hepatitis B vaccine ranged from 80% in the East to 98% in the Centre (three to five 
percent had never received a dose). 91% to 97% of health care workers reported having 
attended a training addressing injection safety in the last two years. The proportion of health 
care workers who self-reported sharp injuries in the last six months ranged from 3% in the 
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East to 10% in the West, and higher among those who recapped needles (5/35, 14%) than 
among those who did not (8/198, 4%, X2=5.9, P<0.05) (Table 33). 
Discussion 
Results of our evaluation suggested that in 2010, sterilizable injection equipment has 
been eliminated in China. Disposable syringes were universally used, with a predominance of 
AD syringes in areas formerly supported by GAVI. These observations took place three years 
after the withdrawal of GAVI support, at a time when the central government paid for all AD 
syringe costs. No national data were available to compare our results with the situation in 
place before. However, a 2000 survey in Gansu province reported that 82% of facilities used 
sterilizable syringes [132]. In 2002, the final report of the implementation of a World Bank loan 
indicated that no facilities used AD syringes in the project areas [136]. In contrast, in our 2010 
assessment, the proportion of facilities using AD syringes was 78% in the West, 73% in the 
Centre, and 25% in the East. The progress observed in the field of immunization occurred in 
parallel with progress in the field of curative injections [134, 137]. A number of factors may 
explain these findings. First, GAVI funds provided support necessary to provide AD syringes 
free of charge through a pro-poor approach focusing on Western regions and poverty-affected 
counties in the central region. This created a demand that resulted in a national, large-scale 
production of AD syringes with several manufacturers competing with each other. As a result, 
the difference of price between AD and disposable syringes fell. Secondly, the implementation 
of the “one syringe, one needle, and one shot” policy started on a large scale after 2001.As a 
result, the local governments supplied co-funding for purchase of AD syringes and operational 
funding for the implementation of the GAVI project. However, despite the progress, a few 
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unsafe practices persisted in 2010 that could harm injection recipients. First, we still observed 
attempts of re-use of disposable equipment. Universal implementation of safe injection 
practices is challenging, even in industrialized countries like the United States [138]. These 
underlined the importance of AD injection devices since these give the highest, 
provider-independent safety. Other breaks in infection control practices included poor hand 
hygiene, handmade disinfection-cotton-balls and touching the injection site after disinfection. 
These should be eliminated through targeted interventions and training. 
Our assessment indicated the proportion of facilities using sharps containers was higher 
in the East (85%) and in the West (79%) than in the Centre (56%). A few factors may explain 
this heterogeneity. First, GAVI supported provision of safety box and needle cutter. However, 
this support was only available to Western regions and poverty-affected counties in the 
Central region. In the Eastern area, local governments purchased sharps container for 
immunization with their own funds. The Central area was divided in GAVI-supported areas 
(20 of the 78 visited facilities, 17 (85%) using safety boxes) and non GAVI-supported areas. 
(58 of the 78 visited facilities, 11 (19%) using safety boxes) in which practices differed. These 
differences of use by area suggested that the cost of the safety boxes could be an obstacle of 
the use. Second, the GAVI project organized a number of injection safety trainings, as 
reflected in the interviews of health care workers. Although progress had been achieved, our 
assessment observed that dangerous practices persisted, especially in Central areas. As a result, 
needle recapping and needle-stick injuries remain too common. Overall, the national situation 
is heterogeneous with respect to sharp collection and needle-stick injury prevention. 
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Standardization of practices and funds to implement policy could address this and further 
improve the situation. 
Our assessment indicated that the main methods used to manage waste were (1) burn and 
bury, (2) destruction after disinfection (mostly in buckets of bleach) and (3) transport off-site 
to referral centers. This was comparable to the observations made in the CFETP 2002-2009 
assessments in Wulong county, Chongqing municipality and Fumeng county, Liaoning 
province[134].In this CFETP evaluation, the proportion of open dumping decreased from seven 
percent in 2001 to five percent in 2009 in Fumeng and from 64% in 2001 to 50% in 2009 in 
Wulong. In contrast to the 2009 situation in Wulongand Fumeng, our survey did not identify 
open dumping as a common practice. Transport of waste to referral centers differed in 
frequency, as it was more common in the East (53%) than in the West (29%) and in the centre 
(26%). Heterogeneity in regional economic situations may explain these differences, as this 
option is expensive. In our 2010 assessment, poor practices persisted, including burn and bury 
and small-scale incineration that could generate toxic fumes [139, 140]. These unsafe waste 
management practices could still lead to needle-stick injuries in the community and to 
environmental pollution. They need to be addressed through a more comprehensive health 
care waste management strategy that aimed at protecting the population and the environment.  
Our assessment suffers from two main limitations. First, as the evaluation was conducted 
internally within EPI, there could have been an observer bias and remaining subjective 
judgment. While this could lead to a picture more optimistic than reality, the availability of 
historical comparison supports the hypothesis of a major improvement. In addition, the 
observed issues, even if underestimated, still allow us to make recommendations. Second, the 
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Central area is made of a mixture of GAVI project counties and non GAVI project counties. 
Hence, the situation there is harder to interpret. Particularly in the context of a cluster 
sampling that strictly specify, does not allow to stratified analysis. However, the western 
region with GAVI supported had high proportion of AD utilization than eastern region, and 
high waste management (safety box) within GAVI supported facilities than no GAVI 
supported facilities within central region.  
On the basis of this evaluation, we formulated three main conclusions. First, use of AD 
syringe and sharps containers increased in vaccination services in China, especially in GAVI 
supported area, leading to sustainable progress in terms of elimination of reuse of injection 
devices. However, risk to patients still existed, including persisting use of standard disposable 
syringes and attempts to re-use disposable devices. Second, shortage of sharp containers and 
persisting unsafe practices still lead to needle stick injuries. Third, the absence of standardized 
approaches to waste management led to heterogeneous practices, some of which could be 
dangerous for the community or the environment. On the basis of these conclusions, we 
formulated a number of recommendations. First, remaining unsafe practices must be improved 
through a regulation implementing a national policy requiring exclusive use of AD syringes in 
EPI. Targeted training of providers needs to also facilitate the transition to AD syringes and 
improve residual unsafe practices. Second, the government should supply enough safety boxes 
or other sharps containers for all facilities, along with the training support to ensure their use. 
Third, pre-service and catch up vaccination of health care workers against hepatitis B must be 
generalized, in accordance with the recommendations of the Chinese Liver Study Association, 
occupational health regulations,[141, 142] and the 2007 and 2010 World Health Assembly 
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resolutions[143] . Fourth, we must frame standardized guidance for sharps waste disposal 
techniques that would protect communities and the environment. Overall, revised, evidence 
based, consensus-derived national standard for immunization injection safety could further 
improve practices, including waste collection and waste management. Political, legislative and 
financial support from the Ministry of Health should ensure implementation of these revised 
immunization injection safety standards to build on the 2000-2010 achievements, eliminate 
persisting unsafe practices and further strengthen public and government confidence in 
immunization services. 
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Table 30: Risks identified during structured observations of health care facilities, GAVI project final evaluation survey, China, 
October 2010 
 
20National estimate weighted for the population size of each of the three regions 
21CI: Confidence interval 
Level of risk Risk observed 
Eastern(N=74) Middle(N=77) Western(N=80) Total20(N=231) 
# （%） 95% CI21 # （%） 95% CI # （%） 95% CI # （%） 95% CI 
Overall Absence of guidelines displayed 15 20  11-29 19 25  15-34 19 24  14-33 53 23  18-29 
Patient 
Open injection equipment lying around 0 0  -  0 0  -  0 0  -  0 0  -  
Attempts to sterilize disposable devices 1 1  0-7 0 0  - 0 0  - 1 0  0-2 
Needles in septum of multi-dose vials 0 0  - 0 0  - 0 0  - 0 0  - 
Handmade disinfection-cotton-balls 6 8  2-14 5 6  1-12 5 6  1-12 16 7  4-11 
Absence of water and soap for hand 
washing 
18 24  15-34 42 55  43-66 37 46  35-57 97 42  36-48 
Absence of first-aid medicine for 
anaphylaxis 
1 1  0-7 2 3  1-6 4 5  0-10 7 3  1-6 
Provider 
Absence of sharps containers 11 15  7-23 34 44  33-55 17 21  12-30 62 27  21-33 
Overfilled or pierced sharp containers 0 0  - 2 3  1-6 0 0  - 2 1  0-3 
Sharps in open containers 6 8  2-14 14 18  1-27 8 10  3-17 28 12  8-17 
Community Used sharps outside health care facility 2 3  0-6 1 1  1-4 5 6  1-12 8 3  2-7 
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Table 31: Frequency of safe practice observed during injections, GAVI project final evaluation survey, China, 2010 
 
Stages Description Eastern(N=72) Middle(N=78) Western(N=79) Total(N=229)22 
No (%) 95% CI23 No （%） 95% CI No （%） 95% CI No （%） 95% CI 
Devices Sterile syringe 0 0  - 0 0  - 0 0  - 0 0 - 
Disposable syringe 65 90  83-97 38 49  38-60 31 39  28-50 134 59 52-65 
AD24 syringe 18 25  15-35 57 73  63-83 62 78  69-88 137 60 53-66 
Before 
injection  
Syringe / needle from a new, sterile 
package  
69 96  91-100 77 99  96-101 77 97  94-101 223 97 95-99 
Preparation on a clean, dedicated area 71 99  96-101 72 92  86-98 76 96  92-100 219 96 92-98 
Skin preparation with antiseptic  70 97  93-101 76 97  94-101 77 97  94-101 223 97 95-99 
No touch of the injection site after 
disinfection  
65 90  83-97 74 95  90-100 74 94  88-99 213 93 89-96 
After 
injection 
No removal of the needle by hand 63 88  80-95 64 82  74-91 68 86  78-94 195 85 80-89 
Absence of two-handed recapping 64 89  82-96 66 85  77-93 64 81  72-90 194 85 80-89 
Collection of sharps into a sharps 
container  
36 50  38-62 28 36  25-47 23 29  19-39 87 38 32-44 
Separate collection of non-sharps  19 26  16-37 17 22  13-31 44 56  45-67 80 35 29-41 
No attempts to re-sterilize disposable 
devices 
72 100  100-100 77 99  96-101 79 100  100-100 228 100 98-100 
22 National estimate weighted for the population size of each of the three regions 
23 CI: Confidence interval 
24Auto-Disable syringe and needle set 
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Table 32: Waste collection and disposal practices, GAVI project final evaluation survey, China, 2010 
Levels Practice 
Eastern(N=74)   Middle(N=77)   Western(N=80)   Total (N=231)25 
No (%) 95% 
CI26 
  No （%） 95% CI   No （%） 95% CI   No （%） 95% CI 
Waste collection Open containers 6 8 2-14 
 
14 18 10-27 
 
8 10 3-17 
 
28 12 8-17 
Needle destruction/ 
removal 
29 39 28-50 
 
27 35 24-46 
 
17 21 12-30 
 
73 32 26-38 
Use of sharps containers 63 85 77-93  43 56 45-67  63 79 70-88  169 73 67-79 
Waste 
management 
Open dumping 0 0 - 
 
1 1 1-7 
 
0 0 - 
 
1 0 0-2 
Shallow burying 0 0 - 
 
1 1 1-7 
 
3 4 0-8 
 
4 2 0-4 
Burn and bury 23 31 21-42 
 
53 69 58-79 
 
37 46 35-57 
 
113 49 43-55 
Small-scale incinerators 2 3 0-6 
 
8 10 4-17 
 
8 10 3-17 
 
18 8 5-12 
Destruction after 
disinfection 
13 18 9-26 
 
11 14 6-22 
 
20 25 16-34 
 
44 19 14-25 
Transport off-site 39 53 41-64  20 26 16-36  23 29 19-39  82 36 30-42 
25 National estimate weighted for the population size of each of the three regions 
26 CI: Confidenceinterval 
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Table 33: Results of interviews of injection providers, GAVI project final evaluation survey, China, 2010 
Indicator Eastern (N=76)   Middle (N=80)   Western(N=77)   Total(N=233) 27 
No （%） 95% 
28 
  No （%） 95% CI   No （%） 95% CI   No （%） 95% CI 
Risk of unsafe injections 
spontaneously 
mentioned  
Abscess on injection 
  
56 74   64-84  
 
52 65   55-75  
 
47 61   50-72  
 
155 67  60-72  
Transmission of HIV  63 83   74-91  
 
61 76   67-86  
 
51 66   56-77  
 
175 75  69-80  
Transmission of 
 
69 91   84-97    64 80   71-89    63 82   73-90    196 84  79-88  
Number of hepatitis B 
vaccine 
doses received  
0 dose 2 3   0-6  
 
2 3   0-6  
 
4 5   0-10  
 
8 3  2-6  
1 dose 6 8   2-14  
 
0 0  - 
 
7 9   3-16  
 
13 6  3-9  
2 doses 7 9   3-16  
 
0 0  - 
 
4 5   0-10  
 
11 5  3-8  
≥ 3 doses 61 80   71-89    78 98   94-101    62 81   72-89    201 86  81-90  
Self reported sharps injuries in last six months 2 3   0-6    3 4   0-8    8 10   4-17    13 6  3-9  
Attendance of an safety injection training in 
    
72 95   90-100    73 91   85-97    75 97   94-101    220 94  91-97  
 
 
27 National estimate weighted for the population size of each of the three regions 
28 CI: Confidenceinterval 
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Background 
Perinatal transmission is a major source of hepatitis B virus (HBV) infection in many 
countries, especially in highly endemic region [144]. Perinatal HBV infections occur among 
infants of mothers with chronic HBV infection (positive for the HBV surface antigen (HBsAg). 
The earlier the timing of HBV infection in a child, the higher the probability of developing 
chronic infection[145]. In addition, the risk of perinatal transmission is higher when the 
mother’s HBV DNA level is high. This correlates with the presence of hepatitis B e antigen 
(HBeAg) in the serum. In the absence of immuno-prophylaxis, 70% to 90% of children born 
to HBeAg-positive mothers develop chronic HBV infection by six month of age [146]. Among 
those born to HBeAg-negative mothers, less than 10% develop chronic infection [146]. 
Providing hepatitis B vaccine (HepB) to all infants within 24 hours of birth (Timely Birth 
Dose, TBD), and subsequently, at one and six month of age is key to preventing perinatal 
HBV infection. Overall, published studies report a 90% efficacy of hepatitis B vaccine for the 
prevention of perinatal HBV infection. Among infants born to hepatitis B surface antigen 
(HBsAg) and HBeAg positive mothers, efficacy is lower (70%-90%) [147-150]. Adding Human 
Hepatitis B Immunoglobulin (HBIG) to vaccination at birth increases efficacy to 95% [147]. 
However, HBIG is much more expensive than hepatitis B vaccine, and appropriate use 
requires testing of pregnant women to identify HBsAg positive women. WHO recommends 
universal hepatitis B vaccine immunization of infants with TBD to prevent perinatal HBV 
infection [14]. In addition to this, many industrialized countries also include screening of 
pregnant women to provide vaccination plus HBIG within 12 hours after birth to children born 
to HBsAg positive mothers [151]. A smaller number of countries, including the United 
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Kingdom and Japan screen pregnant women for HBsAg for selective immuno-prophylaxis in 
the absence of universal hepatitis B vaccine immunization of newborns. In 2009, 177 counties 
had integrated hepatitis B vaccine into routine immunization [14]. 
In 1992, China introduced the hepatitis B vaccine into routine immunization. However, 
parents had to pay for the vaccine, and there were inequities in coverage. In the early 2000s, 
Mother to Child Transmission (MTCT) remained a leading cause of HBV infection, 
accounting for 40% of total infections [152]. Among HBsAg positive women aged 15-39 years, 
30% of them were HBeAg positive, pointing to a high risk of perinatal infection [40]. In 2002, 
with the financial support of the Global Alliance on Vaccine and Immunization (GAVI) 
targeted to Western areas and 223 poverty-affected counties in Central areas, hepatitis B 
vaccine became free throughout China while parents were still charged a small user fee. One 
of the goals of the GAVI China project was to reach 75% TBD coverage among infants born 
in GAVI-supported areas [44]. In 2005, the government provided free vaccination services to 
all infants (user fees eliminated). A 2006 serosurveyreported that chronic HBV infection was 
still common among childbearing age women (HBsAg prevalence: 6.7%), pointing to a 
persisting risk of perinatal infection [80]. 
Between 2002 and 2010, a number of initiatives in China improved the prevention of 
perinatal HBV infection. First, successive pilot projects in Qinghai province, Ningxia 
autonomous region and Gansu province allowed identifying the best operational approach to 
timely birth dose delivery. Second, use of hepatitis B vaccine out of cold chain was considered 
in studies. [91] This option was not scaled up nationally since the market authorization of the 
vaccine did not specifically permit this kind of use. Third, the new rural reform policy 
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reimbursed pregnant women who give birth in hospital. Fourth, in 2007, GAVI funds were 
assigned to support low performance prefectures in Western poverty-affected counties so that 
they could reach the GAVI China project targets [70].These resulted in increased hospital 
delivery rates, and indirectly an increase in TBD coverage. Fifth, in 2010, the Ministry of 
Health formulated a recommendation that (1) pregnant women should be screened for HBsAg 
and (2) infants born to HBsAg mothers should receive vaccine and HBIG within 24 hours 
after birth. However, strategies to implement this new recommendation are in the process of 
being identified. Before this 2010 recommendation, and aside from the GAVI project, many 
hospitals were already implementing HBsAg screening and HBIG delivery at the expense of 
the pregnant women. In 2010, we evaluated the GAVI project in terms of its activities to 
prevent perinatal infections. The objectives of the evaluation were to (1) measure 
achievements in China project in terms of TBD coverage, (2) describe practices in terms of 
HBsAg screening of pregnant women and HBIG use outside the GAVI China project and 
before the official 2010 recommendation and (3) propose recommendations for the future 
prevention of perinatal HBV infection in China. 
Methods 
Sampling methods, evaluation survey, October 2010 
We used the methods recommended by WHO to select a cluster sample of health care 
facilities for the purpose of injection safety assessments[135]. The injection safety assessment 
component of the final evaluation of the GAVI project was used to design the sampling 
strategy as its required confidence intervals that needed to the calculated using the WHO 
reference guidelines. First, we stratified China into three regions (Eastern, Central and 
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Western) based on economic criteria. Second, in each region, we selected eight counties with a 
probability proportional to population size. Third, in each selected county, we selected (a) 10 
townships at random among the list of townships of the county and (b) the one county level 
hospital. Fourth, in each selected township we investigated the township hospital that 
maintained immunization records for the whole township. In each of the three regions (Eastern, 
Central and Western), the sample size was eight clusters of 10 facilities, for a total of 80 
facilities, as per the WHO guidelines [135] which for the whole country totaled to 240 facilities. 
In additional, we reviewed each of the county hospitals, for timely birth dose evaluation. 
Finally, we collected timely birth dose data from the county level hospital that accounted for a 
large proportion of the deliveries in each county. 
Data collection 
In each hospital, we abstracted 2002 - 2009 records to collect information regarding birth 
cohorts, hospitals deliveries, vaccine management, and hepatitis B vaccination delivery, 
HBsAg screening practices and results, and HBIG administration. In addition, in township 
level hospitals, we abstracted records regarding the delivery of TBD. 
In each township, we randomly selected 10 parents in the general population who had a 
child born between 2002 and 2009. We interviewed parents to collect information about 
knowledge, attitude and practice with respect to hepatitis B and its prevention. 
Coverage calculation 
We calculated survey coverage on the basis of the data collected in the field during the 
October 2010 survey. We divided the number of doses administered (as for the reported 
coverage) by the number of children registered on the birth cohort at the township level 
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hospital. To calculate the surveyed TBD coverage among children born in hospitals, we 
divided the number of surviving children born in hospitals who received TBD by the number 
of surviving children born in hospitals. We calculated a ratio of the TBD/HepB3 coverage to 
compare the progress of TBD coverage (reflecting the system in place to facilitate early 
delivery after birth) with the progress in terms of three dose of hepatitis B vaccine coverage 
(reflecting the availability of the vaccine and its integration in EPI). 
Model to estimate the number of perinatal HBV infections 
We used the formula proposed by Goldstein [10] to model the number of perinatal HBV 
infections that occurred in China. 
CIp= [(as ae·90% + as (1- ae) ·10%)x] x 90% 
This calculation was based on the prevalence of HBsAg among women of child-bearing 
age (as; 6.7% in China as per the 2006 national serological survey) [80], the HBeAg prevalence 
among HBsAg-positive women (ae; 30% in China) [80], the risk of perinatal transmission 
among mothers who are HBsAg and HBeAg positive (90%), the risk of perinatal transmission 
among mothers who are HBsAg-positive and HBeAg-negative (10%) and the size of the 
surviving birth cohort (x) obtained from the national yearbook. We multiplied this estimate by 
90% to obtain the number of perinatal HBV infection that would remain chronic [10].We 
estimated the number of chronic perinatal infections prevented assuming (1) 88% vaccine 
effectiveness for children receiving a timely birth dose and completing the three dose series 
and (2) independence between receiving a timely birth dose and completing the three doses 
series. We used the 2002 and 2009 timely birth dose and three-dose coverage from the survey 
conducted in 2010. We neglected the effect of HBIG in the calculations. 
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Result 
Coverage survey 
We visited 244 facilities in the three regions, including 24 county hospitals and 220 
township hospitals (among counties with less than 10 townships, then all townships or facilities 
was selected). 
General population 
Overall, surveyed TBD coverage increased from 60% in 2002 to 91% in 2009 (+31%). In 
Eastern areas, surveyed TBD coverage increased from 82% in 2002 to 96% in 2009 (+14%). 
In Central areas, surveyed TBD coverage increased from 51% in 2002 to 86% in 2009 (+35%). 
In Western areas, surveyed TBD coverage increased from 26% in 2002 to 86% in 2009 (+61%, 
Table 34). Overall, the TBD/HepB3 ratio increased from 0.83 in 2002 to 0.98 in 2009. In the 
Eastern region, it increased from 0.92 in 2002 to 1.04 in 2009. In the Central region, it 
increased from 0.78 in 2002 to 0.89 in 2009. In the Western region, it increased from 0.55 in 
2002 to 0.96 in 2009 (Figure 13). 
TBD coverage among hospital births 
Overall, surveyed TBD coverage among children born at hospital increased from 73% in 
2002 to 98% in 2009. In 2009, all regions had reached high level of coverage for children born 
in hospitals, although the West had started with much lower coverage in 2002. From 2002 to 
2009, coverage increased from 80% to 98% in the East; from 62% to 97% in the Centre and 
from 59% to 98% in the West (Table 35). Between 2003 and 2008, the proportion of hospital 
births increased from 92% to 95% in urban areas and form 62% to 87% in rural areas[153], 
greatly enhanced the impact of the progress in TBD delivery in hospitals. 
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Practices in the terms of HBsAg screening and immuno-prophylaxis 
Overall, between 2002 and 2009, the proportion of pregnant women screened for HBsAg 
among women giving birth in hospitals increased from 64% in 2002 to 85% in 2009. The 
increase was smallest (from 83% to 88%) in the East; intermediate (from 64% to 87%) in the 
Centre and largest (from 48% to 82%) in the West (Figure 14). Between 2002 and 2009, the 
prevalence of HBsAg among pregnant women recorded in hospital was highest (ranging 
between 5% and 6.9%) in the East; intermediate (ranging between 3.9% and 6.5%), in the 
West and lowest (ranging between 1.9% and 3.2%, in the Centre, data not shown). 
Overall, in 2009, the proportion of infants born to women screened and found to be 
HBsAg positive who did not receive any immunization within 24 hours after birth ranged from 
0% to 0.7% across regions (Figure 15). The proportion of children who received hepatitis B 
vaccine plus HBIG was highest in the West (66%) and lowest in the East (34%). The 
proportion of children who received only hepatitis B vaccine was lowest in the West (28%) 
and highest in the East (65%). However, in absolute numbers, in the facilities visited during 
the 2010 survey, the East had the largest number of children received HBIG and hepatitis B 
vaccine (N=980) followed by the West (N=584) and the Centre (N=350, Figure 15). 
Knowledge of parents 
We interviewed 2,323 parents in the three regions. Of these, 1,899 (82%) were less than 
40 years of age. The male to female ratio was 1.4:1. 1,937 (83%) of parents knew that 
hepatitis B vaccine was the first vaccine to be administered after birth (ranging from 77% in 
the Centre to 88% in West); 2,059 (89%) knew the time schedule of the birth dose (ranging 
from 82% in the Centre to 92% in the West), and 1,943 (84%) knew that three doses were 
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needed to complete the series (ranging from 73% in the Centre to 89% in the West). 1,540 
(66%) of parents reported they received this information from doctors while 652 (28%) quoted 
the vaccination certificate as the main source of information. 
Modeled number of perinatal HBV infection  
Our model projected that in 2002, the annual number of chronic perinatal HBV infections 
as 37,185 in the East, 90,123 in the Centre and 86,413 in the West (Total: 202,709). In 2009, 
these numbers decreased to 24,108, 36,593, and 27,954 in the Eastern, Central and Western 
areas, respectively (Total: 84,121 with vaccination versus 202,709 without vaccination, for an 
overall 58% reduction between 2002 and 2009) (Figure 16). 
Discussion 
Our surveyed coverage of the TBD increased from 60% in 2002 to 91% in 2009. A 
number of factors may explain this improvement. First, GAVI funds provided support 
necessary to offer hepatitis B vaccine free of charge all over China focusing on Western 
regions and poverty-affected counties in the Central region. Second, the TBD coverage among 
facility-based births increased from 73% in 2002 to 98% in 2009. Third, the national hospital 
delivery rate increased from 78% in 2002 to 96% in 2009 [115, 154]. Most of the progress in 
terms of institutionalized deliveries took place in Western regions where health care reform 
subsidized pregnant women to give birth in hospitals. The Eastern region already had high 
level of hospital deliveries in 2002 and did not see much progress in the subsequent seven 
years. Fourth, we conducted special demonstration projects between 2007 and 2009 in 13 
low-performance prefectures in Central and Western areas. 1.4 million USD of the first round 
of the GAVI saving was invested to support activities that would increase TBD coverage. 
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Fifth, demand for the vaccine increased in the population. In 2010, in our survey, 83% of 
guardians knew about the need of the hepatitis B birth dose within 24 hours. Although no 
national data is available from before, a survey conducted in 2005 in Gansu province reported 
that only 48% of guardians were aware of this need [92, 155]. While TBD coverage progressed at 
the national level, in 2009, 20% of counties accounting for 21% of the birth cohort in GAVI 
project areas still had not reached the GAVI target of 75% coverage in timely birth dose 
(China CDC unpublished data). Most of these were rural, isolated and poor counties in Tibet, 
Guizhou and Yunnan. Since the TBD coverage among institutional births was close to 100% 
in China, this persisting gap is mostly explained by low coverage among home births. Overall, 
the increase in TBD coverage prevented many HBV infections among newborns. The 2006 
serological survey in China reported a 0.96% prevalence of HBsAg among children less than 
five years of age, versus 9.8% in the same age group in 1992. In addition, our modeled 
estimates of the number of perinatal HBV infections suggested a fall of 58% from 202,709 
cases in 2002 to 84,121 cases in 2009 in China[10].  
Our evaluation indicated from 2002 to 2009, screening of mothers for HBsAg was 
already in use and increasing in China. Screening rate in the West were under 50% in 2002, 
but reached 82% in 2009. Two factors may explain the increase in screening. First, there is 
high level of awareness of hepatitis B prevention among pregnant women [156]. Second, some 
hospitals have included testing of pregnant women for HBsAg among routine procedures [157]. 
This occurred in the absence of any support by the GAVI project and before the policy 
recommendation from the Ministry of Health. HBsAg screening allowed identification of 
HBsAg status and provision of HBIG immuno-prophylaxis [158, 159]. Our survey indicated that 
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overall, the prevalence of HBsAg among women of child bearing area screened in hospital 
ranged between 4% and 6% between 2002 and 2009. This was lower than the 6.7% prevalence 
reported among adults between 15 and 59 years of age in the 2006 national serosurvey [80]. 
Incomplete recording that is another reason for the lower prevalences. However, these two 
estimates cannot be compared directly. Unlike the population-based survey of 2006, pregnant 
women screened in hospital did not constitute a random sample of the general population. 
Following HBsAg screening, immuno-prophylaxis situations were heterogeneous and hard to 
interpret. The Eastern region used more of the combined HBIG –hepatitis B vaccine 
immuno-prophylaxis than in the Central and Western regions, but managed to cover a lower 
proportion of children. Factors influencing these HBIG utilization patterns may include (1) an 
ongoing nationwide shortage of HBIG and (2) the smaller population size and lower hospital 
delivery rate in Central and Western regions. Overall, infants born to HBsAg positive mothers 
had high proportion of TBD, with or without HBIG, which should prevent most HBV 
infection. However, screening is not always followed by adapted intervention and there was 
no system to track children born to HBsAg positive mothers in terms of risk of developing 
infection [160]. Almost none of the hospitals visited during the survey had data on the 
proportion of children born from HBsAg mothers followed up and tested after 
immuno-prophylaxis. 
Our evaluation had limitations. First, surveyed data were based on registered birth 
cohorts and records of doses administered. Migrant children may not have been well covered 
in the evaluation. As a result, coverage may be overestimated. Second, the HBsAg prevalence 
among pregnant women who were not tested remains unknown, and could be higher than in 
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our survey, alternatively, there could be an incomplete recording of positive HBsAg status. 
Third, practices in terms of HBIG use depended on parental preferences and on willingness to 
pay. The government did not mandate those. Therefore, they could have been monitored 
poorly by the system. 
On the basis of this evaluation, we formulated a number of conclusions. First, increased 
availability of hepatitis B vaccine, along with efforts to improve hospital deliveries, increased 
TBD coverage in China. This decreased perinatal HBV transmission and will reduce disease 
burden in the future. However, pockets of unreached children persist in the West, particularly 
in Tibet, Guizhou and Yunnan - our estimates suggest that China continues to have more than 
80,000 perinatal HBV infections each year. Second, screening for HBsAg for HBIG 
administration has begun, but with heterogeneous immuno-prophylaxis practices and a poor 
system for follow up. 
On the basis of these conclusions, we formulated a number of recommendations. First, 
China should continue improving hospital delivery rates national wide, with special efforts in 
provinces such as Tibet, Guizhou and Yunnan. Specific strategies are also need to reach births 
that continue to occur at home. In 2010, China GAVI project used another three million USD 
to increase TBD coverage for a new group of 29 low-performance prefectures in Central and 
Western areas. Among these prefectures, 18 are in Yunnan, Guizhou and Tibet. Second, 
HBsAg screening must be expanded progressively, beginning with aspects of infrastructure 
and system so that women are screened and children followed up. Increased HBIG use can 
then follow with an incremental approach, starting with children born from mothers who are 
HBsAg positive. However, this has programmatic implications in the management of the test 
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results for decision making that may require that testing. Ultimately, China could screen all 
pregnant women, provide HBIG with immunization for all infants born to HBsAg positive 
mothers, and track the consequences of perinatal exposure among those infants. Other options, 
such as anti-viral treatment of infection mothers could also be explored. This comprehensive 
strategy should further reduce the prevalence of HBsAg among children and protect future 
generations from cirrhosis and hepatocellular carcinoma. 
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Table 34: Surveyed29 coverage for hepatitis B timely birth dose among all infants, GAVI final evaluation, 2002-2009 
Region Content 2002 2003 2004 2005 2006 2007 2008 2009 
Eastern No. Live birth 33,170 38,179 42,040 46,030 55,032 57,498 59,055 62,516 
No. TBD 27,101 33,055 37,967 41,503 50,635 56,196 58,673 60,106 
Coverage (%) 81.7 86.6 90.3 90.2 92 97.7 99.4 96.1 
Central No. Live birth 24,665 27,432 30,217 30,604 32,631 33,975 35,763 35,700 
No. TBD  12,667 18,948 22,499 25,263 26,484 28,669 30,204 30,755 
Coverage (%) 51.4 69.1 74.5 82.6 81.2 84.4 84.5 86.2 
Western No. Live birth 13,859 19,891 23,325 24,653 26,108 28,696 28,712 27,658 
No. TBD  3,543 10,783 14,998 17,949 20,699 23,835 24,031 23,907 
Coverage (%) 25.6 54.2 64.3 72.8 79.3 83.1 83.7 86.4 
Total No. Live birth 71,694 85,502 95,582 101,287 113,771 120,169 123,530 125,874 
No. TBD 43,311 62,786 75,464 84,715 97,818 108,700 112,908 114,768 
Coverage (%) 60.4 73.4 79 83.6 86 90.5 91.4 91.2 
29 GAVI final evaluation survey, October 2010 
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Table 35: Hepatitis B timely birth dose coverage among infants born in health care facilities, GAVI final evaluation, 2002-2009 
Region Content 2002 2003 2004 2005 2006 2007 2008 2009 
Eastern No. Live birth 25,130 34,205 39,787 45,737 52,551 60,014 59,972 60,322 
No. TBD  20,149 27,920 34,626 38,456 44,195 51,289 58,684 59,005 
Coverage (%) 80.2 81.6 87 84.1 84.1 85.5 97.9 97.8 
Central No. Live birth 12,943 14,994 24,579 25,073 26,706 29,544 31,872 33,671 
No. TBD  7,982 10,760 14,299 15,041 23,887 24,744 29,341 32,578 
Coverage (%) 61.7 71.8 58.2 60 89.4 83.8 92.1 96.8 
Western No. Live birth 3,582 8,652 15,554 14,474 16,418 18,554 21,609 23,306 
No. TBD  2,120 7,599 10,684 13,754 15,786 17,697 21,020 22,932 
Coverage (%) 59.2 87.8 68.7 95 96.2 95.4 97.3 98.4 
Total No. Live birth 41,655 57,851 79,920 85,284 95,675 108,112 113,453 117,299 
No. TBD  30,251 46,279 59,609 67,251 83,868 93,730 109,045 114,515 
Coverage (%) 72.6 80 74.6 78.9 87.7 86.7 96.1 97.6 
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Figure 13: Ratio of the surveyed TBD/HepB3 coverage by region in China, GAVI final evaluation, China, 2002-2009 
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Figure 14: Frequency of HBsAg screening among pregnant women by region, GAVI final evaluation survey, China, 2002-2009 
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Figure 15: Frequency of various immuno-prophylaxis practices for children born from HBsAg positive mothers, GAVI final 
evaluation survey, by region, China, 2009 
 
0
500
1000
1500
2000
2500
3000
East Central West
N
um
be
r o
f I
nf
an
ts
 re
ce
iv
in
g 
pr
op
hy
la
xi
s 
Region 
None
HBIG
HepB+HBIG
HepB
182 
Results – Chapter 7 
 
Figure 16: Estimated number of chronic perinatal HBV infections, China, by region, 2002-2009 
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Conclusions 
1. Goals achieved 
The initial goals of the GAVI China project were to: 
1) Reach 85% coverage of three dose of hepatitis B vaccine at the county level; 
2) Reach 75% coverage of TBD at the county level; 
3) Introduce AD syringes into immunization services. 
Results of our final evaluation suggest that in 2010, goal #1 was reached in 98% of 
GAVI China project counties that together accounted for 99% of the target population. Goal 
#2 was reached in 80% of counties that together accounted for 79% of the target population 
(Chapter 5). AD syringes were successfully introduced in all GAVI-supported areas, 
although standard disposable syringes remained in use in non-GAVI supported areas in 
Central and Eastern provinces (Chapter 6).  
Our final evaluation went further than a review of the initial goals and examined all the 
components of the GAVI China project as per the logic model to understand the causes of 
the success and identify remaining issues. With respect to hepatitis B immunization, input 
included 76 million USD provided by the GAVI China project to fund hepatitis B vaccine 
between 2002 and 2007 and 21.5 million USD of additional government subsidies to health 
care workers between 2007 and 2009 (Introduction). The health system efficiently 
processed these resources. First, the increase in the HepB3/DPT3 ratio (reaching 94% in 
2009) indicated that EPI absorbed the new vaccine well. Second, the increase in the 
proportion of institutionalized deliveries (reaching 96% in 2009) indicated that Maternal 
and Child Services created conditions that maximized TBD coverage. As a result, from 
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2002 to 2009, three dose of hepatitis B vaccine coverage progressed from 71% to 93% and 
TBD coverage progressed from 60% to 91% (Chapter 5). Both of these factors resulted in 
immunity among vaccinated cohorts as 85% of children 12 to 23 months of age were 
anti-HBs (+) in the 2006 serological survey (Chapter 2).  
With respect to injection safety, input included 14 million USD of GAVI China funds 
to supply AD syringes, safety boxes and needle cutters (Introduction). In 2009, AD syringes 
and safety boxes were used in 78% and 79% facilities in the GAVI-supported areas of the 
Western areas, respectively. In terms of output, sterilizable injection devices disappeared 
and attempts to re-use disposable injection equipment became rare (0% in the 2010 final 
evaluation, Chapter 6). However, no data regarding the incidence of injection-associated 
infections were available to evaluate the outcome of the progress in injection safety.  
With respect to social mobilization and training, 10 million USD were assigned to 
training between 2002 and 2009 (Introduction). Most of these funds were not directly 
funded by GAVI alliance but by the government, through a leverage effect of the GAVI 
China project support. Funding was used in 28,753 training workshops to train health care 
workers resulting in better knowledge among health care workers (in 2010, 98% knew that 
hepatitis B virus can be transmitted from mother to child) and guardians (in 2010, 89% 
knew that the first dose of hepatitis B vaccine had to be given in the first 24 hours of life, 
Chapter 6). This also contributed to higher immunization coverage and safer injections.  
Ultimately, the elements of the GAVI China project combined at the impact level to 
prevent HBV infections. The 2006 national serological survey documented these 
achievements and pointed to a 0.96% prevalence of HBsAg among children under five 
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years of age in China (a decrease of 90% from the 9.67% prevalence in the same age group 
in 1992), and a 1.26% prevalence among children under five years of age in 
GAVI-supported areas (Chapter 2). These improvements will lead to the future prevention 
of cirrhosis and hepatocellular carcinoma which should result in the prevention of early 
deaths and health benefits in terms of disability-adjusted life years (DALYs). However, in 
2010, these elements had not yet been documented and quantified.  
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Box 5: Summary of key indicators of input, process, output, outcome and impact 
for the GAVI project, China, 2002-2010 
Elements Immunization against 
hepatitis B 
Social mobilization 
and training 
Injection safety 
Input - 27 million USD disbursed 
by GAVI for hepatitis B 
vaccine in 2002-2010 
- 21.5 million USD disbursed 
by the government to 
subsidize health care 
workers for vaccination 
2007-2009 
- 10 million USD 
disbursed by the 
government for 
training activities 
- 14 million USD 
disbursed by GAVI 
China for AD syringes in 
2002-2010 
- 100,000 USD 
disbursed by GAVI 
China for safety boxes 
and needle cutters in 
2002-2010 
Process - HepB3/DTP3 target ratio 
increased from 57% in 2002 
to 94% in 2009 
- Hospital delivery rates 
increased from 78% in 2002 
to 96% in 2009 
- TBD/DTP1 ratio increased 
from 0.83 in 2002 to 0.98 in 
2009 
- 28,753 training 
workshops held from 
2002 to 2009 
- 0% of facilities using 
sterilizable equipment 
- 78% of facilities using 
AD syringes in 
GAVI-supported areas 
- 79% of facilities using 
safety boxes in 
GAVI-supported areas 
Output  -98% of healthcare 
workers know about 
perinatal HBV 
transmission 
- 89% of the 
guardians aware of 
the need of the first 
hepatitis B vaccine 
within 24 hours of life 
 
- Surveyed TBD coverage increased 
from 60% in 2002 to 91% in 2009  
- Surveyed HepB3 coverage increased 
from 71% in 2002 to 93% in 2009 
- 0% of injections for which there is 
an attempt to reuse syringe and/or 
needle 
- Safety boxes used in 79% of 
facilities 
Outcome - Prevalence of Anti-HBs: 85% among 
children 12-23 months of age in 2006 
- No data to determine whether or 
not injection-associated infections 
occur  
Impact  
- Prevalence of HBsAg decreased from 9.67% in 1992 to 0.96% in 2006  
- No data on cirrhosis and hepatocellular carcinoma 
- No data on mortality reduction 
- No data on DALY averted 
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2. Reasons why the goals were achieved 
2.1 Burden of disease documented 
China conducted a national serological survey in 1992 that suggested that chronic 
hepatitis B infection affected 9.75% of the Chinese population. Children were especially 
affected (9.67%), with a prevalence as high as adults. The high burden of disease brought it 
to the attention of the MoH that subsequently recognized hepatitis B as a top priority for 
control though vaccination. 
 
2.2 Partnership 
International: Co-management for the project was a unique model that consisted of 
the appointment of national and international co-managers who worked under the guidance 
of an Operational Advisory Group (OAG) comprised of the Ministry of Health, WHO, 
UNICEF and representatives of the GAVI alliance. This was a creative solution for such a 
health project (And unique in the world in the way the GAVI alliance implement projects at 
country level). The national manager was familiar with the domestic vaccination situation 
while the international co-manager provided insight on international circumstances and 
global issues. Both worked together, communicated, and ensured good day-to-day 
management. The OAG made the key decisions during the project years and ensured an 
objective consensus that was based upon scientific evidence. 
National: During the implementation of project, the MoH joined the State Food and 
Drug Administration (SFDA), the Ministry of Education (MoE), and the Ministry of 
Finance (MoF) to create a protocol that guaranteed strong cooperation among these 
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stakeholders. MoH provided strong political support, through (a) development of the 
national protocol and action plan, (b) allocation of operation funds for vaccination, GAVI 
China office trained health professionals, regular monitoring, supervision, and social 
mobilization. 
 
2.3 Local production of vaccine and AD syringes 
When China implemented the GAVI project, the country already had national suppliers 
for hepatitis B vaccines and AD syringes. However, in 2002, these local products were not 
pre-qualified for purchase by the United Nations agencies. Hence, at the beginning of the 
project, concerns were raised calling for GAVI China to consider international procurement. 
Finally, GAVI China opted for domestic procurement. This choice stimulated national 
vaccine production and ensured a continuity of supply and low prices which were essential 
elements for sustainability. These low prices contributed to the accumulation of the GAVI 
China savings that were used for activities in 2007-2010. Throughout the project, there were 
no incidents regarding the quality of the vaccines and of the AD syringes supplied. In 2011, 
the Chinese State Food and Drug Administration was declared functional as per the WHO 
criteria for vaccine regulatory functions[161]. This milestone event opens the door for 
Chinese vaccine manufacturers to apply for the WHO pre-qualification process. Hence, in 
the near future, Chinese vaccine producers will have the opportunity to document that 
national production has reached international quality standards. 
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2.4 Solid processes 
The Chinese government made strong political commitment to the implementation of 
the GAVI China project. At the beginning of the project, China designated responsible staff 
in hospitals and EPI facilities. The project trained health care workers in hospital and rural 
clinics, encouraged cooperation between MCH and EPI to increase hospital deliveries and 
TBD coverage, provided subsidies for hepatitis B vaccination and conducted supervision 
visits to guide activities. As a result, implementation occurred smoothly, as reflected by our 
process indicators. 
The extensive social mobilization campaigns conducted by GAVI China project raised 
the awareness of vaccination among providers and parents.  
The GAVI China project collaborated with a national initiative on health system 
strengthening (HSS) and an international initiative to eliminate the neonatal tetanus. As a 
result, a disbursement policy providing incentives for pregnant women to deliver in 
hospitals increased hospital delivery rates and resulted in increased TBD coverage. 
 
2.5 GAVI China support providing the funding solution that unlocked the situation 
Hepatitis B was preventable through cost-effective immunization and the Chinese 
government recognized it as a priority disease for control. However, in 2002, the Chinese 
government could not afford to pay for free vaccine in the whole country. Hence, China 
made a request for support to GAVI alliance and an agreement was reached to provide the 
funds for hepatitis B vaccination and safe injections in Western provinces and 
poverty-affected counties of the Central region. The financial support from GAVI alliance 
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was just the final element that was missing to trigger the implementation of universal 
immunization against hepatitis B in China. 
 
3. The benefit of vaccination: Impact 
3.1 The effectiveness of hepatitis B vaccine 
The results from the 2006 serosurvey indicated that the prevalence of HBsAg was 7.18% 
overall. However, there were large variations in prevalence by age groups, ranging from 
0.96% among children 1-4 years of age, to 2.42% among children 5-14 years of age, to 8.57% 
among persons 15-59 years of age. This age-specific prevalence profile showing low 
prevalence among children and high prevalence among adults is new for China. The 1979 
and 1992 surveys showed little variation in the prevalence by age, with a slight decrease in 
prevalence among older age groups (probably reflecting selective higher mortality in 
HBsAg positive persons). In contrast with these earlier profiles, the age-specific prevalence 
of HBsAg from the 2006 survey featured a marked reduction among younger age groups 
who were exposed to the immunization programme (Figure 17). 
Overall, the HBsAg prevalence was 7.18% in 2006, compared with 9.75% in 1992 (a 
decrease of 26%). The classification criteria of the World Health Organization (WHO) 
specify that prevalence of HBsAg> 8% means high endemicity area, prevalence of 2%-8% 
means intermediate endemicity areas and prevalence <2% means low endemicity areas. 
Hence, China should now be listed as an intermediate prevalence area [14]. The prevalence 
of HBsAg among children under 5 has already reached the WPRO goal (less than 2% by 
2012), opening the opportunity of China to undergo the formal WHO verification process 
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[27]. Based on the results of the 1992 and 2006 sero-epidemiological studies, we estimated 
that since 1992, nearly 80 million children under the age of 15 had averted HBV infection, 
and that 19 million had averted chronic HBV infections [80]. 
 
Figure 17: The Prevalence of HBsAg among population aged 1-59 in China 
1979, 1992 and 2006 
 
 
3.2 Economic analysis of hepatitis B vaccination 
Although no economic analysis studies on hepatitis B vaccine were conducted during 
the course of the GAVI project, there is a large body of evidence worldwide on the 
cost-effectiveness of universal infant vaccination against hepatitis B (Box 6). 
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Box 6: Economic analysis of hepatitis B vaccination 
International National 
Studies in low HBsAg prevalence countries 
including the USA have indicated that the 
benefit of vaccination can be obtained 
through universal hepatitis B vaccination 
during childhood [162]. 
In the Gambia, vaccinating infants against 
hepatitis B was highly cost-effective. 
Compared with the absence of intervention, 
the vaccination programme would cost 
US$ 28 per DALY averted from the societal 
perspective or US$ 47 per DALY averted 
from the payers perspective. The programme 
also has the potential to be affordable, 
starting at a relatively low budget of 
US$ 160,000 per year. Combining the two 
dimensions of the outcome measure, the 
probability that vaccinating infants would be 
both cost-effective and affordable is 40% at 
an annual programme budget of US$ 182,000 
(the estimated total programme cost from the 
payers perspective), given a threshold 
cost-effectiveness value of US$ 47 per 
DALY averted [163]. 
In China, the analysis of a study conducted in 
2003 in Shanghai indicated that during 10 
years of hepatitis B vaccination (between 
1992 and 2001), 721,509 infants were 
vaccinated, and the estimated number of 
HBV infections, chronic hepatitis B 
infections, cases of cirrhosis and cancers of 
the liver would be reduced by 54,864, 4,885, 
445 and 48, respectively in the study 
population in 10 years. An investment of 
501,129 RMB can prevent one case of liver 
cancer, 10 cases of cirrhosis, 100 cases of 
chronic hepatitis B and 1,000 cases of HBV 
chronic infections [164]. Results of the study 
and analysis showed that 59,762.55 DALYs 
were averted for a population of 712,509 by 
vaccinating against hepatitis B in neonates 
during these 10 years.  
Hepatitis B catch-up vaccination for children 
and adolescents in China is cost-saving across 
a range of parameters, even for adolescents 
aged 15 to 19 years old [165].  
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3.3 Safety of hepatitis B vaccination 
In 2005, China established system to monitor Adverse Events Following Immunization 
(AEFI) in 10 provinces, and expanded it to 16 provinces in 2008. The monitoring data from 
16 provinces indicated that 252 AEFI following hepatitis B vaccine were reported between 
2005 and 2008. This accounted for 5.16% of the total numbers of reported AEFIs. The 
reported incidence was 2.28/100,000, including allergic rash, allergic purpura, vascular 
edema, Arthus reaction and thrombocytopenic purpura. The incidence of adverse events 
with hepatitis B vaccine in China was lower than the global incidence worldwide as 
reported by WHO [166, 167].  
During Jan 2006 to March 2007, the monitoring system of sudden public health events 
in China reported 10 cases of infant death after vaccination with hepatitis B vaccine. They 
were comprehensively analyzed by on-site investigation, clinical examination and/or biopsy. 
Among 6 cases that were subject to biopsy, one case was attributed to acute allergic shock 
induced by vaccination with hepatitis B vaccine. While among 4 cases that were not subject 
to biopsy, one was possibly due to acute allergic shock induced by vaccination 
[166-168].While the AEFI monitoring system in China did not allow a formal relation to a 
denominator expressed in terms of doses used, we used approximations to estimate rate 
based on the birth cohort (16 million) and vaccine coverage in a year. Using these 
calculations, the death rate of AEFIs induced by hepatitis B (2/16 million)was only 0.1/ 
million, lower than the one quoted by UNICEF[169]. All these data suggested that hepatitis B 
vaccine is very safe. Reaction usually includes minor local pain and/or mild fever, and 
recovery occurs without any treatment [8, 170]. Because the hepatitis B vaccine has been 
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shown to be safe and cost-effective, countries worldwide had incorporated it into their 
routine immunization programmes by 2009 [14]. In WPRO, all countries except Japan have 
integrated hepatitis B vaccine into routine immunization. 
 
3.4 Maintaining hepatitis B vaccination (2011 onwards) 
Since 2007, the China/GAVI project has not made additional investments for hepatitis 
B vaccine and AD syringes. The China central government has taken over the responsibility 
for hepatitis B vaccination and injection safety. Hepatitis B vaccine became one of the 
vaccines integrated into the national immunization programme, with all costs fully funded 
by the government of China including vaccine, syringe, subsidy of vaccination, salary of 
HCW, cold chain and operational funds. 
 
4. Remaining issues 
4.1 Persistence of perinatal HBV infections 
Despite achievements in terms of the elimination of perinatal HBV infection, in 2010, 
China still accounted for the largest annual number of perinatal HBV infections (84,121) in 
the WHO WPR region. Two factors explain the difficulties that China is facing when trying 
to eliminate perinatal HBV transmission. First, the efficacy of hepatitis B vaccine alone 
ranges from 85% to 95%. Hence, some children present with breakthrough infection despite 
receiving TBD. Second, challenges remain in the field of TBD administration among 
certain rural, remote, and poorer populations. Vaccination coverage was lower among 
children born at home, especially in remote areas. Thus, in the future, China must identify 
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mechanisms to address these two issued and reach more children with more effective 
prophylaxis regimens. This will require increasing TBD through increased births in 
hospitals and increasing HBsAg screening of pregnant women so that HBIg can be provided 
to infants of HBV carrier mothers. The inclusion of HBIg to the protocol of 
immune-prophylaxis increases effectiveness from about 88% to up to 95%. 
 
4.2 Remaining unsafe injection issues 
Despite the large scale introduction of AD syringes in China because of the GAVI 
China project, the Eastern region and some non-project areas in the Central areas still do not 
use AD syringes. This leaves a risk of reuse of injection equipment in the absence of 
sterilization. Management of sharps waste has made progress in China. However, some 
grassroots level facilities and private hospitals still engage in unsafe sharps waste 
management solutions that may (1) expose the community to sharps injuries or (2) generate 
toxic fumes. In addition, sharps waste collection and management suffers from lack of 
standardization, which exposes health care workers and the community to needle-stick 
injuries. Finally, some health care workers remain unprotected with the hepatitis B vaccine. 
Without a clear national policy that includes a regulatory framework, technical guidelines 
and implementation funds, this situation will not change. 
 
4.3 Vaccination of high risk adults and protection of health care workers 
China has successfully completed a catch up campaign to vaccinate children under 15 
years of age who had missed the hepatitis B vaccine. The next phase in China could 
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consider vaccinating high-risk adults. Health care workers are universally at high risk for 
HBV infection. Two WHO resolutions in 2007 [143] and 2010 [98] recommended vaccinating 
health care workers against hepatitis B. Aside from health care workers, WPRO already has 
a guideline for hepatitis B vaccination of high-risk adults. These resolutions and 
recommendations provide general guidance to China. However, the WPRO guidelines 
recommend using national data to identify high-risk populations so that the national 
guidelines for the vaccination of high-risk adults are based upon evidence. Thus, a solid 
surveillance system is needed to identify risk factors for infection and frame the groups that 
could benefit from immunization. 
 
4.4 Surveillance problems for incidence disease 
The Chinese National Notifiable Disease Reporting System (NNDRS) offers a solid 
foundation for good hepatitis surveillance. Viral hepatitis has been a national notifiable 
disease since 1959, with reporting by type since 1990. Health care workers use a national 
case definition system to report cases through the electronic NNDRS. The basic 
demographic and epidemiological characteristics are routinely compiled. The system is 
implemented nationally in a uniform manner, is Internet-based and person centered. All 
diagnosed hepatitis B cases are entered into system, and then county, prefecture, province 
and national level staff can access the data.  
However, both acute and chronic hepatitis B cases are included in the system and are 
not differentiated. This hides potential new risks and does not accurately reflect the 
occurrence of new infections. Therefore, China should refine the surveillance system, 
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according to sound case definitions, so that acute and chronic infections can be separated. 
This will need to take into consideration the field aspects of disease diagnosis, laboratory 
diagnosis, epidemiologic case investigation and data collection and transmission. 
 
4.5 Burden of chronic infections among adults 
China, having managed the most pressing problem of incident perinatal and early 
childhood infections, is now faced with tackling the prevalent burden of HBV-infected 
patients among adults (8.57% of the population). Since the burden of chronic infections is 
large, the approach to case management needs to address cost effectiveness and willingness 
to pay. Pilot population-based project in selected settings may provide useful guidance on 
the way to proceed. In additional, as China is developing the new reform health system for 
treatment, but due to the affordable capacity of provinces, this is not universal implemented 
and inequity remains. Therefore, China should have eligible medicines integrated into 
national health insurance system, which will benefit many chronic infections and increase 
equities in access to care in the long run. A national guideline should frame screening, case 
management, counseling, medical treatment, and follow up.  
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Recommendations 
A. How to use the lessons learned from GAVI China for the future introduction of new 
vaccines 
The success of the introduction of hepatitis B vaccine into China's EPI was based upon 
careful preparation that addressed all critical points. In the future, to ensure the successful 
introduction of new vaccines in China' EPI, preparation work should address (1) burden of 
disease, (2) cost-effectiveness, (3) financing and (4) local production of the vaccine. In view 
of its developing economy, China is not longer eligible for GAVI alliance support. 
Therefore, in the future, if a new, locally produced, cost-effective vaccine for a disease with 
a heavy burden is considered for introduction in the EPI, the cost of the new vaccine should 
be afforded using domestic funds. With domestic production in mind, the experience from 
the GAVI China project could be used to generate a financing mechanism that will ensure 
equitable coverage (Table 36).  
The GAVI China project set up an example to scale up the introduction of a new 
vaccine into routine immunization in collaboration with the GAVI alliance. The GAVI 
China experience with respect to hepatitis B vaccine in the recent years can be compared 
with the current situation of other new vaccines in China (Table 36). For hepatitis B vaccine, 
documentation of a large burden of disease in view of available information with respect to 
cost effectiveness and in the presence of large-scale domestic production led to a strong 
government commitment. This government commitment progressively led a universal, 
equitable financing. This experience is not so different from the Chinese experience with 
Japanese encephalitis[171, 172], for which information on burden of disease[32, 80] and cost 
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effectiveness [173, 174] combined with the availability of a good national vaccine [175] to 
trigger national introduction in EPI in 2007. Overall, these experiences point to a number of 
criteria with respect to introduction of new vaccines that could be of use for National 
Immunization Technical Advisory Groups (NITAGs) in China and other countries. These 
NITAGs may consider epidemiological, economical and other issues to assist Ministries of 
Health with the decision-making process around new vaccine introduction. When a new 
vaccine is ready to be introduced, NITAGs may benefit from collaboration with 
international partners, including the WHO Strategic Advisory Group of Experts (SAGE) on 
Immunization, the WHO group on New and Under-utilized Vaccines Implementation 
(NUVI), the SIVAC initiative (i.e., Supporting National Independent Immunization and 
Vaccine Advisory Committees). NITAGs can then consider these elements to recommend 
the identification of equitable financing for universal introduction when the right conditions 
are met. 
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Table 36: Lessons learned from hepatitis B vaccine introduction in China with 
respect to the introduction of other new vaccines, GAVI China project evaluation, 
2002-9 
Elements to 
consider for 
introduction of a 
new vaccine  
Hepatitis B vaccine 
in China 
Situation in 2011 with respect to other vaccines 
HIb Rotavirus Pneumococcal 
conjugate 
vaccine 
Burden of disease 
documentation  
- Extensive 
documentation using 
local data 
- Large burden 
- Based on 
extrapolation of 
global data 
- Difficult 
technically  
- Large burden of 
diarrheal disease 
- Low mortality 
- Based on 
extrapolation of 
global data 
- Difficult 
technically  
Vaccine 
effectiveness  
- Documented in 
China 
- Studies 
conducted 
outside of China 
- Studies 
conducted in 
China 
- Studies 
conducted outside 
of China 
Cost effectiveness  - Documentation on 
the basis of studies 
conducted outside of 
China were sufficient 
- Studies 
conducted 
outside of China 
- Studies 
conducted 
outside of China 
- Studies 
conducted outside 
of China 
Local production  - From 1985 
- Multiple producers  
- Available in 
2003 
- Two producers 
- Sufficient 
supplies 
- Available in 
2000 
- One producer 
- Insufficient 
supplies for 
nationwide use 
- Available in 2006 
for adult, but not 
for children 
Equitable 
financing  
- Progressively 
acquired, with key 
milestones in 1992, 
2002, 2005 and 2008 
No No No 
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B. How to address unmet needs with a second generation hepatitis B programme 
Immunization 
Immunization system. The future of hepatitis B immunization in China must be to 
maintain universal infant vaccination. Vaccinating all infants in a timely manner remains 
the highest priority, especially for those living in remote, mountain areas. To this effect, the 
programme must (1) regularly analyze data to identify the difficult to reach, (2) make 
vaccines available in all villages or townships (Which could have implications in terms of 
cold chain), (3) assign the responsibility to vaccinate to the village heath care worker 
(instead of relying on the township hospitals), (4) conduct regular supervision and (5) 
provide hands on training for health care workers.   
Perinatal infections. With respect to the prevention of the transmission from mother to 
children, China first should conduct additional efforts to strengthen the health system and 
further improve hospital delivery rates. This increases TBD coverage and decreases 
perinatal HBV transmission, which results in reduction of disease burden. Tibet, Guizhou 
and Yunnan should be the priority areas. Screening for HBsAg in pregnant mothers and 
provision of HBIG for those born to HBsAg positive mothers would be the second step, 
which will further decrease new infections among susceptible infants.  
Catch-up campaigns. As China has already completed catch-up vaccination for 
children under 15 years old, the strategy will now evolve towards routine activities through 
school entry checks in primary school or middle school, or provision of routine vaccination 
in all vaccination sites. Raising the age to conduct catch-up campaigns leads to less and less 
returns in terms of cost-effectiveness[165]. However, this strategy could be a useful way to 
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reach health care workers in the pre-service stage (e.g., nursing students and medical 
students)[176, 177]. 
Health care worker protection. In addition to the routine immunization of infants, 
catch-up campaigns for children and vaccination for high-risk adults, pre-services 
vaccination for students in medical school and university should be addressed. Hence, 
health care workers would be protected before exposure. This is a cost-effective way to 
protect health care workers[178, 179].  
Addressing remaining unsafe injection issues 
Injection practices. China needs to have clear safe injection guidelines that would be 
mandatory for all injections. For vaccination, use of AD syringes should be generalized. 
This could be achieved through training, supervision, national legislation, regulation or law 
making. A Chinese expert committee could review the WHO best practices and the recent 
national evidence to define best practices for China. China should develop national safety 
injections guideline that require that all vaccinations to be given using AD syringes. 
Waste management. Management of waste could be achieved through national 
legislation, regulation or law making, which should be implemented in the entire country, 
and cover all health units. As heterogeneity of solutions facilitates the adoption of 
sub-standard choices, precise guidance should define what is acceptable and what is not.  
Surveillance for acute disease 
China should develop a clear guideline for the surveillance of hepatitis B. Key aspects 
to address include (1) guiding hospital professionals to make the right diagnosis and report 
according to the right case definition, (2) testing specimens appropriately in the laboratory, 
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(3) case investigation and effective data management. Reliable reporting of acute hepatitis 
B and will allow identification of risk factors for use in policy making. Such work should to 
be done in pilot projects first, before expanding to a national scale. Evidence generated 
could guide vaccination of high-risk adults. 
Towards screening and treatment 
As time will progressively unveil the impact of hepatitis B immunization on the 
incidence of cirrhosis/hepatocellular carcinoma cases, China will need to set up a system 
that will be able to measure these health events to calculate the number of deaths prevented 
and DALYs averted.  
In the meantime, China will have to address the issue of the current burden of chronic 
infections among older age groups. These chronically infected persons have not benefitted 
from the immunization of newborns. A China CDC study already monitors morbidity and 
mortality outcomes among HBV-infected patients identified during the 2006 serological 
survey. This is a first documentation step for future programmes of management. In the 
future, developing pilot approaches for population-based screening for management could 
be an easy first step to identify how China could provide long term care and support for the 
large population already infected. It is through these kinds of small-scale pilot projects that 
the first chapters of the great hepatitis B immunization success story were written some 
thirty years ago in China.  
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Appendix 
Appendix 1: Counties selected in the sample of the final evaluation, China, 2010 
Region Province County Facilities 
East 
Liaoning Liaozhong 10 
Shanghai Chongming 10 
Jiangsu Sheyang 9 
Zhejiang Shangyu 10 
Shandong 
Zhangqiu 10 
Luxian 9 
Guangdong 
Baoshan 8 
Lianshan 8 
Central 
Hebei 
Shenze 11 
Hejian 11 
Jilin Shuangliao 11 
Anhui 
Nanlin 10 
Xuanzhou 11 
Henan 
Kaifeng 10 
Ninglong 11 
Hunan Longhui 11 
West 
Inner Mongolia Linhe 11 
Hubei Macheng 11 
Guangxi Zhongshan 11 
Sichuan 
Fushun 11 
Dazhu 11 
Guizhou Guiding 11 
Shanxi Huxian 11 
Gansu Guanghe 10 
 
  
219 
Appendix 
 
Appendix 2: List of Abbreviations 
ACIP   Advisory Committee on Immunization Practices  
AD   Auto-Disable syringes 
AEFI   Adverse Events Following Immunization 
ALT   Alanine aminotransferase  
BCG   Bacillus Calmette–Guérin (vaccine)  
CDC   Centers for Disease Control (US)   
CFETP Chinese Field Epidemiology Training Programme 
CHO   Chinese Hamster Ovary  
CI   Concentration Index 
DALYs Disability-Adjusted Life Years 
DSP   Disease Surveillance Points  
DTP   Diphtheria, Tetanus, Pertussis Combined Vaccine  
ELISA  Enzyme-Linked Immunosorbent Assay 
EPI  Expanded Programme on Immunization  
GAVI   Global Alliance for Vaccine and Immunization  
GDP   Gross Domestic Product 
GIVS   Global Immunization Vision and Strategy  
GMT   Geometric Mean Titre 
HBIG   Human Hepatitis B Immunoglobulin  
HBsAg   Hepatitis B surface Antigen  
HBeAg   Hepatitis B e Antigen  
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HBIG   Hepatitis B Immune Globulin  
HBV   Hepatitis B Virus  
HCC   Hepatocellular Carcinoma  
HCW   Health Care Worker 
HepB Hepatitis B vaccine  
HepB3 Three dose of hepatitis B vaccine 
IEC   Information, Education and Communication   
IVDC   Institute for Viral Disease Control, China CDC  
JRF   Joint Reporting Form  
KAP   Knowledge, Attitude, Practice 
MCH   Maternal and Child Health 
MMR   Measles, Mumps and Rubella vaccine  
MoH Ministry of Health 
MTCT   Mother to Child Transmission  
OAG   Operational Advisory Group 
PMTCT  Prevention Mother to Child Transmission  
PPS   Probability Proportional to Population Size   
RMB  Ren Min Bi (Chinese Yuan) 
TBD   Timely Birth Dose 
UNICEF   The United Nations Children's Fund   
WHO   World Health Organization   
WPRO   West Pacific Region Office, WHO 
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Appendix 3: Curriculum Vitae 
Personal information  
Name: Cui          Given Name: Fuqiang 
Gender: Male     
Current position 
 Secretary, Chinese National Advisory Committee on Immunization Practices 
 Director of Hepatitis Division, National Immunization Program, Chinese Center for 
Disease Control and Prevention  
 Manager, Ministry of Health/Global Alliance on Vaccine and Immunization 
 Member of Experts committee of Chinese Foundation for Hepatitis B Prevention and 
Control 
Research field 
Epidemiology of Vaccine Preventable Diseases, Viral hepatitis prevention and control  
Work experience  
June 2005 - Present  
 Manager, Ministry of Health, China/Global Alliance for Vaccine and Immunization (GAVI) 
Project  
 Director, Division of Hepatitis, National Immunization Program, Chinese Center for 
Disease Control and Prevention  
June 2001- June 2005 
 Acting director and Deputy Director, Department of immunization, Gansu Provincial 
Center for Disease Control and Prevention  
June 1995 - June 2001 
 Medical officer, Department of immunization, Gansu Provincial Center for Disease 
Control and Prevention   
Education 
2010 – Present 
 PhD Student on Epidemiology, Swiss Tropical and Public Health Institute, University Basel, 
Switzerland 
2003 – 2004 
 School of Public Health, Hebrew University Jerusalem, Israel: Master of Public Health   
1990 – 1995 
 School of Preventive Medicine, Lanzhou Medical colleague, Lanzhou University: Bachelor 
Degree of Medical Doctor  
1987-1990  
 No 2 high school of Jingyuan, Gansu
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The field work records since 2003 
 
 
Investigation to H1N1 outbreak in June, 2009 
 
  TAG Meeting of WPRO in June, 2006 
Consultant in Vietnam in Jan, 2010 
 
 
 
 
 
 
 
 
Technical expert review, in April, 2011                Seminar in WHO China in July, 2009 
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